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Chlamydia trachomatis belongs to a group of highly related obligate 
intracellular bacteria. It is the etiological agent of important human 
sexually transmitted infections and trachoma. C. trachomatis strains can 
be divided in the trachoma biovar, which includes strains that cause non-
invasive infections of conjunctival and genital epithelial cells (ocular and 
urogenital strains, respectively), and the lymphogranuloma venereum 
(LGV) biovar, which is responsible for a more invasive disease, and 
includes strains that are able to infect macrophages and disseminate 
into lymph nodes (LGV strains). The determinants of the different types 
of infection (invasive or non-invasive) and tissue tropism (eyes, genitals, 
and lymph nodes) are only partially studied. Furthermore, it is known 
that the genomes of C. trachomatis strains are nearly identical at the 
DNA level (>98%). Therefore, these differences must be explained by 
small nucleotide variations on a relatively low number of genes, which 
could lead either to proteins with disease group-specific amino acids or 
to differential gene expression. 
Throughout the developmental cycle, C. trachomatis resides and 
replicates within the host cell inside a vacuole (an inclusion). It uses a 
type III secretion system (T3SS) to manipulate the host cell and benefit 
from the host supplies. The inclusion membrane (Inc) proteins are an 
important family of type III secretion (T3S) effectors. These proteins 
have a characteristic bi-lobed hydrophobic domain, likely responsible for 
targeting them to the membrane of the inclusion. Due to their particular 
localization, Inc proteins are obvious candidates to participate in the 
cross-talk between the bacteria and the host cell. Several Incs were 
already implicated in the manipulation of the host cytoskeleton 
dynamics, and vesicular and non-vesicular transport, however, the 
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function of the majority of them is still unknown. Aditionally, not all Incs 
were yet described as being T3S substrates, nor the localization in the 
inclusion membrane was described for all of them. 
In this thesis we aimed to gain insights into the molecular function of Inc 
proteins. First we tested if the presence of a T3S signal could be used 
as additional evidence (other than the bi-lobed hydrophobic motif) that 
an Inc protein will localize at the inclusion membrane. We used Yersinia 
enterocolitica as heterologous host to identify T3S signals in a set of 48 
C. trachomatis known (possessing the hydrophobic motif and described 
to be localized at the inclusion membrane) and putative (possessing the 
hydrophobic motif but not yet described to be localized at the inclusion 
membrane) Inc proteins. We identified a T3S signal in ~80% of the Incs 
analyzed, indicating that they are T3S substrates. However, we did not 
detect a T3S signal in a few known Inc proteins, and therefore, to 
validate a protein as an Inc protein, additional immunofluorescence 
studies in Chlamydia-infected cells are needed to confirm its localization 
at the inclusion membrane. 
Given the particular localization of Inc proteins at the inclusion 
membrane, we next assessed if Inc proteins could participate in the 
tissue tropism and type of infection associated with C. trachomatis. For 
that, we performed phylogenetic, molecular evolution, and gene 
expression analyses, focusing on the same set of 48 Inc proteins 
retrieved from the sequenced genomes of 51 C. trachomatis strains. We 
discovered small differences in the amino acid sequence of a subgroup 
of Inc proteins and in the expression of inc genes that could contribute to 
the specific tissue tropism and type of infection associated with LGV 
strains. 
To test the hypothesis that Incs contribute to tissue tropism and type of 




proteins highlighted in the previous study. For this, we used yeast-two 
hybrid screening with Inc proteins CT228, CT249, and CT288 as baits 
for a mammalian cDNA library. Among the putative candidates found, 
we characterized in more detail the interaction between CT288 and the 
coiled coil domain containing protein 146 (CCDC146). CCDC146 is a 
human protein of unknown function that localizes at the centrosome. We 
used different biochemical methods to validate the interaction 
between CT288 and CCDC146 and immunolocalization studies in 
Chlamydia-infected cells to study their localization. We show that 
during infection by C. trachomatis, CCDC146 co-localizes with CT288 
at the inclusion membrane. It is known that the centrosome is 
targeted by C. trachomatis throughout the infectious cycle. Moreover, a 
few host centrosomal proteins were already identified as host cell targets 
of Inc proteins. We hypothesize that the interaction between CT288 and 
the host cell centrosomal protein CCDC146 might also be relevant for 
the cross-talk between the inclusion and the centrosome. 
In conclusion, we gained novel insights into the pathogenesis of 
infections by C. trachomatis, particularly regarding proteins involved in 
tissue tropism and different types of infection. We also discovered a new 









Chlamydia trachomatis pertence a um grupo de bactérias intracelulares 
obrigatórias. É o agente etiológico de doenças de grande importância 
clínica como o tracoma e doenças sexualmente transmissíveis. As 
estirpes de C. trachomatis podem ser divididas em dois biovares: o 
biovar tracoma, que inclui as estirpes que causam infeções não 
invasivas do tecido epitelial da conjuntiva e do trato genital (estirpes 
oculares e genitais), e o biovar linfogranuloma venéreo (LGV), 
responsável por uma doença mais invasiva e que inclui estirpes que são 
capazes de infetar macrófagos e disseminar para os nódulos linfáticos. 
Os determinantes envolvidos nos diferentes tipos de infeção (não 
invasiva e invasiva) e nos diferentes tropismos celulares (olhos, genitais 
e nódulos linfáticos) estão apenas parcialmente estudados. Sabe-se 
ainda que os genomas das estirpes de C. trachomatis são quase 
idênticos entre si (>98% de semelhança ao nível do DNA). Assim, as 
diferenças no tipo de infeção e no tropismo celular devem ser 
explicadas por pequenas variações nucleotídicas num número restrito 
de genes, que podem dar origem a proteínas com aminoácidos 
específicos de cada grupo de doença e/ou a expressão diferenciada dos 
respetivos genes. 
Durante o seu ciclo infecioso, C. trachomatis instala-se e replica dentro 
da célula hospedeira num vacúolo (designado por inclusão), e usa um 
sistema de secreção do tipo III (T3SS) para manipular a célula 
hospedeira. Um grupo importante de efetores do T3SS são as proteínas 
localizadas na membrana do inclusão (proteínas Inc). Estas proteínas 
são caraterizadas por possuir um domínio bilobal hidrofóbico, 
possivelmente capaz de as direcionar para a membrana do inclusão. 
Dada a sua particular localização, as proteínas Inc são fortes candidatas 
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a serem os fatores bacterianos responsáveis pela interação entre a 
bactéria e a célula hospedeira. Algumas proteínas Inc foram já descritas 
como estando envolvidas na manipulação de alguns processos do 
hospedeiro como a dinâmica do citosqueleto, e o transporte vesicular e 
não vesicular. No entanto, a função da maioria das proteínas Inc ainda é 
desconhecida. Além disso, nem todas as proteínas Inc foram já 
descritas como sendo efetores do T3SS, bem como a localização na 
membrana do inclusão ainda não foi confirmada para todas as Incs. 
O objetivo desta tese foi o de aumentar o nosso conhecimento acerca 
da função molecular das proteínas Inc. Primeiro, testámos se a 
presença de um sinal de secreção do tipo III (T3S) poderia ser usada 
como evidência adicional (além do domínio bilobal caraterístico) de que 
uma proteína Inc se irá localizar na membrana do inclusão. Para isso, 
usámos Yersinia enterocolitica como sistema heterólogo para identificar 
sinais de T3S num conjunto de 48 proteínas Inc de C. trachomatis, 
algumas já conhecidas (sabe-se que têm o domínio bilobal e a sua 
localização na membrana do inclusão já foi descrita), outras apenas 
putativas (sabe-se apenas que têm o domínio bilobal). Identificámos um 
sinal de T3S em 80% das Incs, confirmando a hipótese de que são 
substratos do T3SS. No entanto, não conseguimos identificar um sinal 
de T3S em algumas das Incs já conhecidas. Isto significa que a 
presença de um sinal de T3S não é suficiente para validar uma proteína 
como sendo uma Inc. Experiências adicionais de microscopia de 
imunofluorescência em células infetadas por Chlamydia são 
necessárias para confirmar a localização das proteínas na membrana 
do inclusão. 
Uma vez que as proteínas Inc se localizam na membrana do inclusão, a 
seguir avaliámos se estas proteínas podem contribuir para o tropismo 
celular e tipo de infeção associados às estirpes de C. trachomatis. Para 




expressão génica no mesmo grupo de 48 proteínas Inc obtidas dos 
genomas sequenciados de 51 estirpes de C. trachomatis. Descobrimos 
que pequenas diferenças ao nível da sequência de aminoácidos de um 
subgrupo de proteínas Inc, e ao nível da expressão de alguns genes 
que as codificam, podem contribuir para o tropismo e tipo de infeção 
específico associado às estirpes LGV. 
Para conseguir testar a hipótese de que as Incs contribuem para o 
fenómeno de tropismo celular e tipo de infeção, o objetivo seguinte foi 
descobrir a função molecular de proteínas Inc específicas. Usando 
ensaios de "yeast-two hybrid", o objetivo foi o de descobrir parceiros de 
interação entre uma biblioteca de proteínas humanas e as proteínas Inc 
CT228, CT249 e CT288. De entre os resultados obtidos, caracterizámos 
a interação entre CT288 e a proteína humana "coiled coil domain 
containing protein 146" (CCDC146). CCDC146 tem uma função 
desconhecida, mas sabe-se que localiza no centrossoma. Usámos 
diferentes técnicas bioquímicas para validar a interação entre a Inc 
CT288 e a proteína CCDC146, e experiências de imunofluorescência 
em células infetadas por C. trachomatis para estudar a localização das 
duas proteínas. Descobrimos que em células infetadas por Chlamydia, a 
CT288 e a CCDC146 co-localizam na membrana do inclusão. Sabe-se 
que o centrossoma, que funciona como coordenador da arquitetura do 
citosqueleto da célula eucariótica, é manipulado por C. trachomatis 
durante todo o seu ciclo infecioso. Além disso, já foram descritas outras 
interações entre proteínas centrossomais da célula hospedeira e 
proteínas Inc. Assim, formulamos a hipótese de que a interação entre a 
Inc CT288 e a proteína centrossomal CCDC146 pode contribuir para a 




Em conclusão, nesta tese aumentámos o conhecimento acerca da 
patogénese molecular de infeções por C. trachomatis, particularmente 
no fenómeno do tropismo celular e tipo de infeção. Descobrimos 










This thesis is divided in five chapters. Chapter 1 gives a general picture 
of infections by Chlamydia, and in more detail, by Chlamydia 
trachomatis. It contains also a description of the known Chlamydia-host 
interactions, focusing on the chlamydial developmental cycle and on the 
type III secretion system (T3SS), along with a brief comparison with 
other intravacuolar pathogens. Data presented on Chapter 2 and 3 
consist of published material supplemented with relevant unpublished 
results. Chapter 2 describes the identification of type III secretion (T3S) 
signals in chlamydial inclusion membrane (Inc) proteins using Yersinia 
enterocolitica as heterologous host bacteria. T3S signals were identified 
in the majority of the Inc proteins, suggesting that they are translocated 
into the host cell by this transport mechanism. Chapter 3 describes 
phylogenetic, molecular evolution, and gene expression analyses aimed 
to determine if Inc proteins could play a role in the type of infection and 
tissue tropism associated with C. trachomatis strains. The results show 
that a subgroup of Inc proteins could be involved in the distinct tropism 
and invasiveness associated with C. trachomatis LGV strains. Chapter 4 
describes data that are part of a manuscript in preparation, and was 
aimed at finding host cell interacting partners for Incs. A number of 
candidate host cell interacting partners for Incs CT228, CT249, and 
CT288 were found, however, during the course of this thesis it was only 
possible to validate the interaction between CT288 and the host cell 
centrosomal protein CCDC146. Chapter 5 contains a general discussion 
about the importance of the results obtained and of the possible future 









ARF1 Adenosine diphosphate (ADP)-ribosylation factor 1 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
BHI Brain heart infusion 
BLAST Basic local alignment search tool 
cDNA Complementary DNA 
COG Conserved oligomeric Golgi 
co-IP Co-immunoprecipitation 
CPAF Chlamydial protease-like activity factor 
DMEM Dulbecco’s modified eagle medium 
DNA Deoxyribonucleic acid 
ECDC European Centre for Disease Prevention and Control 
EDTA Ethylenediamine tetraacetic acid 
EGFP Enhanced green fluorescent protein 
ERK Extracellular signal-regulated kinases 
FBS Fetal bovine serum 
GFP Green fluorescent protein 
GTPase Guanosine triphosphate hydrolases 
HA Human influenza hemagglutinin epitope 
HBSS Hank’s balanced salt solution 
IκBα nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
LB Lysogeny broth 
LPS Lipopolysaccharide 
MAPK Mitogen-activated protein kinases 
MOI Multiplicity of infection 
mRNA Messenger RNA 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NGS Next-generation sequencing 
NOD1 Nucleotide-binding oligomerization domain-containing protein 1 
OD600 Optical density at 600 nm 
ORF Open reading frame 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PMSF Phenylmethylsulfonyl fluoride 
RNA Ribonucleic acid 
rpm Rotations per minute 
rRNA Ribosomal RNA 
RT-PCR Reverse transcription coupled with PCR 
RT-qPCR Real-time quantitative PCR 
SDS Sodium dodecyl sulfate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
siRNA Small interfering RNA 
XVI 
 
SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
sRNA Small RNA 
TCA Trichloroacetic acid 
TGN Trans-Golgi network 
TLR Toll-like receptor 
USA United States of America 
UV Ultraviolet 
VAMP Vesicle associated membrane protein 
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1.1 The biology of Chlamydia 
1.1.1 Diversity 
Members of the phylum Chlamydiae are closely related Gram-negative 
bacteria, biologically characterized by obligate intracellular growth within 
eukaryotic cells. The diversity of Chlamydiae, their host range, and their 
occurrence in the environment is a hallmark, as it includes bacterial 
species that infect or establish symbiotic relationships with different 
vertebrates, invertebrates, and even unicellular eukaryotes such as 
amoeba (Everett et al., 1999; Horn, 2008).  
Currently, Chlamydiae is divided in eight families: Chlamydiaceae, 
Parachlamydiaceae, Criblamydiaceae, Waddliaceae, 
Rhabdochlamydiaceae, Simkaniaceae, Clavochlamydiaceae, and 
Piscichlamydiaceae. The Chlamydiaceae family includes the most 
important pathogens of humans and other animals, while the other 
seven families include a growing number of Chlamydia-like organisms 
that are mainly symbionts of eukaryotes (Everett et al., 1999; Horn, 
2008). 
The Chlamydiaceae have been divided in two genera (Chlamydia and 
Chlamydophila) (Everett et al., 1999; Horn, 2008). However, since the 
proposal of this division, a lot of discussion was raised concerning 
whether the distinction between Chlamydia and Chlamydophila was 
necessary. In addition, the majority of the Chlamydia research 
community did not follow this nomenclature. This led to the recently 
recommended emended descriptions of the family Chlamydiaceae and 
the proposal of a single genus to include all currently recognized species 
(Sachse et al., 2015). By this new definition, the family Chlamydiaceae is 
composed of the genus Chlamydia encompassing 11 described species 
and one recently proposed new species (Vorimore et al., 2013; Sachse 





 Chlamydia trachomatis is a human-specific pathogen that causes 
ocular and sexually transmitted genital infections, and is 
considered a major health problem worldwide (Wright et al., 
2007; Bébéar and de Barbeyrac, 2009). 
 C. pneumoniae is another human pathogen, and is one of the 
most prevalent causes of respiratory infections (Blasi et al., 2009; 
Kern et al., 2009). It accounts for ~15% of community-acquired 
pneumonia and is associated with exacerbations of chronic 
bronchitis, pharyngitis and asthma (Blasi et al., 2009; Kern et al., 
2009). C. pneumoniae has also been linked with other diseases 
such as atherosclerosis, central nervous system disorders, and 
Alzheimer’s disease, and there are reports suggesting that C. 
pneumoniae non-human infections can lead to respiratory and 
vascular pathologies in a broad spectrum of animals and reptiles 
(Bodetti et al., 2002; Roulis et al., 2013). 
 C. psittaci has also a great impact in the veterinary economy and 
infects approximately 450 different bird species, including 
psittacine birds, pigeons, ducks, geese, and turkeys (Knittler et 
al., 2014). In birds, C. psittaci is responsible for psittacosis, one 
of the most significant animal diseases, manifested most 
frequently by pneumonia, conjunctivitis and enteritis, among 
other pathologies. C. psittaci is considered an important zoonotic 
agent as transmission to humans often occurs, causing severe 
respiratory diseases and even death (Knittler et al., 2014). 
 C. abortus is of significant economic importance because it can 
colonize the placenta of sheep and goats, leading to abortion in 
these animals. It is also responsible for zoonotic infections and is 
considered a major risk factor for abortion in pregnant women 
who are exposed (Longbottom and Coulter, 2003). 
 C. muridarum is a natural mouse pathogen that causes 





 C. pecorum is an important pathogen of domesticated livestock 
including cattle, sheep, goats, and pigs (Reinhold et al., 2011; 
Bachmann et al., 2014). It is responsible for a wide range of 
diseases such as polyarthritis, pneumonia, conjunctivitis, and 
encephalomyelitis, and has been associated with gastrointestinal 
and urogenital tract diseases, and abortion. This pathogen is also 
known to cause ocular and genital infections in koalas, and is 
considered a major contributing factor to the decline of the 
population of these animals in Australia (Polkinghorne et al., 
2013). 
 C. felis is a common agent of conjunctivitis and upper respiratory 
tract diseases in cats although, there are also reports of humans 
being infected with this bacterium (Cai et al., 2002). 
 C. caviae causes conjunctivitis and genital tract infections in 
guinea pigs (Read et al., 2003; Neuendorf et al., 2015). 
 C. suis infects mainly pigs and is associated with porcine 
conjunctivitis, pneumonia, and various reproductive disorders 
(Schautteet and Vanrompay, 2011; Donati et al., 2014). 
 C. avium strains can infect pigeons and members of psittacine 
birds. Infections appear to be asymptomatic and widely 
disseminated, still, little is known about whether can infect other 
animals (Sachse et al., 2014). 
 C. gallinacea strains were recovered from samples of chickens, 
guinea fowls, and turkeys. As C. avium, infections are 
asymptomatic and widely disseminated (Sachse et al., 2014). 
The newly proposed species is C. ibidis, and was recovered from feral 
African Sacred Ibises (Vorimore et al., 2013). Only a few strains were 
collected and so far there is no evidence of a pathogenic potential. They 
appear to be innocuous in avian species but the health risk to humans or 





Regarding the Chlamydia-like organisms, there are reports suggesting 
an association between Parachlamydia acanthamoebae, Simkania 
negevensis, and Waddlia chondrophila in human respiratory diseases 
and cases of abortion in women (Horn, 2008; Lamoth et al., 2015). 
However, these associations were mostly based on serological and 
molecular data and strains were never isolated from a patient and 
neither their presence was demonstrated at the site of infection (Horn, 
2008; Lamoth et al., 2015). 
 
1.1.2 Genomics of Chlamydia 
Until recently, the major limitations in the development of a host-free 
growth system and in the development of genetic methodologies to 
manipulate Chlamydia hampered the understanding of the biology of 
these organisms. However, about 15 years ago, with the beginning of 
the genomics era, a revolution started with the first sequenced genome 
of a C. trachomatis strain (Stephens et al., 1998). Subsequent advances 
in the NGS technology allowed the increase of the number of available 
Chlamydia genomes to more than 100, encompassing almost all 
recognized species. 
Comparative analyses of the genomes of four environmental Chlamydia-
like species and a large number of Chlamydia species indicated that the 
genomes of these two distinct groups of bacteria are significantly 
divergent, and that the genomes of Chlamydia-like species are also 
divergent within this group. In particular, the genomes of Chlamydia-like 
bacteria display little or no synteny neither to genomes of Chlamydia nor 
to each other, and they are two to threefold larger than those of 
Chlamydia species (Griffiths et al., 2006; Collingro et al., 2011). In 
contrast, although some differences are found between the genomes of 





pathways are conserved, and a high degree of synteny is maintained 
(Griffiths et al., 2006; Harris et al., 2012; Knittler et al., 2014). The typical 
Chlamydia chromosome consists of approximately 1.0 to 1.2 Mb and 
1000-1200 protein-coding genes, depending on the species. Analyses of 
the sequenced genomes revealed that Chlamydia have the minimal 
machinery required for DNA replication, transcription and translation, for 
delivery of proteins by a type III secretion system, for basic lipid 
metabolism, and for essential functions in aerobic respiration (Stephens 
et al., 1998; Yao et al., 2015). The relatively small genome size of 
Chlamydia species, when compared to other bacteria with small 
genomes, suggests that during adaptation to its host they lost a large 
number of genes, most probably because the environment where they 
thrive no longer required those functions (Mendonça et al., 2011). In 
fact, Chlamydia have several incomplete metabolic pathways, such as: 
the tricarboxylic acid cycle, because genes for citrate synthase, 
aconitase, and isocitrate dehydrogenase are not present in the genome; 
and for biosynthesis of all amino acids, as for example, phenylalanine 
and tyrosine, where the enzymes responsible for the last step of 
biosynthesis of these amino acids are present in the genome, but 
enzymes for the preceding steps are not (Stephens et al., 1998). 
Therefore, Chlamydia must rely on their eukaryotic hosts for obtaining 
those nutrients. 
The differences in the genomes of Chlamydia are mainly restricted to a 
region of 10 to 50 kb, designated as the plasticity zone (PZ). This region 
contains several genes that might encode virulence factors, including the 
Chlamydia cytotoxin and putative membrane attack complex/perforin 
(MACPF), and phospholipase D enzymes. The PZ is often a focus in 
comparative genomics analyses of Chlamydia, as the presence or 
absence of these genes could play a role in host specificity (Harris et al., 





differences include: the genes encoding for the highly variable 
polymorphic membrane proteins, a protein family unique to Chlamydia 
(Tan et al., 2006); the gene encoding the type III secretion system 
translocated actin recruiting phosphoprotein (Tarp) (Voigt et al., 2012); 
and genes of the biotine and pyrimidine pathways (Voigt et al., 2012). 
An additional feature of most Chlamydia species is the presence of a 
highly conserved plasmid of about 8 kb and encoding eight ORFs 
(Carlson et al., 2008; Gong et al., 2013). This plasmid appears to have 
an important role during infection and there is also a strong selection 
mechanism to maintain it (Carlson et al., 2008; Gong et al., 2013). 
Evolutionary studies revealed that the plasmid co-evolved with the 
chromosome, as it exhibits segregation of species/strains that co-relate 
with their host range and tissue tropism (Read et al., 2003; Harris et al., 
2012; Ferreira et al., 2013). Plasmid-free Chlamydia strains rarely occur 
in nature and studies using these strains indicated that the plasmid is 
important for glycogen synthesis, in modulating the host cell 
inflammatory response, and in the regulation of expression of a set of 
chromosomal genes (O’Connell et al., 2007; Wang et al., 2011; Song et 
al., 2013; Porcella et al., 2015). 
Another important point on the chlamydial biology research was the 
discovery that recombination often occurs in Chlamydia. It is known that 
these organisms possess a complete system for DNA recombination 
encoded in the genome and there are several reports showing that 
recombination contributed significantly for the genetic diversity of 
Chlamydia, including incorporation of foreign DNA (DeMars et al., 2007; 
Binet and Maurelli, 2009; Jeffrey et al., 2010; Joseph et al., 2011; 






1.1.3 Transcriptomics and proteomics of Chlamydia 
With the data generated from the first sequenced genomes, the attention 
then moved towards the products of the genes. Several proteomic 
studies were developed and aimed at the identification of the complete 
battery of proteins of Chlamydia (Vandahl et al., 2001; Skipp et al., 2005; 
Saka et al., 2011). Similar assays were done focusing on the host 
proteome, to evaluate how infection with Chlamydia alters host protein 
stability (Olive et al., 2014). Transcriptomic studies were also performed 
to assess the changes of expression of chlamydial and host genes 
during infection (E. I. Shaw et al., 2000; Belland et al., 2003; Nicholson 
et al., 2003; Borges et al., 2010; Albrecht et al., 2011; Ferreira et al., 
2013; Omsland et al., 2013; Porcella et al., 2015). These studies 
revealed that Chlamydia are packed with proteins required for central 
metabolism, energy utilization, and in the delivery of virulence proteins in 
distinct phases of the developmental cycle. 
 
1.1.4 New advances in the chlamydial biology 
In the last five years, we witnessed a breakthrough in the Chlamydia 
research field. In 2011, the report of a shuttle vector and a stable system 
for genetic transformation of C. trachomatis allowed for the first time the 
analysis of gene function by complementation (Wang et al., 2011). Since 
then, several adaptations of this system were developed with the design 
of inducible systems that incorporate different fluorescent proteins 
(Agaisse and Derré, 2013; Gérard et al., 2013; Wickstrum et al., 2013). 
Novel insights into the molecular function of chlamydial proteins were 
already achieved using this methodology (Agaisse and Derré, 2014; 
Bauler and Hackstadt, 2014; Mirrashidi et al., 2015; Mueller and Fields, 
2015). Another method recently implemented to genetically manipulate 
Chlamydia is the generation of null mutants by chemical mutagenesis 





Although with this method libraries of mutants can be constructed, it 
generates random mutations in the genome and still requires a 
subsequent step of whole genome sequencing for validation. In addition, 
the mobile group II intron system and other systems have been 
optimized to perform targeted inactivation of chromosomal genes in 
Chlamydia (Johnson and Fisher, 2013; Thompson et al., 2015). Very 
recently, a novel system for targeting chlamydial genes for deletion or 
allelic exchange was developed for C. trachomatis (Mueller et al., 2016). 
In this system, a novel suicide vector allows the generation of fully 
genetically tractable C. trachomatis and the process can be easily 
monitored by the use of fluorescence reporters (Mueller et al., 2016). 
 
1.1.5 The “chlamydial anomaly” resolved 
For a long time, the existence or not of peptidoglycan in Chlamydia has 
generated a lot of controversy. Conflicting data between genomics and 
antibiotic resistance, which indicated that peptidoglycan exists in 
Chlamydia and the unsuccessful attempts in detection and purification of 
chlamydial peptidoglycan components led to the so-called “chlamydial 
anomaly” (Chopra et al., 1998). However, recent advances in mass 
spectrometry and in new cell-wall labeling methods enabled the 
structural characterization of peptidoglycan components from C. 
trachomatis, and to solve a 50 year mystery (Liechti et al., 2014; 
Packiam et al., 2015). 
 
1.1.6 Tissue culture and animal models 
As Chlamydia organisms cannot grow on conventional bacteriological 
medium, tissue culture models have been instrumental to study the 
biology of Chlamydia. Cultured cell lines allowed researchers to isolate, 





made possible advances in the chlamydial biology through further 
proteomic, microscopy and other biochemical experiments (Scidmore, 
2005). 
Animal models are indispensable to study bacterial infections. The most 
commonly used animal models to study female genital tract infections 
with Chlamydia are the mouse, the guinea pig, the pig, nonhuman 
primate models, and to a less extent, the rat and the rabbit (De Clercq et 
al., 2013; Neuendorf et al., 2015). The mouse is used mainly with C. 
trachomatis and C. muridarum, the pig and nonhuman primates are 
mainly used with C. trachomatis, and the guinea pig is used with C. 
caviae. With these models it is possible to mimic several aspects of the 
chlamydial infection, pathogenesis, immunity and treatment, such as the 
specific tissue tropism, sexual transmission, disease manifestations, and 
vaccine development (De Clercq et al., 2013; Neuendorf et al., 2015). 
 
1.1.7 Antimicrobial resistance 
Resistance to antimicrobials in Chlamydia remains rare. Chlamydial 
organisms are susceptible to most common antimicrobials; however, in 
vitro tests of antimicrobial susceptibility are challenging because the 
results are variable, and depend on the cell line used and at which time 
the antimicrobial is added after infection (Knittler et al., 2014; Kong and 
Hocking, 2015). Therapeutic failures have been attributed to events of 
heterotypic resistance, where a small proportion of resistant organisms 
have an advantage over a mostly susceptible population (Somani et al., 
2000). This is in agreement with reports that demonstrate that 
Chlamydia easily and rapidly develop resistance when bacteria are 
continually exposed to antimicrobials in vitro (Binet and Maurelli, 2005; 
DeMars et al., 2007). Due to the characteristic intracellular environment 





antimicrobial resistance genes from other organisms is limited. Instead, 
the acquisition of antimicrobial resistance in Chlamydia occurs mainly 
through point mutations that result in the overexpression or alteration of 
the inhibitory target (Binet and Maurelli, 2005). 
 
1.1.8 Vaccine development 
The development of vaccines is of great importance due to the 
increasing rates of mainly asymptomatic C. trachomatis infections and 
the adverse long-term consequences resulting from these infections. 
However, the lack of knowledge of the genital tract and of the protective 
immune responses triggered by Chlamydia prevents further progress. A 
vaccine against ovine abortions caused by C. abortus was already 
implemented with success and a vaccine currently under development to 
control chlamydial infections in the koala is showing promising results, 
indicating that vaccination against C. trachomatis is also possible in 
humans (Polkinghorne et al., 2013). Several attempts for the 
development of a human vaccine have been made but the results were 
ambiguous. In most cases, there were reports of enhanced disease after 
immunization (Stary et al., 2015). Recently, preliminary experiments 
performed on humanized mice with a vaccine made of a conjugation of 
nanoparticles with UV light-inactivated C. trachomatis showed that the 
immune response generated by this type of vaccine elicited protection in 







1.2 Chlamydia trachomatis 
1.2.1 C. trachomatis strains and infectious diseases 
C. trachomatis strains are divided in two biovars: trachoma and 
lymphogranuloma venereum (LGV) (Schachter, 1999). Differential 
immunoreactivity of the major outer membrane protein (MOMP) of C. 
trachomatis, or genotyping by PCR and sequencing of ompA (the gene 
encoding MOMP), allows the classification of the strains in 15 major 
serovars (A-L) (Schachter, 1999). The trachoma biovar comprises 
strains that mainly cause localized infections of the epithelial surface of 
the conjunctiva (serovars A-C) and genital mucosa (serovars D-K). 
Infection of conjunctival epithelial cells lead to conjunctivitis, with severe 
inflammation and scarring of the conjunctiva, ultimately resulting in 
trachoma, the most frequent cause of preventable blindness (Wright et 
al., 2007). Trachoma is endemic in 51 countries and is responsible for 
the visual impairment of about 2.2 million people, of whom 1.2 million 
are irreversibly blind (WHO, 2014). Infection of genital epithelial cells can 
progress to pelvic inflammatory disease in women, and urethritis in men. 
As most of these genital infections are asymptomatic, there is a high 
probability for the development of salpingitis and epididymitis, and, 
especially in women, tubal factor infertility and ectopic pregnancy 
(Bébéar and de Barbeyrac, 2009). The rate of cases of C. trachomatis 
sexually transmitted diseases reported to the ECDC in Europe in 2012 
was 184 per 100000 population (ECDC, 2014), and the WHO reported 
for the USA in 2008 more that 100 million new cases of C. trachomatis 
sexually transmitted infections (WHO, 2008). Strains of the serovars L1-
L3 are responsible for a more invasive urogenital disease, LGV, due to 
the ability of these strains to infect macrophages and spread to regional 
lymph nodes (Bébéar and de Barbeyrac, 2009). In 2012, 830 cases of 
LGV were reported in eight countries of Europe, a number that has been 





screening program for C. trachomatis infections, but since 2014 it is 
mandatory to report cases of infection with this bacterium. Still, a study 
based on data collected in one diagnostics laboratory reported 2817 
(7.7%) positive C. trachomatis cases among 36621 individuals tested 
(Dinis et al., 2015). 
As mentioned above in section 1.1.7, antimicrobial resistance in C. 
trachomatis rarely occurs, and once diagnosed, infections are easily and 
effectively treated with regular doses of azithromycin or doxycycline. 
However, once a severe infection and pathology are established, 
treatment is often less effective and there is a risk of serious 
reproductive damage, including a link with cervical cancer (Kong and 
Hocking, 2015). The common etiological agent of cervical cancer is the 
human papilloma virus (HPV); however, early epidemiological studies 
have shown that sexual activity is also a risk factor for cervical 
carcinoma (Koskela et al., 2000; Dahlström et al., 2011). This led to the 
suggestion that sexually transmitted diseases, particularly exposure to 
C. trachomatis, could contribute to the development of identical 
pathologies. In vitro studies demonstrated that infection with C. 
trachomatis leads to defects in centrosome dynamics and in DNA repair 
mechanisms that result in abnormal chromosomal segregation to 
daughter cells during cell division (Grieshaber et al., 2006; Chumduri et 
al., 2013). Chromosome instability is known to be one of the main 
factors involved in tumor development, and therefore it is possible that 
C. trachomatis genital infections could contribute to cervical cancer 
(Weitzman and Weitzman, 2014; Nam et al., 2015). 
 
1.2.2 Tissue tropism and type of infection 
The rapid expansion in the number of available sequenced genomes of 





infection (invasive or non-invasive) and tissue tropism (eyes, genitals, 
and lymph nodes) observed with C. trachomatis strains. Interestingly, 
analyses of more than 50 sequenced genomes showed that ocular 
(serovars A-C), urogenital (serovars D-K), and LGV (serovars L1-L3) 
strains exhibit >98% identity and a high degree of synteny (Stephens et 
al., 1998; Carlson et al., 2005; Thomson et al., 2008; Seth-Smith et al., 
2009; Jeffrey et al., 2010; Unemo et al., 2010; Somboonna et al., 2011; 
Harris et al., 2012).  
The differences in type of infection and tissue tropism among C. 
trachomatis strains must reside in the little dissimilarity in their genetic 
background, and there are a number of C. trachomatis genes that have 
been associated with this: 
 The clearer example is the distinction between ocular strains 
from urogenital and LGV strains through specific mutations in the 
tryptophan (trpBA) operon (Allan C. Shaw et al., 2000; Fehlner-
Gardiner et al., 2002; Caldwell et al., 2003). In ocular strains, 
polymorphisms in the tryptophan synthase gene B (trpB) result in 
a nonfunctional protein. In urogenital and LGV strains there is a 
strong selective pressure to maintain a functional tryptophan 
synthase, as this mechanism is necessary for the bacteria to 
produce tryptophan in response to the host induction of 
tryptophan-degrading enzymes (Allan C. Shaw et al., 2000; 
Fehlner-Gardiner et al., 2002; Caldwell et al., 2003). 
 Another genetic difference that can explain the tissue tropism of 
C. trachomatis strains is the variation in the Chlamydia cytotoxin 
gene that is located in the PZ (Carlson et al., 2004). This gene 
has extensive mutations and deletions among the different 
serovars that clearly distinguish the three groups of strains. The 
urogenital strains all encode an intact N-terminal-encoding toxin 





glycosyltransferase domains, the LGV strains lack both of these 
domains, while the ocular strains only encode the UDP-glucose 
binding domain (Carlson et al., 2004). It has been hypothesized 
that the N-terminal region of the cytotoxin could play a key role in 
allowing C. trachomatis to colonize the genital tract. 
 In the PZ there is also a group of genes encoding for proteins 
with identity to the phospholipase D (PLD), that might be involved 
in the acquisition and processing of host lipids (Nelson et al., 
2006). In the genomes of C. trachomatis there is an 
accumulation of multiple deletions and frameshift mutations in 
these genes that may be associated with the strain-specific 
features of infection (Nelson et al., 2006). 
 Polymorphic membrane proteins (Pmps) participate in adhesion 
of the bacterium to the host, and also present characteristics that 
might contribute to tissue tropism (Becker and Hegemann, 2014; 
Kari et al., 2014). Phylogenetic reconstructions based in the 
amino acid sequence of Pmps showed a separation of the strains 
into groups with similar disease properties (Gomes et al., 2006). 
 Tarp is a protein delivered by Chlamydia into host cells that 
participates in the invasion process by inducing actin 
polymerization at the site of bacterial entry (Jewett et al., 2010). 
Nucleotide and amino acid sequence analysis of the gene 
encoding Tarp and of Tarp itself, respectively, indicated an 
evolutionary relationship with disease phenotype, separating 
LGV and ocular strains from urogenital strains. Tarp proteins 
from LGV strains contain higher number of tyrosine-rich repeat 
regions and fewer predicted actin binding domains, in contrast 
with ocular strains that contain more actin binding domains and 





It has also been suggested that the plasmid plays a key role in tissue 
tropism. A transcriptomics study found for the majority of the plasmid 
ORFs lower expression profiles for ocular strains (Ferreira et al., 2013). 
Further genome comparisons and single nucleotide polymorphism 
analyses highlighted additional spots putatively involved in the type of 
infection and tissue tropism (Brunelle et al., 2004; Nunes et al., 2008; 
Thomson et al., 2008; Joseph et al., 2011; Borges et al., 2012; Lutter et 
al., 2012). For example, LGV strains appear to have lost some metabolic 







1.3 Chlamydia developmental cycle 
1.3.1 Elementary bodies and reticulate bodies 
All Chlamydiae have a unique infectious cycle, different from other 
intracellular bacteria in that growth is associated with a biphasic 
developmental cycle, alternating between two morphologically distinct 
forms: the elementary body (EB) and the reticulate body (RB) (Figure 
1.1) (AbdelRahman and Belland, 2005). EBs are the infectious and non-
replicative form, and are responsible for the dissemination of the 
infection. They are relatively small (approximately 0.3 μm of diameter) 
and have a highly cross-linked outer membrane that confers protection 
in the outside environment. In contact with a host cell, EBs present a 
polarized architecture, with a highly compact DNA material on one side 
and an array of type III secretion systems on the other side, oriented to 
the host cell (AbdelRahman and Belland, 2005; Nans et al., 2014). Upon 
infection, EBs are internalized in a membrane-bound vacuole, where 
they start a primary differentiation into RBs (Figure 1.1), the non-
infectious and replicative form, which are larger than EBs (approximately 
1 μm of diameter) and have a high metabolic activity (AbdelRahman and 
Belland, 2005). After repeated cycles of bacterial binary fission, the 
vacuole enlarges and becomes filled with progeny. Strictly speaking, it is 
the larger vacuole that corresponds to an “inclusion”, but this term is 
normally used to refer to chlamydial vacuole since its formation soon 
after bacterial invasion. At a certain stage of Chlamydia cell division, a 
second differentiation of the bacteria occurs, back to EBs (Figure 1.1). At 
the end of the cycle, EBs are released, either by host cell lysis or 








Figure 1.1 – Representation of the Chlamydia biphasic developmental cycle. 
Chlamydial organisms cycle between two different morphological forms: the EBs (light 
grey), the infectious form, and the RBs (dark grey), the replicative form. EBs invade the 
host cell and localize within a membrane-bound vacuole, known as inclusion. Within this 
vacuole, EBs differentiate into RBs. The inclusion then migrates towards the centrosome 
(the main microtubule organizing center [MTOC]), where RBs start to replicate. As the 
inclusion expands with progeny, RBs re-differentiate back to EBs that will exit the cell by 
extrusion or cell lysis. Chlamydia use a type III secretion system (T3SS) to deliver 
effector proteins into host cells (see section 1.4). These effectors manipulate host 
processes at different stages of the developmental cycle. Some effector proteins, known 
as inclusion membrane (Inc) proteins, localize at the inclusion membrane. Adapted from 






Under certain conditions of stress, the developmental cycle is deviated 
from the normal route, resulting in the appearance of an aberrant form 
(often called AB) and the bacteria remain in a state of persistence 
(AbdelRahman and Belland, 2005; Schoborg, 2011). Persistence in 
Chlamydia is defined as an in vitro reversible condition in which the 
bacteria remain in a viable but culture-negative state. The ABs are 
normally described as enlarged RBs that neither differentiate back to 
EBs nor replicate normally. It is unknown, however, whether this 
persistent form occurs also in vivo (Schoborg, 2011). 
 
1.3.2 Regulation of the chlamydial developmental cycle 
The precise mechanisms that regulate the transition between Chlamydia 
EBs and RBs unknown. Soon after internalization, Chlamydia start using 
its internal machinery for protein synthesis, and this event is consistent 
in time with the first differentiation step. Then, another stage of protein 
synthesis is initiated to allow bacterial growth and division. The last 
period of protein synthesis is triggered at the same time that RBs re-
differentiate back to EBs. The developmental cycle takes about 48 to 72 
h, depending on the species (E. I. Shaw et al., 2000; Vandahl et al., 
2001; Belland et al., 2003; Nicholson et al., 2003; Skipp et al., 2005; 
Saka et al., 2011; Omsland et al., 2013). Some authors suggested the 
presence of a quality control system that regulates the chlamydial 
transition from RBs to EBs. In the presence of some inhibitors, RBs 
seem to fail the expression of selective late-cycle genes and the 
differentiation to EBs is interrupted (Nguyen et al., 2011). The highly 
condensed DNA exhibited by EBs has been proposed to confer a 
complete transcriptional shutdown. However, recent studies indicated 
that despite the compact chromosome, EBs are still able to perform 





It is unknown how specific genes are selectively transcribed at each 
stage of the developmental cycle. Three σ subunits of RNA polymerase 
have been identified in Chlamydia: σ66 is the homolog of Escherichia coli 
σ70, and two alternative σ subunits show sequence identity to E. coli σ54 
and Bacillus subtilis σ28. Early- (2 to 8 h), mid- (12 to 20 h), and late-
cycle (30 to 48 h) chlamydial genes are mostly transcribed by the σ66 
RNA polymerase (Tan et al., 1998; Mathews and Timms, 2006; Hefty 
and Stephens, 2007; Mallios et al., 2009; Case et al., 2010). This implies 
that there must be specific mechanisms that differentially regulate the 
temporal classes of gene expression. Expression of mid-cycle genes 
has been proposed to be regulated by differential levels of DNA 
supercoiling in mid-cycle (Niehus et al., 2008; Cheng and Tan, 2012). 
Expression of late chlamydial genes has been shown to be mediated 
also by the σ28 (Mathews and Timms, 2006). The chlamydial protein 
early upstream ORF (EUO) has been proposed as a repressor of late 
genes, as it is encoded in all Chlamydia genomes, is expressed early in 
the cycle, and contains a DNA-binding domain described to selectively 
bind to promoter regions of known chlamydial late genes (Rosario and 
Tan, 2012). The chlamydial protein general regulator of genes A (GrgA) 
was also described to be a DNA-binding protein that can stimulate 
transcription from a range of σ66-dependent promoters, suggesting its 
role as a regulator of σ66-dependent transcription in Chlamydia (Bao et 
al., 2012). 
 
1.3.3 Manipulation of host cell processes at different stages of the 
chlamydial developmental cycle 
In all stages of the developmental cycle, Chlamydia release effector 
proteins into the host cell cytosol by a type III secretion system, a 
common virulence mechanism used by Gram-negative bacteria 





responsible for the manipulation of host cell processes to the benefit of 
the bacteria (Mota and Cornelis, 2005; Galán et al., 2014). 
 
1.3.3.1 Adhesion 
Infection by Chlamydia primary starts with adhesion of EBs to the host 
cell plasma membrane. This process is mediated by electrostatic 
interactions of the bacteria and binding to receptors. Different bacterial 
adhesins have been proposed, such as MOMP and Pmps (Kari et al., 
2014; Nans et al., 2015). Pmps were described to mediate adhesion of 
the bacteria to mammalian cells in vitro and to be involved in the 
adaptation of the different chlamydial species to their specific niches 
(Mölleken et al., 2010; Becker and Hegemann, 2014; Kari et al., 2014). 
On the host side, among others, heparan sulfate containing 
glycosaminoglycans, mannose receptors, and Ephrin A2 have been 
implicated in the adhesion process (Kim et al., 2011; Rosmarin et al., 
2012; Karunakaran et al., 2015; Nans et al., 2015; Subbarayal et al., 
2015). 
 
1.3.3.2  Invasion 
The process of Chlamydia entry into host cells is accomplished by 
bacterial-mediated endocytosis, in which the host cell plasma membrane 
envelops around the EB, tightly enclosing it until the vacuole is formed 
(Nans et al., 2015). This process requires delivery of bacterial proteins 
into host cells (Carabeo et al., 2002; Chin et al., 2012). Tarp and the 
cytotoxin were described to be delivered immediately after adhesion and 
to participate directly in the recruitment and remodeling of actin to the 
sites of attachment (Belland et al., 2001; Carabeo et al., 2007; Lane et 
al., 2008; Jewett et al., 2010; Thalmann et al., 2010; Bothe et al., 2015). 





and affect the formation of host-cell actin stress fibers (Hower et al., 
2009; Bullock et al., 2012). Another protein delivered into host cells by 
C. trachomatis is the translocated early phosphoprotein (TepP), which 
was reported to act in the entry process by modulating innate immune 
responses (Chen et al., 2014). A C. caviae and C. pneumoniae specific 
protein, ChlaOTU, was described to be involved in the clearance of 
ubiquitin at the invasion sites (Furtado et al., 2013).  
 
1.3.3.3 The inclusion 
Although Chlamydia remain enclosed in the inclusion throughout the 
entire developmental cycle, they are still able to continually manipulate 
the host and subvert host pathways to maintain an environment not only 
suitable for replication and protection from the host but also to scavenge 
essential nutrients from the host for efficient metabolic activity (Valdivia, 
2008; Betts et al., 2009; Kumar and Valdivia, 2009). The inclusion 
membrane appears to be permeable to small solutes but it is 
impermeable to components >0.5 kDa. The inclusion membrane is also 
extensively decorated with inclusion membrane (Inc) proteins, which are 
thought to play a major role in mediating the cross-talk between the 
pathogen and the host (Rockey et al., 2002; Mital et al., 2010; Dehoux et 
al., 2011). 
Chlamydia typically replicate within a single large inclusion, containing 
thousands of bacteria. Even when a cell is infected with more than one 
individual bacterium, the inclusions fuse into a single vacuole. However, 
this is not observed for all Chlamydia species. In C. caviae for example, 
infection leads to multiple inclusions that do not fuse (Hackstadt et al., 
1999; Richards et al., 2013). The fusion of the inclusions was 





1999; Jahn and Scheller, 2006; Delevoye et al., 2008; Ronzone and 
Paumet, 2013; Ronzone et al., 2014). 
 
1.3.3.4 Interference with host vesicular trafficking pathways 
Immediately after internalization, one of the first events promoted by 
Chlamydia is the subversion of the host endocytic pathway (Fields and 
Hackstadt, 2002; Scidmore et al., 2003). This enables the bacteria to 
create a unique compartment, devoid of the majority of the markers for 
early and late endosomes, and lysosomes, thus escaping from one of 
the major host defense mechanisms (Fields and Hackstadt, 2002; 
Scidmore et al., 2003). Another essential step for the inclusion 
biogenesis is the intersection of a different set of vesicles from those 
involved in lysosomal fusion. Within few hours post-infection, Chlamydia 
intercept the exocytic pathway and acquire endogenous synthesized 
sphingomyelin, in transit from the Golgi to the plasma membrane 
(Hackstadt et al., 1996; Scidmore et al., 1996; Elwell et al., 2011). 
Infection with Chlamydia induce Golgi fragmentation and formation of 
Golgi ministacks to enhance lipid acquisition and ensure bacterial 
replication (Heuer et al., 2009). These organisms also hijack the COG 
complex to redirect the population of Golgi-derived retrograde vesicles to 
the inclusion (Pokrovskaya et al., 2012). In addition, Chlamydia 
sequester multivesicular bodies and lipid droplets as another source of 
lipids and cholesterol (Beatty, 2006; Kumar et al., 2006; Beatty, 2008; 
Cocchiaro et al., 2008; Saka et al., 2015). The retromer plays a central 
role in the retrieval of several different cargo proteins from the 
endosome to the TGN. During infection, Chlamydia affect the function of 
the retromer by interacting with sorting nexins (SNXs) (Kabeiseman et 





benefic for the bacteria since depletion of retromer components 
enhances progeny production (Mirrashidi et al., 2015). 
The eukaryotic small GTPase Rab family of proteins regulates host 
intracellular membrane trafficking processes including vesicle budding, 
tethering, and fusion. There are several studies demonstrating the 
recruitment of some of these proteins to the inclusion membrane, 
suggesting a direct implication in the regulation of the trafficking or 
fusogenic properties of the inclusion (Rzomp et al., 2003; Rzomp et al., 
2006; Cortes et al., 2007; Capmany and Damiani, 2010; Moorhead et 
al., 2010; Leiva et al., 2013; Sherwood and Roy, 2013). 
 
1.3.3.5 Acquisition of nutrients and lipids by non-vesicular 
pathways 
During the developmental cycle, Chlamydia need to acquire many 
biochemical precursors from the host cell for its growth (Stephens et al., 
1998). Chlamydia accumulate sugars in the form of glycogen in the 
inclusion lumen. This process is dependent on the plasmid, since 
plasmidless strains do not exhibit this phenotype (Carlson et al., 2008; 
Wang et al., 2011). Chlamydia are also able to transport host-derived 
glycerophospholipids into the inclusion lumen to modify and incorporate 
them in the chlamydial membrane (Wylie et al., 1997). Peroxisomes are 
imported into the inclusion and its enzymatic capacity is used for the 
synthesis of bacterial-specific phospholipids (Boncompain et al., 2014). 
The association between the inclusion and the endoplasmic reticulum 
(ER), and the formation of ER-inclusion membrane contact sites (MCSs) 
has been extensively studied (Giles and Wyrick, 2008; Derré et al., 
2011; Dumoux et al., 2012). Several proteins were described to be 
enriched at MCSs, including the chlamydial inclusion membrane protein 





interaction molecule 1 (STIM1), sphingomyelin synthase 2 (SMS2),  
vesicle-associated membrane protein-associated protein A (VAPA), and 
VAPB (Elwell et al., 2011; Agaisse and Derré, 2014; Agaisse and Derré, 
2015). It was suggested that MCSs could represent portals for the 
selective Influx of cellular material into the inclusion such as lipids and 
sphingomyelin. The interaction with the ER also appears to induce the 
ER stress response, but this response is quickly dampened by 
Chlamydia to promote host cell survival (Shima et al., 2015). 
 
1.3.3.6 Migration to the centrosomal region 
Chlamydia then hijack the host minus-end-directed microtubule motor 
complex dynein to migrate the inclusion along the microtubules towards 
the centrosome, the major microtubule organizing center (MTOC) in 
animal cells (Grieshaber et al., 2003; Richards et al., 2013). The Inc 
protein CT850 was described to be necessary for a proper localization of 
the inclusion at the centrosome (Mital et al., 2015). The association 
between the inclusion and the centrosome is maintained throughout the 
entire developmental cycle and has several consequences for the host 
cell (Grieshaber et al., 2003; Grieshaber et al., 2006). A loss of control of 
the centrosome duplication pathway, a block in host cell cytokinesis, and 
an impairment of the DNA damage repair mechanism leads to amplified 
centrosome numbers, increased accumulation of host cell nuclei within 
cells, and the subsequent formation of multipolar spindles that unevenly 
distribute chromosomes during cell division (Greene and Zhong, 2003; 
Grieshaber et al., 2006; Alzhanov et al., 2009; Johnson et al., 2009; 
Knowlton et al., 2011; Chumduri et al., 2013; Brown et al., 2014; 






1.3.3.7 Subversion of the host cytoskeleton 
In addition to modifications in the host actin cytoskeleton that are 
involved in bacterial uptake, Chlamydia need to modify the inclusion 
membrane and alter the cytoskeletal structure of the host cell to allow for 
the expansion of the inclusion caused by the increasing numbers of 
bacteria generated during replication (Carabeo et al., 2007; Kumar and 
Valdivia, 2008; Engström et al., 2015). During infection, the inclusion is 
encased in a network of host cytoskeletal structures composed of F-
actin and intermediate filaments. Disruption of these structures leads to 
a loss of inclusion shape and leakage of inclusion contents into the host 
cytoplasm, indicating that this structural scaffold is important for 
inclusion integrity (Kumar and Valdivia, 2008; Kokes et al., 2015). The 
chlamydial inclusion protein acting on microtubules (IPAM; CT223) and 
the inclusion membrane protein for actin assembly (InaC; CT813) were 
described to be important for the assembly of these superstructures that 
are crucial to maintain the inclusion shape and vital for the chlamydial 
developmental cycle (Dumoux et al., 2015; Kokes et al., 2015). 
 
1.3.3.8 Immune detection of Chlamydia 
Chlamydia infections are detected by the host immune system through 
the recognition of chlamydial LPS and other pathogen-associated 
molecular patterns (PAMPs), via TLR, MAPK/ERK, and NOD1 signaling 
pathways (Bastidas et al., 2013). The NF-κB signaling pathway is 
immediately shutdown by reversing IκBα ubiquitination through the 
activity of secreted chlamydial proteins and through the proteolysis of 
the p65/RelA subunit of NF-κB (Misaghi et al., 2006; Lad, Li, et al., 2007; 
Lad, Yang, et al., 2007; Bastidas et al., 2013). In addition, Chlamydia 
inhibit apoptosis in the host cell by degrading proteins that control 





protein synthesis and upregulating anti-apoptotic proteins (Sharma and 
Rudel, 2009; Sharma et al., 2011; Flores and Zhong, 2015). 
 
1.3.3.9 Host cell egress 
To complete the developmental cycle and ensure proper dissemination 
and transmission, Chlamydia must exit the host cell. Currently there are 
two proposed mechanisms: cellular lysis and extrusion (Hybiske and 
Stephens, 2007; Traven and Naderer, 2014). Lysis is a destructive mode 
of release, consisting of the sequential rupture of the inclusion and 
cellular membranes by the action of cysteine proteases, leading to host 
cell death. In contrast, extrusion involves a process in which a portion of 
the chlamydial inclusion is released, leaving the original cell and the 
residual inclusion intact (Hybiske and Stephens, 2007). Chlamydia 
encode a protein containing a MACPF domain, used by different 
parasites to facilitate the egress from cells (Kadota et al., 2004; Rosado 
et al., 2008; Kafsack et al., 2009; Taylor et al., 2010). Chlamydia also 
recruit elements of the myosin phosphatase pathway to favor the 






1.4 Type III secretion in Chlamydia 
1.4.1 Bacterial protein secretion systems 
Bacteria have evolved an array of specialized nanostructures that 
secrete a wide range of proteins, which participate in several processes 
of bacterial adaptation and pathogenicity. In Gram-negative bacteria, 
these protein transport systems are mostly classified as type I secretion 
system (T1SS), T2SS, T3SS, T4SS, T5SS and T6SS (Costa et al., 
2015). The T1, T2, and T5SSs secrete proteins across the two bacterial 
membranes into the extracellular milieu. The T3, T4, and T6SS are more 
specialized because they can function as injection devices enabling the 
delivery of effector proteins from the bacterial cytosol into a eukaryotic or 
prokaryotic host cell. At a mechanistic level, protein secretion by the T2 
and T5SS is a two-step process involving a first translocation step 
across the inner bacterial membrane that is mediated by the general 
secretory pathway (Sec system). In contrast, protein transport by the T1, 
T3, T4, and T6SS occurs in one-step and is Sec-independent (Costa et 
al., 2015). 
The T1SSs are closely related to multidrug efflux pumps and secrete 
ions, drugs, and toxins. The T2SS secretes mainly hydrolyzing enzymes 
and toxins to the extracellular milieu. The T4SSs are the most ubiquitous 
secretion systems in nature, being found in both Gram-negative and 
Gram-positive bacteria, and in some archaea; their most common role is 
transfer of DNA between bacteria (conjugation) but they are also 
required to support the life-cycle of many intracellular pathogens through 
the delivery of effector proteins into eukaryotic host cells. The T5SS is 
unique in that the substrate, normally a virulence factor, contains a 
“auto-transporter” domain that forms a pore in the bacterial outer 
membrane and drives translocation of a “passenger” domain within the 





released in the extracellular milieu or remain attached to the auto-
transporter domain. Because of this, the T5SS is normally known as the 
auto-transporter system. The T6SSs are known to translocate effector 
proteins into both prokaryotic and eukaryotic cells but their major role 
appears to be in bacterial competition, by secreting toxins directly into a 
neighbor competing bacterium (Costa et al., 2015). 
More recently, secretion of curli by Gram-negative bacteria has been 
termed type VIII secretion (Cao et al., 2014), and proteins involved in 
gliding motility of Bacteriodetes have been described to be secreted by 
type IX secretion (McBride and Nakane, 2015). Furthermore, in Gram-
positive bacteria (actinobacteria and firmicutes), including pathogens 
such as Mycobacterium tuberculosis, Staphylococcus aureus or Bacillus 
anthracis, possess genes encoding a protein secretion machinery that 
has been termed type VII secretion. 
 
1.4.2 Type III secretion systems 
Type III secretion systems (T3SSs) are one of the most complex protein 
transport systems used by Gram-negative bacteria and have been most 
intensively studied in pathogenic bacteria such as enteropathogenic and 
enterohemorrhagic Escherichia coli (EPEC and EHEC), Pseudomonas 
aeruginosa, Salmonella spp., Shigella spp, and Yersinia spp. (Mota and 
Cornelis, 2005; Galán et al., 2014). The assembly of the type III 
secretion (T3S) apparatus (the injectisome) requires approximately 25 
proteins and is composed of a base structure embedded in the bacterial 
envelope and a needle-like extension that protrudes from the bacterial 
surface (Figure 1.2). The injectisome is connected to host cell 
membranes by proteins that form the translocon pore complex (Figure 
1.2) (Mota and Cornelis, 2005; Galán et al., 2014). The T3SS works in 





select substrates in sequential order, and to deliver them directly across 
the bacterial envelope into the cytosol of eukaryotic cells (Galán et al., 
2014). 
While many of the proteins involved in the assembly of the injectisome 
are well conserved among the different T3SSs, the primary structure of 
T3S effectors usually do not show significant identity to proteins found in 
other organisms and also do not show significant homology among each 
other. Furthermore, the lack of a clear secretion signal distinguishes 
T3SSs from other protein secretion systems where an obvious signal is 
evident on the basis of the protein sequence, structure or special 
properties. Nevertheless, experiments done using hybrid proteins 
containing parts of Yersinia enterocolitica Yop effectors fused to reporter 
proteins led to the discovery that the secretion recognition domain 
normally lies within the first 30 amino acids of the T3S substrate 
(Michiels and Cornelis, 1991; Sory et al., 1995). Even though, 
comparison of the different N-termini sequences of these effectors did 
not reveal sequence similarity, suggesting that the secretion signal could 
be conformational. Although for a while some controversy existed 
regarding whether the T3S signal was encoded in the peptide sequence 
or on the messenger RNA sequence, now it is generally believed that 
the secretion signal resides in the first 30 amino acids of the effector 
(Anderson and Schneewind, 1997; Lloyd et al., 2001; Lloyd et al., 2002; 
Page and Parsot, 2002; Galán et al., 2014). In addition, bioinformatics 
analyses of the amino acid composition and secondary structure of the 
first 100 amino acids of the N-termini of known T3S substrates from 
Salmonella, Yersinia, E. coli and Pseudomonas (animal and plant 
pathogens) suggested the existence of a conserved, though highly 
variable, secretion signal in that region (Arnold et al., 2009; Löwer and 
Schneider, 2009; Samudrala et al., 2009; Hovis et al., 2013; Wang et al., 





amino acids (such as serine, proline and threonine) and depletion of 
leucine. The data accumulated allowed also the development of T3S 
signal prediction tools and to create lists of novel putative T3S 
substrates from several bacterial genomes, including Chlamydia 
organisms. However, most of these predictions remain to be tested. 
Despite the illusive nature of the T3S signal, one important characteristic 
is that the signal is universal and T3S substrates from one system can 
be recognized and secreted by other T3SSs (Anderson et al., 1999). 
 
1.4.3 The chlamydial T3S apparatus 
The first evidence of the existence of a structure similar to the T3SS in 
Chlamydia was probably given by Matsumoto and colleagues in 1973, 
about 20 years before the first injectisomes from Salmonella were seen 
by electron microscopy (Matsumoto, 1973; Kubori, 1998). At that time 
electron micrographs of EBs and RBs from C. psittaci revealed 
structures that were called “rosettes”, which were very similar to the now 
known structure of the injectisome. Very recent electron microscopy 
studies complemented those observations and showed a significant 
structural similarity with the T3SS apparatus of Yersinia, confirming the 
presence of T3SS in Chlamydia (Dumoux et al., 2014; Nans et al., 
2014). However, early in 1998, with the first available chlamydial 
genome, it had been already hypothesized that Chlamydia could 
possess a T3SS (Stephens et al., 1998). Nevertheless, while in the 
majority of the bacteria the genes encoding injectisome and translocon 
proteins are clustered in chromosomal pathogenicity islands or in 
plasmids, in Chlamydia, the genes were found in four distinct conserved 
genomic clusters (Peters et al., 2007). Focusing on chlamydial genes 
encoding proteins with amino acid similarity to chaperones, injectisome 
components, and a secreted protein (CopN) from other T3SSs, 





that Chlamydia have an active T3SS throughout the developmental 
cycle (Fields et al., 2003). In this work, the authors also observed that 
CopN could be secreted by the Yersinia T3S apparatus, indicating that 
chlamydial T3S substrates could be identified by using other bacteria as 
heterologous hosts. The finding of a functional T3SS was further 
confirmed by genome wide transcriptomic analyses during the 
developmental cycle and mass spectrometry studies performed in EBs 
and RBs (Vandahl et al., 2001; Belland et al., 2003; Brunelle et al., 2004; 
Skipp et al., 2005). In another study, the authors could reconstitute to 
some extent the Chlamydia T3S apparatus by generating E. coli 
expressing all genes of the chlamydial T3SS, providing a platform for 
further structural studies (Bao, Beatty, et al., 2012). Although these 
studies recognized that a T3SS is active throughout the chlamydial 
developmental cycle, it was also important to determine the importance 
of T3S during Chlamydia infection of host cells. Experiments using 
molecule inhibitors known to block T3S in other bacteria were performed 
in Chlamydia to suggest that the T3SS is essential in all stages of the 
developmental cycle, including intracellular replication and infectivity 
(Muschiol et al., 2006; Wolf et al., 2006; Muschiol et al., 2009). It was 
also demonstrated that chlamydial EBs can be induced to secrete T3S 
effectors in special inducing conditions and in the absence of host cells 







Figure 1.2 – Predicted assembly of the T3SS in Chlamydia. The T3S apparatus is a 
needle-like structure protruding from the bacterial surface that enables the translocation 
of virulence proteins (effectors) from the bacterial cytoplasm into the host cell cytosol or 
membranes. Adapted from (Peters et al., 2007; Spaeth et al., 2009). 
 
1.4.4 T3S translocators of Chlamydia 
Translocation of T3S effector proteins across a eukaryotic cell 
membrane requires a set of proteins, known as “translocators”, that are 
also T3S substrates. As described above, these proteins form a 
translocation pore, the translocon, in a host cell membrane and together 
with the injectisome needle enable the formation of a continuous 
channel between the bacteria and the target cell (Figure 1.2). Generally, 





domains and insert into the target cell membrane, and the other is a 
hydrophilic protein that forms a complex at the needle tip, possibly 
functioning as an assembly platform for the formation of the pore by the 
hydrophobic translocators (Mueller et al., 2008). 
In Chlamydia, there are two copies of each of the hydrophobic 
translocator proteins (CopB1 and CopB2, and CopD1 and CopD2), 
which might function in the formation of specific translocons in the host 
cell membrane and in the inclusion membrane (Stephens et al., 1998; 
Peters et al., 2007). Until now, it is unclear which Chlamydia protein 
might form the needle tip complex and function as the hydrophobic 
translocator. A biophysical characterization of CT584 from C. 
trachomatis suggested it could be the needle complex protein (Markham 
et al., 2009), but subsequent studies indicated that this might not be the 
case (Spaeth et al., 2009; Stone et al., 2012; Barta et al., 2013; Pais et 
al., 2013). 
 
1.4.5 T3S chaperones of Chlamydia 
The presence of specific cytoplasmic chaperones is also a hallmark of 
T3SSs. They can been divided into three classes: the ones that bind 
effectors (class I; the best studied), the pore forming translocators (class 
II), or the subunits of the injectisome (class III) (Page and Parsot, 2002; 
Feldman and Cornelis, 2003). T3S chaperones share low sequence 
similarity between each other but display a conserved three-dimensional 
structure. They bind to one or several partners, thus preventing 
premature, or incorrect, intra- or intermolecular interactions that would 
occur in the absence of the chaperone. T3S chaperones participate in 
the assembly and regulation of the injectisome and assist in the 
secretion of effectors, possibly establishing a hierarchy of secretion 





(approximately 15 kDa), have acidic pI and normally form dimers. The 
chaperone binding domain within effectors is generally localized 
downstream from the secretion signal (Page and Parsot, 2002; Feldman 
and Cornelis, 2003). 
There are already several proteins acting as T3S chaperones described 
in Chlamydia: Mcsc, Slc1, Scc1, Scc2, Scc3, Scc4, and CT584. Mcsc 
binds to and stabilizes at least Cap1 and the Inc protein CT618 (Spaeth 
et al., 2009). Slc1 was described to enhance the secretion of the T3S 
effectors Tarp, CT694, TepP and the T3S substrate CT695 (Brinkworth 
et al., 2011; Pais et al., 2013; Chen et al., 2014). Scc1 and Scc4 are the 
chaperones of CopN (Silva-Herzog et al., 2011). CT584, initially 
described as the needle tip protein (Stone et al., 2012), as discussed 
above, was shown to bind, stabilize and promote secretion of the 
putative T3S substrate CT082 (Pais et al., 2013), suggesting it could 
function as a T3S chaperone. It is possible that CT584 might have 
additional functions, which is not unusual for T3S chaperones. Finally, 
Scc2 and Scc3 are likely class II chaperones possibly promoting 
secretion of Chlamydia translocator proteins (CopB1 and CopB2) (Fields 
et al., 2005). 
 
1.4.6 T3S effectors of Chlamydia 
It is predicted that approximately 5–10% of the Chlamydia genomes 
encode for T3S effectors (Arnold et al., 2009; Samudrala et al., 2009). 
Before the discovery of genetic methodologies to manipulate Chlamydia, 
chlamydial effector proteins were mainly searched for by: 
 Constructing Saccharomyces cerevisiae strains expressing 
Chlamydia-specific genes in order to identify chlamydial proteins 
that impair various yeast cellular functions or that display tropism 





 Exploiting the universality of the T3S signal and using 
Salmonella, Shigella, or Yersinia as heterologous host bacteria 
carrying T3SSs (Fields and Hackstadt, 2000; Clifton et al., 2004; 
Ho and Starnbach, 2005; Subtil et al., 2005; Chellas-Géry et al., 
2007; Hower et al., 2009; Pennini et al., 2010; Dehoux et al., 
2011; Muschiol et al., 2011; Furtado et al., 2013; Hovis et al., 
2013; Pais et al., 2013); 
 Using T3S signal prediction tools to identify novel putative T3S 
substrates (Arnold et al., 2009; Löwer and Schneider, 2009; 
Samudrala et al., 2009; Hovis et al., 2013; Wang et al., 2013); 
 Using specific antibodies enabling the detection of translocation 
into host cells of chlamydial proteins predicted to be effectors (Li, 
Chaoqun Chen, et al., 2008; Gong et al., 2011; Lei et al., 2011); 
 Using T3S molecule inhibitors to confirm secretion of an effector 
by the T3SS (Hobolt-Pedersen et al., 2009; Gong et al., 2011); 
 Using mass spectrometry analyses to identify the battery of 
proteins secreted into the host cytosol during infection (Kleba 
and Stephens, 2008); 
 Using in vitro biochemical assays directed to test specific 
properties of predicted chlamydial effectors (Misaghi et al., 2006; 
Le Negrate et al., 2008). 
 
The chlamydial T3S effectors discovered to date, specifically the ones 
that are known to be translocated across the inclusion membrane in 
infected cells and/or are known to interfere with host cell functions, are 







Table 1.1 – List of chlamydial T3S effectors known to be translocated across the 
inclusion membrane and/or known to interfere with host cell functions. 











? ? Chlamydia (Fields and 
Hackstadt, 2000) 
CT456/Tarp Cytosol Actin Polymerizes actin at 
the site of entry 
Chlamydia (Clifton et al., 
2004; Jewett et 




? Stimulates a CD8+ 
T cell response 
Chlamydia (Fling et al., 2001) 
CT620 Nuclei ? ? Chlamydia (Muschiol et al., 
2011) 
CT621 Nuclei ? ? Chlamydia (Hobolt-Pedersen 
et al., 2009; 
Muschiol et al., 
2011) 
CT622 Cytosol ? ? Chlamydia (Gong et al., 
2011) 




(Hower et al., 
2009; Bullock et 
al., 2012) 
CT695 Cytosol ? ? Chlamydia (Mueller and 
Fields, 2015) 
CT711 Nuclei ? ? Chlamydia (Muschiol et al., 
2011) 
CT737/NUE Nuclei Histones Acts as histone 
methyltransferase 
Chlamydia (Pennini et al., 
2010) 
CT847 ? GCIP Interferes with cell 
cycle checkpoints 
Chlamydia (Chellas-Géry et 
al., 2007) 
CT875/TepP Cytosol ? Acts in signaling 
pathways of 
regulation of innate 
immune responses 
C. trachomatis (Chen et al., 
2014) 
CPn0483/ChlaOTU ? Ubiquitin 
NDP52 
Acts in the 
clearance of 
ubiquitin at the 
invasion sites 
Chlamydia 
except             
C. trachomatis 
and                
C. muridarum 








Alters the nuclear 
envelope function 
C. psittaci (Mojica et al., 
2015) 
Inc CT101 Inclusion 
membrane 
? Co-localizes with 
proteins of the Src 
family 
Chlamydia 
except             
C. muridarum 



















proteins to the 
inclusion 
Chlamydia 
except             
C. pneumoniae 
(Derré et al., 
2011; Agaisse 
and Derré, 2014) 
Inc CT116/IncE Inclusion 
membrane 




(Mirrashidi et al., 
2015) 
Inc CT118/IncG Inclusion 
membrane 








Promotes fusion of 
membranes 
Chlamydia 
except             
C. caviae         
C. pneumoniae 
(Hackstadt et al., 
1999; Delevoye et 
al., 2008) 
Inc CT222 Inclusion 
membrane 
? Co-localizes with 
proteins of the Src 
family 
C. trachomatis (Mital et al., 2010) 
Inc CT223/IPAM Inclusion 
membrane 
CEP170 Assembles  
microtubule 
superstructures 
crucial to maintain 
the inclusion shape 
C. trachomatis 
C. muridarum  
C. pneumoniae 
(Dumoux et al., 
2015) 
Inc CT228 Inclusion 
membrane 
MYPTI Regulates the 
extrusion 
mechanism to exit 
from the host cell 
C. trachomatis 
C. muridarum  
C. caviae 
(Mital et al., 2015) 
Inc CT229 Inclusion 
membrane 
Rab4 ? C. trachomatis 
C. muridarum 
(Rzomp et al., 
2006) 
Inc CT232/IncB Inclusion 
membrane 
? Co-localizes with 
proteins of the Src 
family 
Chlamydia (Mital et al., 2010) 








crucial to maintain 
the inclusion shape 
C. trachomatis 
C. muridarum 
(Chen et al., 2006; 
Kokes et al., 
2015) 
Inc CT850 Inclusion 
membrane 
DYNLT1 Promotes the 
correct positioning 
of the inclusion at 
the MTOC 
Chlamydia (Mital et al., 2015) 
Inc Cpn0517 Inclusion 
membrane 
Act1 Inhibits NF-κB 
activation 
C. pneumoniae (Wolf et al., 2009) 
Inc Cpn0127 ? Caprin2 Inhibits apoptosis C. pneumoniae (Flores and 
Zhong, 2015) 





inclusions with the 
microtubule network 






aBased on the protein sequence annotation of C. trachomatis strain D/UW3, C. 
pneumonia CWL029, and C. psittaci CAL10. The Inclusion membrane (Inc) proteins are 
indicated as Inc followed by their genome sequence annotation. 
bThe Chlamydia species where a homolog of the protein is found, among C. trachomatis, 
C. muridarum, C. caviae, C. felis, and C. pneumoniae (Lutter et al., 2012; Mirrashidi et 
al., 2015). 
 
1.4.6.1 Chlamydia inclusion membrane (Inc) proteins 
The Inc proteins are a particular and important class of Chlamydia T3SS 
effectors. It is known since 1995 that Chlamydia secrete proteins that 
localize at the inclusion membrane (Rockey et al., 2002). Among these 
proteins, several have a characteristic bi-lobed hydrophobic domain 
(possibly enabling them to intercalate in the inclusion membrane) and 
are collectively known as Inc proteins (Figure 1.3) (Bannantine et al., 
2000). 
Inc proteins have been identified by searching the genome for the 
unique signature of the bi-lobed hydrophobic domain (Bannantine et al., 
2000). Depending on the species, Chlamydia encode a vast number of 
Incs: ~60 in C. trachomatis, ~60 in C. muridarum, ~85 in C. caviae, ~80 
in C. felis, and ~100 in C. pneumoniae (Bannantine et al., 2000; Dehoux 
et al., 2011; Lutter et al., 2012). The Inc proteins appear to be specific of 
Chlamydiae, as they were also identified in the endosymbiont of free-
living amoebae Protochlamydia amoebophila but not in other bacteria 
(Griffiths et al., 2006; Heinz et al., 2010). The entire collection of Inc 
proteins is not conserved among all species, which indicate that the 
diversity among these proteins likely contributes to the subtle, species-
specific differences observed in host range. About 25 Inc proteins are 







Figure 1.3 – The inclusion membrane (Inc) proteins possess a bi-lobed 
hydrophobic motif that targets them to the inclusion membrane. (A) Typical 
hydrophilicity profile of an Inc protein. Reprinted from Cellular Microbiology; Vol. 2; John 
P. Bannantine, R. S. Griffiths, W. Viratyosin, Wendy J. Brown, Daniel D. Rockey; A 
secondary structure motif predictive of protein localization to the chlamydial inclusion 
membrane; 35-47; 2000; with permission from John Wiley and Sons. (B) HeLa 229 
mammalian cells infected with C. trachomatis L2/434 and visualized by fluorescence 
microscopy. Cells were immunolabeled with anti-MOMP (green) for Chlamydia and anti-
Inc (red) for the Inc. Scale bar is 10 μm. 
 
Given that Inc proteins have the distinctive localization at the inclusion 
membrane, most probably facing the host cytosol, they are believed to 
be key mediators of Chlamydia-host interactions. Nevertheless, not all 
predicted Inc proteins were yet validated as the distinctive localization at 
the inclusion membrane was only experimentally confirmed for ~25 of 
them (Cortes et al., 2007; Li, Chaoqun Chen, et al., 2008; Mital et al., 
2010; Dehoux et al., 2011; Flores and Zhong, 2015). A recent study 
used the newly developed genetic tools to identify 10 additional Inc 
proteins localizing at the inclusion membrane (Weber et al., 2015). 
Inc proteins lack predicted signal sequences required for secretion by 
other transport mechanisms such as the general secretory pathway. 
This led to the hypothesis that they could be translocated to the host cell 





flexneri have been used to corroborate this hypothesis (Subtil et al., 
2001; Subtil et al., 2005; Dehoux et al., 2011).  
The molecular function of many Inc proteins is still unknown; 
nevertheless, considerable advances have been made for several of 
them (Table 1.1). Inc CT115/IncD was described to be enriched in MCSs 
and interact with the host lipid transfer protein CERT and VAPB. As 
mentioned above in section 1.3.3.5, this interaction enables the transfer 
of ER content into the inclusion (Derré et al., 2011; Agaisse and Derré, 
2014; Agaisse and Derré, 2015). 
Inc CT118/IncG is known to be phosphorylated during infection and was 
described to bind to the phosphoserine-binding protein 14-3-3-β, 
involved in signal-transduction pathways (Scidmore and Hackstadt, 
2001). 
Inc CT119/IncA mediates the homotypic fusion of the inclusions during 
infection by Chlamydia through the action of a SNARE domain, and 
possibly by the interaction with host VAMP3 and VAMP8 (Hackstadt et 
al., 1999; Delevoye et al., 2008; Ronzone and Paumet, 2013; Ronzone 
et al., 2014). In a recent study, where the authors documented the first 
inactivation of a chromosomal gene in Chlamydia, it was demonstrated 
that the lack of IncA production renders non-fusogenic inclusions in cells 
infected with this mutated strain (Johnson and Fisher, 2013). 
There is a group of Inc proteins that localize in microdomains at the 
inclusion membrane (Incs CT101, CT222, CT232/IncB, and CT850). 
These microdomains are localized at the point of contact of the 
centrosome with the inclusion and are also enriched in a family of host 
Src kinases that interact with many host proteins, modifying them by 
phosphorylation of tyrosine residues. It is suggested that these 
microdomains may function as a platform for interactions between the 





Inc CT850 was recently described to interact with the dynein light chain 
(DYNLT1) and to contribute to the correct migration of the inclusion 
along microtubules to the centrosome region (Mital et al., 2015). 
As mentioned above in section 1.3.3.7, the Inc proteins CT223/IPAM 
and CT813/InaC are capable of reprogramming the host microtubule 
network. IPAM interacts with the host centrosomal protein CEP170 
(Dumoux et al., 2015), and InaC binds host ARF1 and 14-3-3 proteins 
(Kumar and Valdivia, 2008; Kokes et al., 2015). 
Inc CT228 was shown to interact with the myosin phosphatase target 
subunit 1 (MYPT1), an element of the myosin phosphatase pathway, 
and as mentioned above in section 1.3.3.9, this interaction favors the 
extrusion mechanism (Lutter et al., 2013). 
The C. pneumoniae-specific Inc Cpn0127 was described to interact with 
the host cell cytoplasmic activation/proliferation-associated protein 2 
(Caprin2), indicating an active role in the manipulation of host Wnt 
signaling pathway for enhancing the chlamydial anti-apoptotic activity 
(Flores and Zhong, 2015). 
Although Inc CT232/IncB is present in all Chlamydia species, the 
homolog of this protein of C. psittaci, Inc G5Q-0512/IncB, has only ~50% 
amino acid identity to CT232/IncB of C. trachomatis. Inc G5Q-0512/IncB 
was shown to interact with host Snapin and dynein, indicating that 
Snapin connects the inclusion with the microtubule network by 
interacting with both IncB and dynein (Böcker et al., 2014). Interestingly, 
this interaction was not observed with CT232/IncB of C. trachomatis, 
highlighting the species specificity of the function of this protein (Böcker 
et al., 2014). 
Recently, the development of a systematic affinity purification-mass 





comprehensive Inc-host interactome. In this work, the authors could find 
high-confidence host targets for 38 out of 58 C. trachomatis Inc proteins 
(Mirrashidi et al., 2015). Of the 20 validated Incs (experimentally 
confirmed to localize at the inclusion membrane) used in this study, the 
authors identified host targets for 15, of which two had been already 
described by other methods (Incs CT115/IncD and CT228) (Derré et al., 
2011; Lutter et al., 2013; Mirrashidi et al., 2015). In this study, Inc 
proteins were found to target several host structures, organelles and 
pathways, including the ER, mitochondria, vesicle transport, cell 
cycle/division, apoptosis, and protein transport. The biological 
significance of the interactions found was further investigated for one of 
the Inc proteins. Inc CT116/IncE was described to contribute to the 
disruption of retromer function, by interacting with SNX5 and SNX6, 
revealing that retromer restricts Chlamydia infection (Mirrashidi et al., 
2015). Nevertheless, the other identified host interacting partners still 
lack experimental validation. 
Two different studies highlighted an alternative role for Inc proteins. In 
one study Incs were described to interact with each other and in another 
study Incs were proposed to form complex membrane structures (Mital 
et al., 2013; Gauliard et al., 2015). This led to the hypothesis that instead 
of having a direct host interacting partner, some Inc proteins could form 
specific multi-protein complexes in the inclusion membrane to act as 
scaffolds for host interactions or to confer structural stability to the 
inclusion (Mital et al., 2013; Gauliard et al., 2015). 
 
1.4.6.2 Other Chlamydia T3S effectors 
The Inc proteins are not the only chlamydial proteins directed to the 
membrane of the inclusion. Chlamydia secrete two T3S effectors 





distinct localization, and do not possess the typical architecture of an Inc 
protein (Table 1.1) (Fields and Hackstadt, 2000; Fling et al., 2001). 
However, nothing is known about the molecular function of these two 
proteins. 
Among the remaining T3SS effectors known so far (Table 1.1), Tarp is 
crucial for the chlamydial entry step. As soon as EBs attach to the 
plasma membrane, Tarp is secreted to the host cytosol and it is 
immediately phosphorylated. Then, actin is recruited to the site of 
attachment in a WAVE2 and Arp2/3-dependent manner, where it is 
polymerized by Tarp to promote bacterial endocytosis (Clifton et al., 
2004; Jewett et al., 2006; Lane et al., 2008). The TepP is also secreted 
early in infection to induce signaling cascades that modulate the immune 
response against the bacteria (Chen et al., 2014).  
CT694 is another T3SS effector secreted in the invasion process and is 
known to interact with the human protein Ahnak, affecting the formation 
of host-cell actin stress fibers (Hower et al., 2009; Bullock et al., 2012). 
The homolog of this protein of C. psittaci, G5Q-0070/SINC, has a low 
amino acid sequence identity to CT694 of C. trachomatis (Mojica et al., 
2015).  SINC (secreted inner nuclear membrane–associated Chlamydia 
protein) was reported to target the nuclear envelope of C. psittaci–
infected cells and to interact with proteins of the nuclear membrane, 
including the nucleoporin ELYS, lamin B1, emerin, MAN1, LAP1, and 
LBR. Therefore, in C. psittaci, SINC is believed to control other 
processes such as nuclear structure and chromatin organization (Mojica 
et al., 2015). 
Chlamydia has 4 more proteins that are targeted to the host cell nucleus: 
CT620, CT621, CT711, and CT737/NUE (Hobolt-Pedersen et al., 2009; 
Pennini et al., 2010; Muschiol et al., 2011). CT737 is named nuclear 





Microscopy experiments revealed that during infection NUE is 
translocated to the host cell nucleus and in vitro enzymatic assays 
confirmed the activity of NUE as a histone methyltransferase (Pennini et 
al., 2010). For the other three proteins (CT602, CT621, and CT711), 
there is evidence of a T3S signal encoded in their N-termini and specific 
antibodies raised against these proteins showed that they are present in 
the nuclei of Chlamydia-infected cells (Hobolt-Pedersen et al., 2009; 
Muschiol et al., 2011). 
CT847 was found to interact with the mammalian Grap2 cyclin D-
interacting protein (GCIP). During infection, reduced levels of GCIP were 
observed, indicating that this protein might be targeted for degradation. 
Though, the authors could not directly implicate the interaction of the two 
proteins on the observed Chlamydia-mediated effect of reduced levels of 
GCIP (Chellas-Géry et al., 2007). 
 
1.4.7 Other Chlamydia effectors 
Although the majority of the effectors known so far are translocated to 
the host cell by the T3SS, Chlamydia also secrete proteins by other 
transport systems. These include the CT166/cytotoxin, CT311, 
CT441/Tsp (tail specific protease), CT795, CT798/GlgA (glycogen 
synthase), CT823/HtrA (high temperature requirement protein A), 
CT858/CPAF (chlamydial protease-like activity factor), and the plasmid 
ORF Pgp3 (Lad, Yang, et al., 2007; Li, Ding Chen, et al., 2008; 
Thalmann et al., 2010; Lei et al., 2011; Qi et al., 2011; Wu et al., 2011; 
Zhong, 2011; Lei et al., 2013; Lu et al., 2013; Bothe et al., 2015). 
Furthermore, other proteins highlighted in previous studies could be T3S 
substrates but this has never been confirmed, and therefore, we will 
describe their known functions here (Kumar et al., 2006; Misaghi et al., 





The most extensively studied non-T3S substrates are the 
CT166/cytotoxin and the CT858/CPAF. The CT166/cytotoxin is present 
in EBs, prior to infection, and is detected in the host-cell cytosol in the 
first stages of infection. The cytotoxin was reported to cause actin re-
organization events when expressed in uninfected mammalian cells 
(Carlson et al., 2004; Thalmann et al., 2010; Bothe et al., 2015). As the 
same effect was observed with the Clostridium difficile Toxin B (TcdB), 
the authors hypothesized that the chlamydial cytotoxin could also act in 
actin re-organization, possibly through the interaction with Rac1 (Carlson 
et al., 2004; Thalmann et al., 2010; Bothe et al., 2015). 
CPAF is an extensively characterized protease with numerous potential 
host substrates of importance to Chlamydia infection  (Zhong, 2011). 
However, there has been some controversy around this protein and 
whether the identified substrates indeed constitute bona fide targets of 
proteolysis in infected cells or correspond to artifacts of post-lysis 
degradation (Chen et al., 2012). In a recent study, where CPAF mutants 
were generated, the authors reported that some of the effects previously 
associated with CPAF were indeed independent of this protein (Snavely 
et al., 2014). Nevertheless, they could confirm other targets as being 
CPAF-dependent and suggested a role for CPAF late in infection, 
possibly during the stages leading to the disruption of the host cell prior 
to the release of EBs (Snavely et al., 2014). 
C. trachomatis secretes at least three proteins into host cells that 
localize at distinct lipid droplet-like structures surrounding the inclusion 
(Kumar et al., 2006). These proteins were named lipid droplet 
associated proteins (CT156/Lda1, CT163/Lda2 and CT473/Lda3), and 
encode phospholipase domains, present in lipid-modifying enzymes. 
They are suggested to participate in the recruitment of host lipids into 
the inclusion (Beatty, 2006; Kumar et al., 2006; Beatty, 2008; Cocchiaro 





known protein transport systems, it is believed that they are secreted 
across the inclusion membrane through the T3SS (Kumar et al., 2006). 
Bioinformatics analyses of the C. trachomatis genome revealed other 
hypothetical proteins that could function as T3S effectors, as the case of 
CT153/MACPF (Samudrala et al., 2009; Taylor et al., 2010). This protein 
contains a MACPF domain that is used by different parasites to facilitate 
the egress from cells (Kadota et al., 2004; Kafsack et al., 2009). This 
suggests that Chlamydia could also employ a similar process of 
producing pores in membranes to facilitate disruption of the inclusion 
and the host cell (Rosado et al., 2008; Taylor et al., 2010). Another 
possible role for this protein could be in the import of host lipids into the 
inclusion, in conjunction with the Lda proteins, as their genes are located 
adjacently in the genome of C. trachomatis (Rosado et al., 2008; Taylor 







1.5 Other intracellular pathogens 
There are pathogenic bacteria that successfully thrive in the host 
cytosol, as the case of S. flexneri and Listeria monocytogenes (Cossart 
and Toledo-Arana, 2008; Schroeder and Hilbi, 2008). In general, these 
bacteria avoid killing by the host through inactivation of the autophagic 
pathway (Kumar and Valdivia, 2009; Asrat et al., 2014). Nevertheless, 
the majority of the intracellular pathogens reside within membrane-
bound compartments. Those are typically the case of Chlamydia, 
Mycobacterium tuberculosis, Legionella pneumophila, Brucella abortus, 
Coxiella burnetii and Salmonella enterica (Fields and Hackstadt, 2002; 
Vergne et al., 2004; van Schaik et al., 2013; Xu and Luo, 2013; Celli, 
2015; LaRock et al., 2015). This intracellular lifestyle might be 
advantageous for the bacteria, as this environment enables them to 
escape more easily from the host immune response soon after invasion 
(Kumar and Valdivia, 2009; Hilbi and Haas, 2012; Asrat et al., 2014). 
 
1.5.1 Vacuole interactions with the host by intravacuolar 
pathogens 
Although remaining within a vacuole inside the host cell for the duration 
of the intracellular infectious cycle, each intravacuolar pathogen evolved 
different approaches to modify its compartment, and to manipulate the 
host endocytic and the secretory pathway to prevent killing by the host 
(Figure 1.4) (Kumar and Valdivia, 2009). 
 
1.5.1.1 Salmonella enterica 
S. enterica replicates in epithelial cells inside the Salmonella containing 
vacuole (SCV) (LaRock et al., 2015). Maturation of the SCV involves 





endosomal markers that are subsequently replaced with late endosomal 
markers and some lysosomal markers. Despite the direct fusion of the 
SCV with lysosomes, the endocytic pathway is interrupted and bacteria 
are able to endure throughout the rest of the infectious cycle (LaRock et 
al., 2015). 
 
1.5.1.2 Mycobacterium tuberculosis 
Mycobacterium tuberculosis is highly adapted to infect macrophages, 
and manages to escape killing by the host through the establishment of 
the Mycobacteria pathogen vacuole (MPV) (Vergne et al., 2004). The 
MPV deviates from the canonical endocytic pathway between early and 
late endosomes and is characterized by an incomplete acidification of its 
lumen, and the absence of lysosomal hydrolases and Rab proteins 
(Vergne et al., 2004). 
 
1.5.1.3 Coxiella burnetii 
C. burnetii has a tropism for professional phagocytes and replicates 
within the Coxiella-containing vacuole (CCV) (van Schaik et al., 2013). 
Unlike other bacterial pathogens, where maturation of the vacuole 
involves the arrest in early or late endosomes, or lysosomes, the CCV 
follows the endocytic pathway till the end. The main difference between 
the generation of the CCV and lysosomes is the time at which lysosomal 
markers are delivered in each compartment. A delay in the transport of 
these markers to the CCV allows the expansion of the vacuole and the 
accumulation of further cellular material that benefits bacterial survival 








Figure 1.4 - Vacuole interactions with the host by intravacuolar pathogens. The M. 
tuberculosis vacuole interrupts the endocytic pathway between early and late 
endosomes. S. enterica avoids the acquisition of lysosomal markers and establishes its 
vacuole near the Golgi. The Chlamydia inclusion does not interact with the endocytic 
pathway, and instead fuses with exocytic vesicles and migrates towards the 
centrosomes. The B. abortus vacuole acquires markers of early and late endosomes but 
then change into an endoplasmic reticulum (ER)-derived vacuole. The L. pneumophila 
vacuole interacts with smooth vesicles from the ER, originating an ER-derived vacuole 
that recruits other organelles such as mitochondria. The C. burnetii vacuole follows the 
endocytic pathway till the end, acquiring all the characteristics of lysosomes. EB –
elementary body; RB – reticulate body; SCV – Coxiella small cell variant; LCV – Coxiella 





1.5.1.4 Brucella abortus 
B. abortus infects mainly professional phagocytes, and upon entry of a 
host cell, bacteria are engulfed in the Brucella-containing vacuole (BCV) 
(Celli, 2015). The BCV acquires markers of early and late endosomes 
but not of lysosomes. Instead, the BCV intercepts the early secretory 
pathway at the ER and is drastically modified from a phagosome to an 
ER-derived organelle, by following the autophagic pathway (Celli, 2015). 
 
1.5.1.5 Legionella pneumophila 
L. pneumophila survives and replicates within macrophages in the 
Legionella-containing vacuole (LCV) (Xu and Luo, 2013). Upon invasion 
of a host cell, the LCV rapidly deviates from the endocytic pathway to 
the secretory pathway. Instead of acquiring markers of late endosomes, 
the LCV is covered with smooth vesicles originating from the ER. During 
the remaining of the infectious cycle, the LCV becomes more enriched in 
ER material and other organelles such as mitochondria, conferring not 
only protection but also providing the bacteria with nutrients (Xu and 
Luo, 2013). 
 
1.5.2 Interference with host cell pathways by intravacuolar 
pathogens 
Alongside with the different vacuolar biogenesis, each intravacuolar  
pathogenic bacterium employs different virulence mechanisms and 







1.5.2.1 Salmonella enterica 
S. enterica sequentially employs two distinct T3SSs (LaRock et al., 
2015). The Salmonella pathogenicity island-1-encoded T3SS (SPI-1 
T3SS) delivers effectors necessary for the invasion process, to induce 
bacterial internalization and to promote the first steps of the SCV 
maturation. The SPI-2 T3SS delivers effectors associated with bacterial 
replication and the correct positioning and maintenance of the SCV at 
the perinuclear region. Although each T3SS has its own set of effectors, 
there are a few that are shared by both T3SSs (LaRock et al., 2015). 
 
1.5.2.2 Mycobacterium tuberculosis 
M. tuberculosis secretes proteins through a T7SS (ESX-1 to -5) 
(Simeone et al., 2009). Despite being essential for virulence, the ESX 
systems are also suggested to be involved in more general aspects of 
the physiology of the bacteria. The ESX-1 is the main system related to 
pathogenicity and the effectors of this system are responsible for 
modulating apoptosis and assisting in the late stages of the MPV 
maturation (Simeone et al., 2009). 
 
1.5.2.3 Coxiella burnetii 
C. burnetii cycles between two bacterial forms: the metabolically inactive 
small cell variant and the metabolically active large cell variant (van 
Schaik et al., 2013). Transition from the small to the large cell variant 
coincides with the vacuole maturation. C. burnetii is known to encode 
several transport systems, still, the T4SS is the best studied (van Schaik 
et al., 2013). Translocation of T4S effectors only occurs 8 hours after 
infection, indicating that maturation of the CCV is not dependent of the 
T4SS. To date more than 100 T4S substrates were identified and most 





the C. burnetii T4SS effectors interact with host proteins to maintain the 
CCV integrity and to modulate other processes such as apoptosis and 
proteasome-mediated degradation (van Schaik et al., 2013). 
 
1.5.2.4 Brucella abortus 
B. abortus also uses a T4SS described to be essential for the BCV 
biogenesis and replication (Celli, 2015). The B. abortus T4S effectors 
are known to modulate host functions involved in the early secretory 
pathway and vesicle trafficking to the ER, enabling the bacteria to 
associate with this organelle and proliferate within the mature BCV 
(Celli, 2015). 
 
1.5.2.5 Legionella pneumophila 
L. pneumophila entirely depends on its T4SS to overcome the killing 
mechanisms of the host (Xu and Luo, 2013). From the moment of 
invasion till the egress of the bacteria, L. pneumophila actively secretes 
almost 300 T4S effectors that fulfill the needs of the bacteria to intercept 
the endocytic and the secretory pathways, to interfere with host death 
mechanisms, and to acquire nutrients (Xu and Luo, 2013). Nevertheless, 
this high abundance of effectors likely leads to an increased probability 
for functional redundancy among the effectors, which prevents further 








1.6 General aims and overview 
This PhD thesis aimed at increasing our understanding of Chlamydia-
host cell interactions. It focused in analyses of C. trachomatis Inc 
proteins, which were hypothesized to play a major role in host cell 
tropism and types of infection, and to modulate host cell processes 
during infection. Three main topics were addressed: 
1) The identification of all Incs that are T3S substrates; 
2) The contribution of Inc proteins to the tissue tropism and type of 
infection associated with C. trachomatis strains; 
3) The study of the molecular function of Incs, including the search 
for host cell protein targets. 
In Chapter 2, we used Yersinia enterocolitica as heterologous bacteria to 
identify all Incs that are T3S substrates, in an attempt to define a 
chlamydial protein as an Inc based on the presence of the typical 
hydrophobic motif and of a T3S signal. As we were unsuccessful in 
finding a T3S signal for three known Incs, we considered for further 
studies the group of all Incs. In Chapter 3 we determined the differences 
in the amino acid sequence of Inc proteins and the temporal expression 
levels of inc genes among different C. trachomatis strains, and found a 
subgroup of Incs possibly involved in the distinct tropism and 
invasiveness associated with C. trachomatis LGV strains. In Chapter 4 
we performed a search for interacting host cell proteins for the subgroup 
of Inc proteins found in Chapter 3, and further characterized the 
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2.1 Abstract  
Chlamydia trachomatis multiplies exclusively within a membrane-bound 
vacuole (known as inclusion), and uses a type III secretion system to 
manipulate host cells by injecting them with effector proteins. In this 
Chapter, we identified type III secretion (T3S) signals in C. trachomatis 
inclusion membrane (Inc) proteins, a group of >60 proteins 
characterized by a bi-lobed hydrophobic domain that might mediate their 
insertion into the inclusion membrane. We focused our work in 23 known 
Incs (previously described to localize at the inclusion membrane) and in 
25 putative Incs (not yet described to localize at the inclusion 
membrane, but containing the characteristic bi-lobed hydrophobic 
domain). We analyzed T3S of hybrid proteins comprising the first 20 
amino acids of Inc proteins and the mature form of β-lactamase TEM-1, 
using Yersinia enterocolitica bacteria as heterologous host. Overall, we 
identified 19 Inc proteins of C. trachomatis as novel T3S substrates, of 
which 14 were putative Inc proteins. Bioinformatics further indicated the 
presence of a T3S signal in the first 20 amino acids of these Inc 
proteins. Our data supports the notion that most Inc proteins are T3S 
substrates and confirms that definitive indication of a protein as being an 







During its developmental cycle, Chlamydia trachomatis reside and 
multiply intracellularly in a membranous compartment known as an 
inclusion. Throughout this cycle, C. trachomatis uses a type III secretion 
system (T3SS) to translocate several effector proteins both across the 
host cell plasma membrane and the inclusion membrane (Valdivia, 
2008; Betts et al., 2009). C. trachomatis type III secretion (T3S) effector 
proteins should play a central role in bacterial invasion (Lane et al., 
2008; Hower et al., 2009; Jewett et al., 2010; Chen et al., 2014), host 
cytoskeleton reorganization (Chen et al., 2006; Dumoux et al., 2015; 
Mital et al., 2015), exit of host cells (Lutter et al., 2013), and in 
subversion of many others host cell processes (Hackstadt et al., 1999; 
Scidmore and Hackstadt, 2001; Belland et al., 2003; Kumar et al., 2006; 
Rzomp et al., 2006; Chellas-Géry et al., 2007; Delevoye et al., 2008; 
Mital et al., 2010; Pennini et al., 2010; Derré et al., 2011; Agaisse and 
Derré, 2014; Mirrashidi et al., 2015). There are, however, chlamydial 
effector proteins, such as CPAF/CT858 or Tsp/CT441, which are not 
T3S substrates (Betts et al., 2009). 
Given their likely central role during infection, considerable efforts have 
been placed at identifying chlamydial effector proteins. This is not a 
trivial task because the amino acid sequence of most effectors does not 
display significant similarity to proteins of known function. Furthermore, a 
T3S signal is not evident on the basis of the amino acid sequence, 
predicted secondary structure, or other special properties. Moreover, in 
spite of the recent development of systems for transformation of 
Chlamydia (Wang et al., 2011; Gérard et al., 2013), for a long time no 
methods have been available for genetic manipulation of Chlamydia. 
To overcome these obstacles chlamydial effectors have been searched: 
i) by systematic phenotypic analyses of yeast Saccharomyces cerevisiae 




expressing individual chlamydial proteins (Sisko et al., 2006); ii) by using 
Salmonella (Ho and Starnbach, 2005), Shigella (Subtil et al., 2005; 
Pennini et al., 2010; Dehoux et al., 2011; Muschiol et al., 2011; Furtado 
et al., 2013), or Yersinia (Fields and Hackstadt, 2000; Clifton et al., 
2004; Chellas-Géry et al., 2007; Hower et al., 2009; Hovis et al., 2013; 
Pais et al., 2013) as genetically tractable heterologous host bacteria 
carrying well characterized T3SSs; or iii) by complex computational 
predictions of T3S signals (Arnold et al., 2009; Löwer and Schneider, 
2009; Samudrala et al., 2009; Hovis et al., 2013; Wang et al., 2013). The 
subsequent use of specific antibodies enabled to detect translocation 
into host cells of some of the C. trachomatis proteins singled out in these 
searches, including a family of >60 proteins containing a hydrophobic 
motif thought to mediate their insertion into the inclusion membrane (Inc 
proteins) (Li et al., 2008; Dehoux et al., 2011). However, this distinct 
localization was only described for half of them (Li et al., 2008; Mital et 
al., 2010). 
The majority of Inc proteins lacks predicted signal sequences required 
for secretion by other transport mechanisms, and therefore they are 
good candidates for being T3S effectors. Indeed, they appear to be 
transported into the inclusion membrane by a T3SS (Fields et al., 2003; 
Subtil et al., 2005; Dehoux et al., 2011). However, not all Incs were 
tested for the presence of a T3S signal. Aiming to test if it is possible to 
define a chlamydial protein as an Inc based on the presence of the 
typical hydrophobic motif and of a T3S signal, in this Chapter, we used 
Y. enterocolitica as a heterologous bacterium to identify T3S signals in 
putative Inc proteins of C. trachomatis (having a typical hydrophobic 
motif but not yet described to localize at the inclusion membrane) by 







2.3 Materials and Methods 
2.3.1 Bacterial strains and growth conditions 
We used Escherichia coli TOP10 (Life Technologies) as host to help in 
the construction of plasmids and in the purification of the plasmid DNA. 
Y. enterocolitica ΔHOPEMT strain [MRS40 pYML421 (yopHΔ1-352, 
yopOΔ65-558 yopP23 yopE21 yopM23 yopT135)], deficient for the T3S 
effectors YopH, -O, -P, -E, -M, -T (Iriarte and Cornelis, 1998), but T3S-
proficient, was used for T3S assays. To construct a T3S-deficient 
derivative of ΔHOPEMT, we deleted in this strain the complete coding 
sequence (codons 1 to 354) of the yscU gene, which encodes an 
essential component of the Y. enterocolitica T3SS (Sorg et al., 2007). 
This was done by allelic exchange with the mutator plasmid pLY16. The 
yscUΔ1-354 mutation had been previously shown to be non-polar (Sorg et 
al., 2007). The resulting Y. enterocolitica ΔHOPEMT ΔYscU strain 
(MRS40 pFA1001) was also used in the T3S assays. E. coli and Y. 
enterocolitica were routinely grown at 37ºC and 28ºC, respectively, in LB 
medium with the appropriate antibiotics and supplements. Plasmids 
were routinely introduced into E. coli and Y. enterocolitica by 
electroporation. 
 
2.3.2 Construction of plasmids 
Plasmids were constructed and purified using proofreading Phusion 
DNA polymerase, restriction enzymes, T4 DNA Ligase, and DreamTaq 
DNA polymerase (all from Life Technologies), NucleoSpin gel and PCR 
cleanup kit (Macherey-Nagel) and GeneElute plasmid miniprep kit 
(Sigma). The accuracy of the nucleotide sequence of the inserts in the 
constructed plasmids was verified by DNA sequencing (Stab Vida). To 
analyze T3S signals we constructed plasmids harboring hybrid genes 
encoding the first 10, 15, 20, or 40 amino acids of each protein (C. 




trachomatis Inc proteins, SycT and YopE) and the mature form of TEM-1 
β-lactamase (TEM-1)  (Charpentier and Oswald, 2004). These hybrids 
were constructed using as vector pLJM3, a low-copy plasmid which 
enables expression of the cloned genes driven by the promoter of the Y. 
enterocolitica yopE gene (Marenne et al., 2003). This was done either by 
overlapping PCR between the first 60 nucleotides of each inc and the 
TEM-1-encoding gene or by using primers containing a restriction site 
followed by 60 nucleotides encoding the first 20 amino acids of each 
protein in frame with a sequence complementary to the 3’ extremity of 
the transcribed strand of the TEM-1-encoding gene. Primers are listed in 
Table A.1 and plasmids are listed in Table A.2 (Annexes). For primer 
design, the DNA sequence of each inc gene in C. trachomatis strain 
L2/434 was used, except for ct036, ct115 (incD), and ct119 (incA), in 
which the sequence from strain D/UW3 was used (Table A.3 in 
Annexes). The gene encoding for TEM-1 was amplified by PCR from 
pCX340 (Charpentier and Oswald, 2004) and the DNA sequence of 
sycT was obtained from Y. enterocolitica pYVe227 (accession number 
AF102990). 
 
2.3.3 Y. enterocolitica T3S assays 
The T3S assays were performed as previously described (Sorg et al., 
2007). Briefly, Y. enterocolitica strains harboring the plasmids encoding 
TEM-1 hybrid proteins were diluted from overnight cultures to an OD600 
of 0.1 in BHI medium supplemented with 20 mM sodium oxalate, 20 mM 
MgCl2 and 0.4% (w/v) glucose, and grown for 2 h at 28ºC with 150 rpm 
shaking. The bacterial cultures were then quickly shifted to 37ºC and 
incubated for an additional 4 h with 150 rpm shaking. After incubation, 
OD600 of the cultures was measured and culture supernatants and 
bacterial pellets were separated by a centrifugation of 1 min, at room 





precipitated with TCA 10% (w/v). The TCA protein precipitate 
corresponding to 1 ml of the culture was resuspended in OD600 x 10 μl of 
SDS-PAGE Laemmli buffer [Tris-HCl 50 mM, pH 6.8, SDS 2.0% (w/v), 
glycerol 10% (v/v), β-mercaptoethanol 0.1 M, bromophenol blue 0.1% 
(w/v)], while the bacterial pellet, corresponding to 1.5 ml of the culture, 
was resuspended in OD600 x 100 μl of SDS-PAGE Laemmli Buffer. Both 
fractions were denatured at 100ºC for 10 min. 
 
2.3.4 Immunoblotting 
Supernatant and pellet fractions were resolved in 12% SDS-PAGE, 
followed both by Coomassie staining and by immunobloting. Proteins in 
the gel were transferred onto PVDF membranes (Bio-Rad) in a Trans-
Blot® SD Semi-Dry System (Bio-Rad), blocked in 5% (w/v) dried 
skimmed milk diluted in PBS containing 0.1% (v/v) Tween-20. The 
membranes were probed with mouse anti-TEM1 antibody (QED 
Bioscience; used at 1/500) and rabbit anti-SycO antibody [(Letzelter et 
al., 2006); used at 1/1000], horseradish peroxidase-conjugated 
secondary antibodies (GE Healthcare; used at 1:10000), and detected 
using the Western Lightning Plus-ECL kit (Perkin Elmer) in a Chemidoc 
XRS+ system (Bio-Rad). The amount of protein in the culture 
supernatant and bacterial pellet fractions was determined from the 
immunoblot images using Image Lab (Bio-Rad). The percentage of 
secretion was calculated as the ratio between the amounts of secreted 
protein (in the culture supernatant fraction) relative to the total amount of 
protein (in the culture supernatant and in the bacterial pellet fractions). 
The results from the quantifications are the average ± SEM from at least 
three independent experiments.  




2.4 Results and discussion 
2.4.1 TEM-1 β-lactamase can be used as a reporter protein to 
analyze T3S by Y. enterocolitica 
The T3S signal is normally located within the first 20-30 amino acids of 
the substrate (Sory et al., 1995; Samudrala et al., 2009). Therefore, we 
analyzed secretion of hybrid proteins comprising the first amino acids of 
each C. trachomatis Inc protein and a reporter protein. We tested if the 
mature form of TEM-1 β-lactamase, which had been already described 
as a reporter protein for assays of T3S translocation into host cells 
(Charpentier and Oswald, 2004), could be used in the identification of 
T3S signals using Y. enterocolitica as a heterologous host. For this, we 
incubated in T3S-inducing conditions T3S-proficient Y. enterocolitica 
ΔHOPEMT or T3S-deficient Y. enterocolitica ΔHOPEMT ΔYscU strains 
harboring plasmids encoding an hybrid protein comprising the first 15 
amino acids of the Yersinia effector YopE and TEM-1 (YopE15-TEM-1) or 
TEM-1 alone. The first 15 amino acids of YopE have been previously 
shown to drive secretion of a Cya hybrid (Sory et al., 1995). The different 
bacterial cultures were then fractionated into culture supernatants and 
bacterial pellets, which were subsequently analyzed by immunoblotting. 
This showed that the first 15 amino acids of YopE drove secretion of the 
TEM-1 hybrid, while mature TEM-1 alone was not secreted (Figure 2.1). 
Secretion of YopE15-TEM-1 was T3S-dependent, as this protein was not 
detected in the supernatant fraction of the Y. enterocolitica ΔHOPEMT 
ΔYscU strain (Figure 2.1). This indicated that TEM-1 is a suitable 
reporter protein for the identification of T3S signals using Y. 







Figure 2.1 – Validation of mature TEM-1 β-lactamase as a reporter protein to 
identify T3S signals using Y. enterocolitica as a heterologous bacterium. The 
indicated Y. enterocolitica strains were incubated in T3S-inducing conditions (see 
Materials and Methods). Proteins in the supernatant (S) and in the bacterial pellet (P) 
were collected and analyzed by Coomassie staining (~5x108 and ~1x108 bacteria per 
lane for supernatant and pellet, respectively) and by immunoblotting (~2x108 and ~2x107 
bacteria per lane for supernatant and pellet, respectively) with anti-TEM-1 and anti-SycO 
antibodies. SycO is a cytosolic T3S chaperone and was used as a control for possible 
contamination of the supernatant fractions with the bacterial pellet; SycO was not 
detected in the ΔHOPEMT ΔYscU background because its expression requires a 
functional T3SS (Stainier et al., 1997). 
 
2.4.2 The first 20 amino acids of C. trachomatis T3S substrates 
are sufficient to drive efficient secretion of TEM-1 hybrid proteins 
by Y. enterocolitica 
Before analyzing T3S signals in Inc proteins, we sought to ascertain the 
optimal amino acid length of the chlamydial T3S signal that drives 
secretion of TEM-1 hybrid proteins in Yersinia. For this, we analyzed 




secretion of proteins comprising the first 10, 20 and 40 amino acids of 
known C. trachomatis Incs that are T3S substrates (IncA or IncC) fused 
to TEM-1 (IncA10-TEM-1, IncA20-TEM-1, IncA40-TEM-1, IncC10-TEM-1, 
IncC20-TEM-1, IncC40-TEM-1) by Y. enterocolitica ΔHOPEMT or 
ΔHOPEMT ΔYscU (Figure 2.2). As negative controls we analyzed 
secretion by Y. enterocolitica ΔHOPEMT of TEM-1 alone and of a hybrid 
protein comprising the first 20 amino acids of the Yersinia T3S 
chaperone SycT and TEM-1 (SycT20-TEM-1). As positive control, we 
analyzed secretion by ΔHOPEMT of YopE15-TEM-1. Bacteria expressing 
these proteins were incubated in T3S-inducing conditions, and 
processed as described above (Figure 2.2). As observed before, mature 
TEM-1 alone was not secreted and, as expected, the SycT20-TEM-1 
fusion showed a basal percentage of secretion of 3.0 (SEM, 0.3). Based 
on this, to decide if a TEM-1 hybrid protein was secreted or not we set 
the threshold of percentage of secretion to 5.0 (Figure 2.2). We 
observed that the six Inc-TEM-1 hybrid proteins were type III secreted 
(Figure 2.2A and B). However, IncA10-TEM-1 and IncC10-TEM-1 were 
secreted less efficiently than YopE15-TEM-1, while IncA20-TEM-1, IncA40-
TEM-1, IncC20-TEM-1 and IncC40-TEM-1 were secreted at levels 
comparable to YopE15-TEM-1 (Figure 2.2A). Overall, these experiments 
indicated that the first 20 amino acids of C. trachomatis T3S substrates 
are sufficient to drive secretion of TEM-1 hybrid proteins by Y. 
enterocolitica ΔHOPEMT as efficiently as the first 15 amino acids of the 






Figure 2.2 – The first 20 amino acids of known C. trachomatis T3S substrates (IncA 
or IncC) are sufficient to efficiently drive T3S of TEM-1 hybrid proteins by Y. 
enterocolitica. Y. enterocolitica T3S-proficient (ΔHOPEMT) (A) and T3S-deficient 
(ΔHOPEMT ΔYscU) (B) were used to analyze secretion of hybrid proteins comprising 
the first 10, 20, or 40 amino acids of C. trachomatis IncA or IncC, or the first 15 or 20 
amino acids of Y. enterocolitica YopE or SycT, respectively, fused to the mature form of 
TEM-1 β-lactamase (TEM-1). Immunoblots show the result of T3S assays in which 
proteins in culture supernatants (S, secreted proteins) and in bacterial pellets (P, 
nonsecreted proteins) from 5x107 bacteria were loaded per lane. YopE15-TEM-1 was 
used as positive control, and TEM-1 and SycT20-TEM-1 were used as negative controls 
for the T3S assays. The percentage (%) of secretion of each TEM-1 hybrid was 
calculated by densitometry, as the ratio between the amount of secreted and total 
protein. The threshold to decide whether a protein was secreted was set to 5.0% 
(dashed line), based on the % of secretion of SycT20-TEM-1. Data are the mean ± SEM 
from at least 3 independent experiments. 
 
2.4.3 The majority of Inc proteins of C. trachomatis have a T3S 
signal recognized by the Y. enterocolitica T3SS 
We focused the identification of T3S signals in a group of 48 C. 
trachomatis known or predicted Inclusion membrane proteins studied by 
Li et al. (Table 2.1) (Li et al., 2008). Only 23 of those 48 predicted Inc 
proteins have been detected at the inclusion membrane by 




immunofluorescence microscopy using specific antibodies [referred to as 
known Inc proteins (Li et al., 2008; Mital et al., 2010; Dehoux et al., 
2011). The remaining 25 Inc proteins studied by Li and colleagues still 
lack conclusive experimental evidence about their localization in infected 
cells (referred to as putative Inc proteins) (Li et al., 2008; Lutter et al., 
2012). We did not consider other chlamydial proteins previously 
described to be localized at the inclusion membrane (Cap1 and CopN), 
as they do not possess the characteristic bi-lobed hydrophobic domain 
of an Inc protein (Fields and Hackstadt, 2000; Fling et al., 2001).  
 
Table 2.1 – List of known and putative Inc proteins from C. trachomatis analyzed in 
this Chapter. 
Inc proteina T3S signal Reference 
Known Incsb 
CT101 No This work 
CT115/IncD Yes (Subtil et al., 2005); this work 
CT116/IncE Yes (Subtil et al., 2005) 
CT117/IncF Yes This work 
CT118/IncG Yes (Subtil et al., 2005) 
CT119/IncA Yes (Subtil et al., 2005); this work 
CT147 NDe - 
CT222 Yes This work 
CT223 Yes (Subtil et al., 2005) 
CT225 No This work 
CT226 Yes (Dehoux et al., 2011) 
CT228 Yes (Dehoux et al., 2011); this work 
CT229 Yes (Subtil et al., 2005) 
CT232/IncB Yes This work 
CT233/IncC Yes (Fields et al., 2003; Subtil et al., 2005); this work 
CT249 Yes (Dehoux et al., 2011); this work 
CT288 Yes (Subtil et al., 2005) 
CT358 Yes (Dehoux et al., 2011); this work 
CT440 Yes (Dehoux et al., 2011); this work 
CT442 Yes (Subtil et al., 2005) 
CT618 Yes This work 
CT813 Yes This work 
CT850 Yes/Nod (Dehoux et al., 2011); this work 
Putative Incsc 





Inc proteina T3S signal Reference 
CT006 NDe - 
CT036 Yes This work 
CT058 Yes (Dehoux et al., 2011); this work 
CT134 No This work 
CT135 Yes This work 
CT164 No This work 
CT179 No This work 
CT192 No/Yesd (Dehoux et al., 2011); this work 
CT195 Yes (Dehoux et al., 2011); this work 
CT196 Yes This work 
CT214 Yes This work 
CT224 Yes This work 
CT227 Yes This work 
CT300 Yes This work 
CT345 Yes This work 
CT357 Yes This work 
CT365 Yes This work 
CT383 Yes (Dehoux et al., 2011); this work 
CT449 Yes This work 
CT483 Yes This work 
CT484 No (Dehoux et al., 2011); this work 
CT565 No (Dehoux et al., 2011); this work 
CT728 No This work 
CT789 Yes This work 
aProteins containing a bi-lobed hydrophobic motif that were analyzed by Li et al (Li et al., 
2008), which we selected to study in this work. We did not consider proteins (Cap1 and 
CopN) which localize at the inclusion membrane but which do not possess the bi-lobed 
hydrophobic domain (Fields and Hackstadt, 2000; Fling et al., 2001). More recent 
bioinformatics-based analyses identified additional putative Inc proteins (CT018, CT079, 
CT081, CT244, CT324, CT326, CT556, CT578, CT616, CT618, CT642, CT645, CT788, 
CT789, CT814.1, CT819, CT837, CT846, and CT873) in C. trachomatis (Fields et al., 
2003; Subtil et al., 2005; Dehoux et al., 2011), but these proteins were not analyzed in 
this Chapter. 
bKnown Inc proteins contain a bi-lobed hydrophobic motif and have been localized at the 
inclusion membrane by immunofluorescence microscopy using specific antibodies (Li et 
al., 2008; Mital et al., 2010; Dehoux et al., 2011). 
cPutative Inc proteins contain a bi-lobed hydrophobic motif but have not yet been 
localized at the inclusion membrane. 
dConflicting data between our observations and previous analyses obtained by using 
Shigella flexneri as a heterologous bacterial host. 
eND, not determined. 
 
 




We analyzed secretion of hybrid proteins comprising the first 20 amino 
acids of each putative or known Inc and TEM-1 by ΔHOPEMT or 
ΔHOPEMT ΔYscU Y. enterocolitica (Figure 2.3). The different Y. 
enterocolitica strains were incubated in T3S-inducing conditions, 
followed by fractionation of the bacterial cultures into culture 
supernatants and bacterial pellets and subsequent immunoblotting 
analyses of the proteins in the two fractions. In total, we have analyzed 
T3S signals in 24 putative Incs (18 have not been previously analyzed 
for T3S) and in 15 known Incs (7 have not been previously analyzed for 
T3S) (Figure 2.3 and Table 2.1). The expression levels of the TEM-1 
hybrid of putative Inc CT006 were extremely low, which hampered the 
analysis of a T3S signal in this protein. These experiments led to the 
identification of a T3S signal in 18 putative Incs and in 12 known Incs 
(Figure 2.3 and Table 2.1). This revealed 5 known and 14 putative Incs 
as novel C. trachomatis T3S substrates (Figure 2.3 and Table 2.1). 
However, we did not detect a clear T3S signal in three known Incs 
(CT101, CT225, and CT850; Figure 2.3 and Table 2.1). Their T3S signal 
could extend beyond the first 20 amino acids or might not be recognized 
by the Y. enterocolitica T3S system; alternatively, they might be 
transported into the inclusion membrane by a distinct mechanism. 
Regardless of the exact explanation, this implies that the lack of a 
detectable T3S signal could not be taken as a definitive indication that a 
putative Inc does not localize at the inclusion membrane. Furthermore, 
the percentage of putative and known Incs analyzed whose first 20 
amino acids could be recognized by the Y. enterocolitica T3S machinery 
was nearly identical [75% (18 out of 24) and 80% (12 out of 15), 
respectively]. Overall, these analyses indicated that most of the putative 
Incs analyzed have a T3S signal recognized by Y. enterocolitica and 







Figure 2.3 – Type III secretion (T3S) signals in C. trachomatis Inc proteins. Y. 
enterocolitica T3S-proficient (ΔHOPEMT) and T3S-deficient (ΔHOPEMT ΔYscU) 
bacteria were used to analyze secretion of hybrid proteins comprising the first 20 amino 
acids of Incs, or of Y. enterocolitica SycT, fused to the mature form of TEM-1 β-
lactamase (TEM-1). (A) and (B) Immunoblots show the result of representative assays in 
which proteins in culture supernatants (S - secreted proteins), and in bacterial pellets (P 
- nonsecreted proteins) from 5x107 bacteria were loaded per lane. SycT and SycO are 
strictly cytosolic Yersinia T3S chaperones (Iriarte and Cornelis, 1998; Letzelter et al., 
2006). SycT20-TEM-1 was a negative control for the T3S assays. Immunodetection of 




SycO ensured that presence of TEM-1 hybrid proteins in culture supernatants was not a 
result of bacterial lysis or contamination. (C) The percentage (%) of secretion of each 
TEM-1 hybrid was calculated by densitometry, as the ratio between the amount of 
secreted and total protein. The threshold to decide whether a protein was secreted was 
set to 5% (dashed line), based on the % of secretion of SycT20-TEM-1. Data are the 
mean ± SEM from at least 3 independent experiments. Please note that in this work we 
did not analyze all described putative Incs (see legend of Table 2.1) and that T3S signals 
were not analyzed for all known Incs. 
 
majority of Inc proteins are T3S effectors. Our work also shows that the 
analysis of T3S signals in proteins possessing a bi-lobed hydrophobic 
domains suggesting that they are Incs cannot be used to deduce 
whether they localize at the inclusion membrane. Instead, specific 
immunofluorescence analyses of Chlamydia-infected cells are required 
for such identification. 
We analyzed the presence of a T3S signal in 14 Incs that have been 
previously analyzed by others (Table 2.1) (Fields et al., 2003; Subtil et 
al., 2005; Dehoux et al., 2011). Our results were in agreement with the 
published data except for two proteins. CT192 was secreted by Yersinia 
in our study as a TEM-1 hybrid but not as a Cya hybrid by Shigella 
(Dehoux et al., 2011). CT850 was not secreted by Yersinia in our study 
as a TEM-1 hybrid but was secreted as a Cya hybrid by Shigella 
(Dehoux et al., 2011). These results might be explained by the different 
length of the amino acid sequences used in the fusions of TEM-1 and 
Cya, and also differences in the recognition of the C. trachomatis T3S 
signal by Yersinia and Shigella. 
 
2.4.4 Prediction of T3S signals in C. trachomatis Inc proteins 
In the last 6 years, several algorithms have been developed aimed at 
identifying T3S substrates in silico (Arnold et al., 2009; Löwer and 





2013). Arnold and colleagues developed a machine learning tool 
[Effective; (Arnold et al., 2009)] that searches for T3S signals based on 
the protein secondary structure, and frequency and physico-chemical 
properties of amino acids in the N-terminal region of known T3S 
substrates. Lower and colleagues developed a neural network [Modlab; 
(Löwer and Schneider, 2009) that scans the entire protein for common 
features shared by a dataset of known T3S effectors. Samudrala and 
colleagues created a machine learning tool [Sieve; (Samudrala et al., 
2009)] to identify T3S signals based on evolutionary relationships, amino 
acid composition, and G+C content of the first 30 amino acid residues of 
a protein. Hovis and colleagues modified this last tool to create another 
machine learning tool [cSieve; (Hovis et al., 2013)] that includes 
Chlamydia genus specific properties to better predict C. trachomatis T3S 
effectors. Wang and colleagues developed a Hidden-Markov model 
[T3_MM; (Wang et al., 2013)] that analyzes not only the amino acid 
composition, but also the preferable position of each amino acid in 
relation to the others in the N-terminal 100 residues. 
In this Chapter, we analyzed in Yersinia the secretion of 39 different 
TEM-1 hybrid proteins directed by the first 20 amino acids of C. 
trachomatis Inc proteins. We obtained the prediction of secretion for the 
TEM-1 hybrid proteins using the 3 prediction tools available online 
(Effective, Modlab, and T3_MM), and retrieved the list of Inc proteins 
from the chlamydial T3S substrates predicted by cSieve (Hovis et al., 
2013) (Table 2.2). We also compared our data and the predictions to 
previous T3S assays using Shigella as heterologous bacteria (Subtil et 
al., 2005; Dehoux et al., 2011). 
Overall, out of the 39 TEM-1 hybrids analyzed in this Chapter, Effective 
predicted 26 (66.7%), Modlab 23 (59.0%), and T3_MM 10 (25.6%) as 
being T3S substrates. In relation to our data, out of the 30 TEM-1 hybrid 
proteins in which a T3S signal was recognized by Yersinia, Effective 




predicted 24 (80.0%), Modlab 22 (73.3%), and T3_MM 8 (26.7%) as 
possessing a T3S signal. The cSieve tool predicted 22 of the 39 (56.4%) 
Incs analyzed in this Chapter as TEM-1 hybrids as being T3S 
substrates, and 19 out of 30 Incs (63.3%) whose first 20 amino acids 
drive T3S of TEM-1 hybrids by Yersinia were among the chlamydial T3S 
substrates predicted by cSieve.  
Specifically, and in agreement with our work, 6 out of 30 Incs (20.0%; 
CT228, CT358, CT813, CT345, CT357, and CT383) whose first 20 
amino acids drove T3S of TEM-1 hybrids by Yersinia were predicted to 
have a T3S signal by all methods (Effective, Modlab, T3_MM, and 
cSieve). In addition, ten (33.3%) and eight (26.7%) of the TEM-1 hybrids 
secreted in Yersinia were predicted to have a T3S signal by 3 or 2, 
respectively, prediction tools simultaneously. Moreover, we found 5 out 
of 9 (55.6%) TEM-1 hybrids that were not secreted by Yersinia and for 
which the predictions also indicated that they do not have a T3S signal 
(the first 20 amino acids of CT225, CT850, CT134, CT179, and CT484). 
In these proteins, the T3S signal could extend beyond the 20 amino 
acids and might be truncated due to the fusion to the TEM-1 protein. 
 
Table 2.2 – Comparison of the T3S signals identified in this Chapter with in silico 
predictions and results from other studies. 
Inc proteina Effectiveb Modlabc T3_MMd cSievee Dehouxf Y. enterocoliticag 
Known Incsh 
CT101 No No No Yes NTj No 
CT115/IncD Yes No No No Yes Yes 
CT117/IncF No No No No NT Yes 
CT119/IncA Yes Yes Yes No Yes Yes 
CT222 Yes Yes No Yes NT Yes 
CT225 No No No No NT No 
CT228 Yes Yes Yes Yes Yes Yes 
CT232/IncB Yes No No Yes NT Yes 
CT233/IncC Yes Yes No Yes Yes Yes 
CT249 No No No Yes Yes Yes 





CT440 Yes Yes No Yes Yes Yes 
CT618 Yes Yes No No NT Yes 
CT813 Yes Yes Yes Yes NT Yes 
CT850 No No No No Yes No 
Putative Incsi 
CT005 Yes Yes Yes No NT Yes 
CT036 No No No Yes NT Yes 
CT058 Yes Yes No Yes Yes Yes 
CT134 No No No No NT No 
CT135 Yes Yes No No NT Yes 
CT164 Yes Yes Yes Yes NT No 
CT179 No No No No NT No 
CT192 Yes Yes No No No Yes 
CT195 No No No No Yes Yes 
CT196 Yes Yes No Yes NT Yes 
CT214 No Yes No Yes NT Yes 
CT224 Yes Yes No No NT Yes 
CT227 Yes Yes No No NT Yes 
CT300 Yes Yes No Yes NT Yes 
CT345 Yes Yes Yes Yes NT Yes 
CT357 Yes Yes Yes Yes NT Yes 
CT365 Yes Yes No Yes NT Yes 
CT383 Yes Yes Yes Yes Yes Yes 
CT449 Yes No No Yes NT Yes 
CT483 Yes Yes No Yes NT Yes 
CT484 No No No No No No 
CT565 Yes No Yes No No No 
CT728 No No No Yes NT No 
CT789 No No No No NT Yes 
aInc proteins analyzed as TEM-1 hybrids in this Chapter. 
bInc proteins predicted to be secreted as TEM-1 hybrids by Effective (Arnold et al., 2009) 
using a cutoff of 0.6. 
cInc proteins predicted to be secreted as TEM-1 hybrids by Modlab (Löwer and 
Schneider, 2009) using a cutoff of 0.4. 
dInc proteins predicted to be secreted as TEM-1 hybrids by T3_MM (Wang et al., 2013) 
scoring a positive value. 
eInc proteins predicted to have a T3S signal by cSieve (Hovis et al., 2013). 
fCya hybrids that were secreted by Shigella (Dehoux et al., 2011). 
gTEM-1 hybrid proteins that were secreted by Y. enterocolitica in this Chapter. 
hInc proteins previously shown lo localize at the inclusion membrane. 
iInc proteins not yet described to localize at the inclusion membrane. 
jNT not tested. 
 




On the other hand, we found 3 out of 30 Incs (10.0%; CT117, CT195, 
and CT789) whose first 20 amino acids drove T3S of TEM-1 hybrids by 
Yersinia but for which all predictions failed to detect a T3S signal. 
Furthermore, among the 9 Incs whose first 20 amino acids did not drive 
T3S of TEM-1 hybrids by Yersinia, one (11.1%, CT164) was predicted to 
have a T3S signal by all 4 methods, and two (22.2%; CT101 and CT728) 
and one (11.1%; CT565) were predicted not to have a T3S signal by 3 or 
2, respectively, prediction tools. 
In summary, for 3 Incs (CT228, CT358, and CT383), data from Yersinia, 
Shigella, and the predictions indicate that these proteins are T3S 
substrates, and on the other hand, we found one Inc (CT484) that was 
not considered a T3S substrate by any of the analyses mentioned 
above. In general, Effective was the strongest prediction tool, generating 
a higher number of T3S substrates (80.0% of the 30 Yersinia secreted 
TEM-1 hybrids), although Modlab also gave similar results (~70.0%). 
Only eight of the 39 Incs (20.5%) were not predicted to have a T3S 
signal by any of the 4 prediction tools, indicating that these prediction 
tools have a good predictive potential but still there is room for 
improvement. The length of the N-terminal used in the fusions to the 
reporter protein also influences these predictions as in some cases the 
T3S signal could extend beyond the 20 amino acids considered as the 
prototypical length of the T3S signal.  
 
2.4.5 Composition analysis of the first 20 amino acids of the N-
terminal of Inc proteins of C. trachomatis 
Although previous studies did not reveal any obvious feature defining a 
universal T3S signal, we analyzed our data for common features. The 
comparison between known T3S effectors and non-T3S effectors has 





the amino acid composition of the N-terminal regions of these proteins 
indicated several characteristics that were crucial to develop the 
prediction tools mentioned above (Arnold et al., 2009; Löwer and 
Schneider, 2009; Samudrala et al., 2009; Hovis et al., 2013; Wang et al., 
2013). Among these characteristics, we focused on enrichment or 
depletion of specific amino acids or groups of amino acids. We 
calculated the total amino acid composition of the N-terminal 20 amino 
acids of the 30 Inc proteins that were secreted as TEM-1 hybrids in this 
Chapter (Figure 2.4, Figure 2.5 and Figure 2.6). Like reported before, we 
observed a predominant frequency of serine and proline (14.5% and 
11.0%, respectively, of all the amino acid composition of the first 20 
amino acids of the 30 secreted TEM-1 Inc hybrids), and to a less extent 
of threonine (7.8%). The observed reduced frequency of lysine and 
glutamate (2.3% and 2.7%, respectively) were also consistent with the 
previous data, however, the reduced frequency in leucine (6.7%) was 
not a feature in our set of proteins. We could also see a reduced 
frequency of charged residues (arginine, histidine, tyrosine, cysteine, 
and aspartate; the sum is 14.2%). Analyzing the position of the amino 
acids in the sequence we observed that hydrophobic (non-polar) 
residues were more scattered and alternated with hydrophilic (polar) 









Figure 2.4 – Unaligned N-terminal sequences of the 30 Inc proteins that were 
secreted as TEM-1 hybrids in this Chapter. Hydrophilic or polar residues (C, D, E, H, 
K, N, P, Q, R, S, T, W and Y) are colored in blue and hydrophobic or non-polar residues 







Figure 2.5 – Composition analysis of the 20 amino acids at the N-termini of Inc 
proteins. Total amino acid composition of the first 20 amino acids of the 30 Inc proteins 
that were secreted as TEM-1 hybrids in this Chapter. 
 
 
Figure 2.6 – Consensus-like sequence motif of the T3S signal present in Inc 
proteins. Sequence motif of the T3S signal of the 30 Inc proteins that were secreted as 
TEM-1 hybrids in this Chapter, showing the amino acids with the highest positive weight 
for each amino acid position, from 1 to 20. For comparison we show below the sequence 
motif for S. Typhimurium T3S effectors (Samudrala et al., 2009), showing the amino 
acids with the highest positive weight for each amino acid position, from 1 to 20. 
Positions with an ‘‘x’’ have no representation in the sequence motif. 
 
 




Samudrala and colleagues (Samudrala et al., 2009) analyzed the N-
terminal of effectors from Salmonella enterica serovar Typhimurium (S. 
Typhimurium) and Pseudomonas syringae and were able to derive a 
consensus-like sequence motif. We compared the sequence motif found 
for Salmonella effectors with the sequence motif found in this Chapter 
for the Inc proteins from C. trachomatis that were secreted as TEM-1 
hybrids (Figure 2.4 and Figure 2.6). Besides the methionine in the first 
position, both consensus sequences had a serine in the 8th and 12th 
position. Although a conserved motif was not found between the two 
species, some similarities could be identified. Both sequence motifs are 
highly represented (only 2 and 4 positions for the sequence motif of C. 








To understand if the presence or lack of a T3S signal together with a 
hydrophobic domain characteristic of Incs could be used to identify a 
protein as an Inc or not, we analyzed T3S signals in a pool of C. 
trachomatis known and putative Inc proteins. As we were unable to 
identify a T3S signal in a few known Inc proteins (CT101, CT225, and 
CT850), we conclude that definitive identification of a protein as an Inc 
requires their immunolocalization at the inclusion membrane in 
Chlamydia-infected cells. However, these analyses led to the 
identification of 19 novel T3S substrates, including 14 putative Inc 
proteins. Additionally, data from 4 T3S signal prediction tools available in 
the literature and analyses of the amino acid composition of the N-
terminal of Inc proteins revealed common characteristics to known T3S 
effectors of other bacteria like Salmonella. Our data supports the notion 
that the majority of Inc proteins possess a T3S signal that enables the 
translocation into the host cell. It remains to be understood how after 
crossing the inclusion membrane and reaching the host cell cytosol the 
Inc proteins are inserted into the inclusion membrane. The characteristic 
hydrophobic domain likely plays a fundamental role in this process, but 
the mechanistic details are still unknown. 
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3.1 Abstract  
Chlamydia trachomatis is a human bacterial pathogen that multiplies 
only within an intracellular membrane-bound vacuole, the inclusion. C. 
trachomatis includes ocular and urogenital strains, usually causing 
infections restricted to epithelial cells of the conjunctiva and genital 
mucosa, respectively, and lymphogranuloma venereum (LGV) strains, 
which can infect macrophages and spread into lymph nodes. However, 
C. trachomatis genomes display >98% identity at the DNA level. In this 
Chapter, we studied whether C. trachomatis Inc proteins, which have a 
bi-lobed hydrophobic domain that might mediate their insertion in the 
inclusion membrane, could be a factor determining these different types 
of infection and tropism. Analyses of polymorphisms and phylogeny of 
48 Inc proteins from 51 strains encompassing the three disease groups 
showed significant amino acid differences that were mainly due to 
variations between Inc proteins from LGV and ocular or urogenital 
isolates. Studies of the evolutionary dynamics of inc genes suggested 
that 10 of them are likely under positive selection and indicated that 
most non silent mutations are LGV specific. Additionally, real-time 
quantitative PCR analyses in prototype and clinical strains covering the 
three disease groups identified three inc genes with LGV-specific 
expression. We determined the transcriptional start sites of these genes 
and found LGV-specific nucleotides within their promoters. Thus, subtle 
variations in the amino acids of a subset of Inc proteins and in the 
expression of inc genes may contribute to the unique tropism and 







Chlamydia trachomatis is a human obligate intracellular pathogen that 
includes the trachoma and LGV (lymphogranuloma venereum) biovars 
(Schachter, 1999). The trachoma biovar comprises ocular and urogenital 
strains, which cause localized infections of the epithelial surface of the 
conjunctiva and genital mucosa, respectively; strains of the LGV biovar 
cause invasive urogenital disease, due to their ability to infect 
macrophages and spread into lymph nodes. C. trachomatis strains can 
be further classified into ocular serovars A to C, urogenital serovars D to 
K, and LGV serovars L1 to L3. 
The genomic sequences of different ocular, urogenital, and LGV strains 
exhibit >98% identity and a high degree of synteny (Stephens et al., 
1998; Carlson et al., 2005; Thomson et al., 2008; Seth-Smith et al., 
2009; Jeffrey et al., 2010; Unemo et al., 2010; Somboonna et al., 2011; 
Harris et al., 2012). Therefore, the determinants of the different types of 
infection (invasive or noninvasive) and tissue tropism (eyes, genitals, 
and lymph nodes) must rely on the few genes present in some strains 
but not in others and on nucleotide differences which could lead either to 
proteins with disease group-specific amino acids or to differential gene 
expression. Some of these determinants were suggested in previous 
studies: the tryptophan (trpRBA) operon (Allan C. Shaw et al., 2000; 
Fehlner-Gardiner et al., 2002; Caldwell et al., 2003) and genes encoding 
cytotoxin (Carlson et al., 2004), phospholipase (Nelson et al., 2006), 
polymorphic membrane proteins (Pmps) (Gomes et al., 2006), and Tarp 
(Lutter et al., 2010). 
Throughout development, C. trachomatis reside and multiply within a 
membranaceous compartment, known as the inclusion, and manipulate 
host cells by using a type III secretion system (T3SS) to translocate 
effector proteins into host cells (Valdivia, 2008; Betts et al., 2009). These 




effectors include the inclusion membrane (Inc) proteins, characterized by 
a bi-lobed hydrophobic motif thought to mediate their insertion into the 
inclusion membrane (Fields et al., 2003; Subtil et al., 2005). In Chapter 
2, we found T3S signals in the majority of Inc proteins, supporting the 
notion that they are indeed T3S substrates. Inc proteins from the same 
chlamydial species are normally unrelated to each other, and only a 
subset of ~25 Inc proteins is conserved between species (Dehoux et al., 
2011; Lutter et al., 2012). The C. trachomatis Inc proteins have been 
shown or suggested to subvert host cell vesicular and non-vesicular 
transport (Hackstadt et al., 1999; Rzomp et al., 2006; Delevoye et al., 
2008; Derré et al., 2011). More recently, a few Incs were shown to be 
involved in the exit of the host cell by the bacteria (Lutter et al., 2013), 
cytoskeleton reorganization (Dumoux et al., 2015; Kokes et al., 2015; 
Mital et al., 2015), and disruption of endosomal trafficking (Mirrashidi et 
al., 2015). Recently, it was also hypothesized that Inc proteins could 
interact with each other and act as scaffolds to form specific multi-
protein complexes in the inclusion membrane (Mital et al., 2013; 
Gauliard et al., 2015). However, virtually nothing is known about the 
biological role of most Inc proteins.  
In this Chapter, we used phylogenetic, molecular evolution, and gene 
expression analyses to determine whether Inc proteins could affect the 
type of infection and tissue tropism associated with C. trachomatis. Our 
studies suggest that a subset of Inc proteins might play a role in the 
unique capacity of C. trachomatis LGV strains to infect macrophages 






3.3 Materials and Methods 
3.3.1 Bacterial strains and growth conditions 
C. trachomatis prototype strains B/Har36, C/TW3, E/Bour, L2/434, and 
L3/404 [from the American Type Culture Collection (ATCC)] and clinical 
strains F/CS465-95 and L2b/CS19-08 (from the collection of the 
Portuguese National Institute of Health) were used as detailed below 
and propagated in HeLa 229 cells (from the ATCC) using standard 
techniques (Scidmore, 2005).  
 
3.3.2 DNA sequences of C. trachomatis inc, pmp and 
housekeeping genes 
Regardless of the origin of the C. trachomatis gene, throughout this work 
we used the nomenclature of the annotated D/UW3 strain (see Table 
A.3 in Annexes). The nucleotide sequences of the inc, pmp, and 
housekeeping genes analyzed were from the available genomes of 51 
C. trachomatis strains (Stephens et al., 1998; Carlson et al., 2005; 
Thomson et al., 2008; Seth-Smith et al., 2009; Jeffrey et al., 2010; 
Unemo et al., 2010; Somboonna et al., 2011; Harris et al., 2012). The 
strains and corresponding genome accession numbers are listed in 
Table A.3 (Annexes). The DNA sequences were retrieved from pairwise 
alignments obtained by BLAST. All sequences were manually inspected 
and corrected for accuracy and completeness. We excluded from further 
analysis a few DNA sequences containing ambiguous nucleotides. 
Whenever there were distinct annotations in GenBank for the start 
codon of the same inc gene in C. trachomatis archetype ocular 
(A/Har13), urogenital (D/UW3), and LGV (L2/434) strains, we used the 
following: for ct036 and ct119 (incA), in all cases the start codons of 
each gene as annotated for D/UW3 and A/Har13; for ct115 (incD) and 
ct192, the start codons of each gene as annotated for A/Har13, D/UW3, 




or L2/434, in ocular, urogenital or LGV strains, respectively; for ct226, in 
all cases the start codon as annotated for A/Har13 (see Table 3.1 and 
Table A.3 in Annexes). 
 
3.3.3 Sequence alignments and analyses of polymorphisms, 
phylogeny, and molecular evolution 
Alignments of the amino acid sequences of the Inc, Pmp, and 
housekeeping proteins, deduced from the retrieved nucleotide 
sequences, were generated using the ClustalW algorithm in MEGA5 
(Tamura et al., 2011). All alignments were manually inspected and 
corrected for artifacts. We excluded all strain-specific pseudogenes 
(Table 3.1) from further phylogenomic and evolutionary analyses. For 
the analyses of polymorphism, phylogeny, and molecular evolution, 
various tools present in MEGA5 were used, essentially as previously 
described (Gomes et al., 2006). Briefly, for analyses of polymorphism, 
we computed pairwise, overall, within-group (ocular, urogenital, or LGV), 
and between-group (ocular versus urogenital, ocular versus LGV, or 
urogenital versus LGV) amino acid p distances. For analyses of 
phylogeny, trees were generated using the neighbor-joining method 
(Saitou and Nei, 1987). The generated phylograms of Inc proteins were 
inspected for separate branches (segregation) of all ocular, urogenital, 
and LGV strains. This analysis was supported by comparison of pairwise 
amino acid p distances between and within disease groups. The 
phylogeny of an Inc protein was considered to segregate a disease 
group if the maximum pairwise amino acid p distance within groups was 
less than any of the pairwise amino acid p distances between groups. 
For molecular evolution analyses, we used the Kumar method (Nei and 
Kumar, 2000) to compute overall means of nonsynonymous (dN) and 
synonymous (dS) substitutions (per nonsynonymous or synonymous site, 





using the codon-based Z test of selection in MEGA5, genes were 
considered under positive selection if they showed a statistically 
significant value (P < 0.05) to reject the null hypothesis of strict neutrality 
(dN = dS) in favor of both positive selection (dN > dS) and lack of neutrality 
(dN ≠ dS). All these analyses were performed by bootstrapping with 1,000 
replicates and with the pairwise deletion option selected. 
 
3.3.4 Real-time quantitative PCR 
The expression of inc genes during the developmental cycle of C. 
trachomatis B/Har36, C/TW3, E/Bour, F/CS465-95, L2/434, L2b/CS19-
08, and L3/404 was estimated by determining inc mRNA levels at 
different times postinfection by real-time quantitative PCR (RT-qPCR). 
These experiments were essentially done as previously described 
(Nunes et al., 2007; Borges et al., 2010). Briefly, for each strain, six 
tissue culture flasks with a surface area of 25 cm2 containing 
monolayers of HeLa 229 cells were inoculated at a multiplicity of 
infection of 1; cells were harvested at 2, 6, 12, 20, 30, and 42 h 
postinfection by scraping in ice-cold phosphate-buffered saline. The cell 
suspension was sonicated to disrupt mammalian cells and promote 
bacterial release, followed by low-speed centrifugation at 4°C. The 
supernatant was then frozen in liquid nitrogen and stored at -80°C. 
These samples were used for total RNA purification and generation of 
cDNA, as previously described (Borges et al., 2010). Primers were 
designed for each inc gene using Primer Express (Applied Biosystems), 
based on identical C. trachomatis sequences between strains (Table A.1 
in Annexes). The RT-qPCR assays were done using the ABI 7000 SDS, 
SYBR green chemistry, and optical plates (Applied Biosystems), as 
previously described (Nunes et al., 2007; Borges et al., 2010). At each 
time point, raw RT-qPCR data for each inc gene were normalized 
against the data obtained for the 16S rRNA transcript, as it was 




previously demonstrated that this is a good endogenous control (Borges 
et al., 2010). The final results were based on at least two independent 
experiments. 
 
3.3.5 Transcription linkage and identification of transcriptional 
start sites 
We searched for disease group-specific nucleotides within the promoter 
region of three inc genes (ct058, ct192, and ct214) that showed 
differential gene expression. For this, we determined their transcriptional 
start sites (TSSs). For ct058 and ct192, it was ambiguous whether their 
promoters would lie immediately upstream from their predicted start 
codons. Therefore, we used reverse transcription coupled with PCR 
(RT-PCR) to determine if ct058 and ct059, or ct192 and ct193, are part 
of the same transcriptional unit. For this, RNA was isolated from HeLa 
229 cells infected for 30 h with C. trachomatis L2/434 using an NZY total 
RNA kit (NZYTech). cDNA was then generated by using random 
hexamers and iSCRIPT (Bio-Rad). Primers were designed to generate 
PCR products containing ~300 bp upstream and downstream from the 
predicted start codons (Table A.1 in Annexes). PCR products were 
obtained using DreamTaq DNA polymerase (Life Technologies). As 
controls for the PCRs, we also used as the template the product of a 
typical reverse transcription reaction but without iSCRIPT or total DNA 
isolated using an NZY tissue gDNA kit (NZYTech), from cells that were 
either infected with strain L2/434 for 42 h or left uninfected. The 
identification of the TSSs of ct059 (upstream from ct058 and in the same 
transcriptional unit), ct192, and ct214 in L2/434 was done by 5’ rapid 
amplification of cDNA ends (RACE), using a 5’/3’ RACE kit (second 
generation; Roche). We used RNA isolated as described above from 
HeLa 229 cells infected for 30 h with C. trachomatis L2/434 and the 





stranded cDNA was done with Phusion DNA polymerase (Life 
Technologies). PCR products were purified after agarose gel 
electrophoresis, using a High Pure PCR purification kit (Roche), and 
then subjected to DNA sequencing (Stab Vida). To analyze the 
determined TSSs in the context of the promoter regions of ct059-ct058, 
ct192, and ct214 in all strains used in the RT-qPCR assays, the 
corresponding nucleotide sequences were either retrieved from 
GenBank (E/Bour, L2/434, and L3/404; Table A.3 in Annexes) or 
determined by DNA sequencing (C/TW3, B/Har36, F/CS465-95, and 
L2b/CS19-08), as previously described (Gomes et al., 2006) and using 
the primers listed in Table A.1 (Annexes). All these manipulations were 
done according to instructions from the indicated manufacturers. 
 
3.3.6 Nucleotide sequence accession numbers 
The sequences of the promoter regions of ct192 and ct214 and of ct059-
ct058 in C/TW3, B/Har36, F/CS465-95, and L2b/CS19-08 determined in 
this study were submitted to GenBank and are available under 
accession numbers JX451863 to JX451874.  





3.4.1 Differences in the amino acid sequences of Inc proteins 
among C. trachomatis strains correlate with the type of infection 
and with tissue tropism 
As in Chapter 2 we have seen that lack of a T3S signal in a protein 
containing a bi-lobed hydrophobic motif does not exclude its possible 
localization at the inclusion membrane, in this Chapter we focused on 
the complete set of 48 known and putative Inc proteins that was 
analyzed in Chapter 2 (Table 2.1 in Chapter 2). The nucleotide 
sequences of the genes encoding the selected proteins were retrieved 
from 51 fully sequenced C. trachomatis genomes (7 ocular, 23 
urogenital, and 21 LGV strains) (Table A.3 in Annexes). In an initial 
analysis, 7 inc genes proved to be pseudogenes in different C. 
trachomatis strains (ct058, ct101, ct135, ct192, ct227, ct228, and ct300) 
(Table 3.1). ct358 was described as a pseudogene in L2/434 and 
L2/UCH-1 (Thomson et al., 2008), and its nucleotide sequence is 100% 
identical in all LGV strains. However, analysis of its nucleotide sequence 
suggests that ct358 may encode a functional protein that is 7 amino 
acids shorter at its C-terminus than CT358 (178 amino acid residues) in 
ocular and urogenital strains (Table 3.1). In the seven inc genes that we 
identified as pseudogenes, the full-length gene is disrupted by a 
mutation that leads to a significantly truncated protein. The only disease 
group-specific correlation was observed with ct300, which is a 
pseudogene in all LGV strains analyzed. Therefore, the encoded protein 
is expendable for LGV infections. In addition, ct058 and ct101 revealed 
to be pseudogenes in almost all analyzed ocular and urogenital strains, 





















ct058 333 1 A/Har13 123 1 A/Har13 Ocular except 
A/Har13 
834 4 LGV except 
L1/440 
    




ct115b    before 
start 
codon 
10 Ocular  
   before 
start 
codon 
14 LGV  
   411 4 LGV  
   423 1 LGV  





ct147 279 1 A/363, 
A/2497, and 
A/5291 








67 Ocular     
210 8 D/SotonD1 
and all E 
and F 
strains 
    
ct214    1110 1 Ocular  
ct222 222 1 LGV     
ct223 399 1 LGV     
786 1 LGV     
ct226d 21 2 Ocular     
ct227       A/Har13 
ct228 
 




ct288    1419 1 LGV  
ct300       LGV 
ct358e 477 1 B/Jali20     
492 3 LGV     
519 5 LGV     
















ct383 717 4 A/363 and 
A/7249 
    
ct442 162 1 LGV 66 2 All except 
D/SotonD5, 
D/SotonD6, 
and G, Ia, 
J, and K 
strains 
 




    
aThe position is based in the relative inc gene sequence of C. trachomatis D/UW3. 
Whenever different start codons for the same inc gene were annotated in different 
strains, we followed the annotations from archetype ocular (A/Har13), urogenital 
(D/UW3), and LGV strains (L2/434) (except ct226 and ct358, as indicated). 
bConsidering that ct115 (incD) from urogenital strains have a different start codon from 
ocular and LGV strains, as annotated for A/Har13, D/UW3, and L2/434; however, if the 
start codon of ct115 is identical for all strains and corresponds to the one annotated for 
C. trachomatis D/UW3 [as suggested by an upstream strong putative ribosome binding 
site (GUGAGG-N3-AUG; predicted start codon underlined) that is present in all strains in 
the same position], then ct115 is a pseudogene in ocular strains. 
cConsidering that ct192 from ocular, urogenital and LGV strains have a different start 
codon, as annotated for A/Har13, D/UW3, and L2/434; however, similarly to ct115/incD, 
if the start codon of ct192 is identical for all strains and corresponds to the one annotated 
for C. trachomatis L2/434/Bu [as suggested by an upstream strong putative ribosome 
binding site (AGGAGG-N5-GUG; predicted start codon underlined) that is present in all 
strains in the same position], then ct192 is a pseudogene in ocular strains. This is the 
predicted start codon of ct192 annotated in A/2497, B/Jali20, and B/TZ1A428/OT (Seth-
Smith et al., 2009), and ct192 is indicated as a pseudogene in these ocular strains (Seth-
Smith et al., 2009). 
dConsidering that the start codon of ct226 is in all cases the one annotated for strain 
A/Har13. Otherwise, assuming the start codons annotated for strains D/UW3 and L2/434 
for urogenital and LGV strains, then ocular strains have a 5 codon- and LGV strains an 
11 codon-deletion relative to the start codon of urogenital strains, and ct226 is a 
pseudogene in strain D/SotonD6. 
ect358 is annotated as a pseudogene in L2/434 and its nucleotide sequence is 100% 
identical among LGV strains. However it is likely that in LGV strains this gene encodes a 
protein that is 7 amino acid residues shorter at its C-terminus than CT358 in ocular and 







pseudogenes in a few strains, with no obvious correlation with ocular, 
urogenital, or LGV disease groups (Table 3.1). Furthermore, 12 inc 
genes showed small deletion and insertion events (Table 3.1). 
To understand if the amino acid sequences of Inc proteins vary among 
strains, we determined the overall mean genetic distance (amino acid p 
distance) for each Inc protein among all 51 C. trachomatis strains 
(discarding strain-specific pseudogenes) (Figure 3.1A). As a reference, 
we also analyzed the 9 Pmps and 9 housekeeping proteins of C. 
trachomatis previously shown to be polymorphic (Nunes et al., 2008) 
(Figure 3.1A). The Pmps should localize at the bacterial outer 
membrane and the housekeeping proteins within the bacterial cell. The 
average p distance was 0.017 (SEM, 0.002) for Inc proteins, 0.020 
(SEM, 0.007) for Pmps, and 0.013 (SEM, 0.003) for housekeeping 
proteins. Based on this, and considering the average p distance for Inc 
proteins as a cutoff value, we defined 19 (40% of the total) Inc proteins 
as polymorphic (p distance ≥ 0.017) (Figure 3.1A). As comparison, 4 
Pmps (44%) and 2 housekeeping proteins (22%) displayed a p distance 
of ≥ 0.017. This showed that the overall degree of polymorphism in Inc 
proteins among C. trachomatis strains is similar to that of Pmps and is 
higher than that of known polymorphic housekeeping proteins. 
To understand if the amino acid differences between Inc proteins were 
related to the type of infection and with tissue tropism, we determined 
the average p distances of Inc proteins within and between the three 
groups of strains (ocular, urogenital, and LGV) (Figure 3.1B). This 
showed that the differences were largely due to variations between Inc 
proteins from LGV strains and ocular (average p distance = 0.031; SEM, 
0.004) or urogenital strains (average p distance = 0.029; SEM, 0.004) 
(Figure 3.1B). These average p distances were significantly higher (in all 
cases, P < 0.0001; two-tailed t test) than those between Inc proteins  
 









Figure 3.1 – Polymorphisms in C. trachomatis Inc proteins. Polymorphic membrane 
proteins (Pmps) and housekeeping proteins (HKs) were analyzed as references. (A) 
Overall mean genetic distance (polymorphisms) based on the p distance between all 
possible pairs of amino acid (aa) sequences of Inc proteins, Pmps, and HKs among C. 
trachomatis strains. Proteins marked with an asterisk have a p distance that is equal to 
or higher than the average value for Inc proteins [0.017 (dashed line)]. (B) Average 
mean genetic distance, based on the p distance between all possible pairs of amino acid 
sequences within [ocular (OC), urogenital (UROG), or LGV] or between (OC-UROG, 
OC-LGV, or UROG-LGV) C. trachomatis disease groups. (C) Venn diagrams showing 
the phylogenetic segregation of C. trachomatis disease groups based on neighbor-
joining trees of Inc proteins, Pmps, or HKs and on pairwise p distances between and 
within disease groups for all possible pairs of Inc protein, Pmp, or HK sequences from 
the C. trachomatis strains analyzed. All these analyses were performed by bootstrapping 
with 1,000 replicates. Error bars represent SEM. 
 
from ocular and urogenital strains (average p distance = 0.011; SEM, 
0.002) or within Inc proteins from the same disease groups (average p 
distance < 0.006) (Figure 3.1B). Similar observations were made for  
Pmps except that, in contrast to Inc proteins, the average p distance 
between Pmps from ocular and urogenital strains was not significantly 
different than that between Pmps from LGV strains and ocular or 
urogenital strains (in both cases, P > 0.05; two-tailed t test) (Figure 
3.1B). Also in contrast to the Inc proteins, the variation in the amino acid 
sequences of housekeeping proteins between each of the three groups 
was clearly not different (in all cases, P > 0.05; two-tailed t test) (Figure 
3.1B). Furthermore, the amino acid sequences of housekeeping proteins 
varied nearly as much between or within groups (Figure 3.1B). The main 
exception was the LGV group, within which the housekeeping proteins, 
like Inc proteins and Pmps, proved to be extremely highly conserved 
(average p distance < 0.002 for the three cases) (Figure 3.1B). Thus, the 
separation (p distance) between LGV strains and ocular or urogenital 
strains is much more marked for Inc proteins than for Pmps or 
housekeeping proteins. 
 




We then made and analyzed phylogenetic reconstructions based in the 
amino acid sequence of Inc proteins. The phylograms of five Inc proteins 
(10%) showed tropism, i.e., segregation of the three disease groups, 
and those of 38 Inc proteins (84%) evidenced segregation of at least one 
disease group (Table 3.2 and Figure 3.1C). The phylograms of a total of 
35 Inc proteins (73%) showed segregation of LGV strains, while only 12 
(25%) and 8 (17%) displayed clustering of ocular and urogenital strains, 
respectively (Table 3.2 and Figure 3.1C). This scenario was mirrored by 
the phylograms of Pmps but was in contrast to the phylograms of 
housekeeping proteins, in which segregation by disease group was less 
often seen (Table 3.2 and Figure 3.1C). 
 
Table 3.2 – Distribution of the segregation into disease groups displayed by amino 
acid-based phylograms of Incs, Pmps, and housekeeping proteins (HKs). 
Segregation Incs Pmps HKs 
Tropism CT115, CT135, CT214, CT223, 
CT383 
PmpF, PmpH  
Ocular & 
Urogenital 
CT232   
Ocular & LGV CT116, CT195, CT224, CT442, 
CT850 
PmpE, PmpI YraL 
LGV & Urogenital CT226   
Ocular CT225   
Urogenital CT233   
LGV CT006, CT036, CT101, CT117, 
CT118, CT147, CT179, CT192, 
CT196, CT222, CT227, CT228, 
CT229, CT249, CT288, CT345, 
CT357, CT358, CT365, CT449, 





None CT005, CT058, CT119, CT134, 
CT164, CT300, CT440, CT483, 
CT728, CT789 








In summary, there are significant differences in the amino acid 
sequences of Inc proteins among C. trachomatis strains, and they 
correlate with the type of infection and with tissue tropism. In particular, 
differences are mostly between Inc proteins from LGV strains and Inc 
proteins from ocular or urogenital strains. 
 
3.4.2 inc genes of C. trachomatis have distinct evolutionary 
dynamics, and several inc genes are likely under positive selection 
To understand the underlying evolutionary pressures that drive amino 
acid changes in Inc proteins, we analyzed the molecular evolution of inc 
genes. We first determined overall dN/dS values for inc genes by 
comparing them to the 9 pmp genes and the 9 selected housekeeping 
genes of C. trachomatis. We found that 24 inc genes (50%) had dN/dS 
values of >1 and that in four inc genes, all substitutions were 
nonsynonymous (Figure 3.2A and Table A.4 in Annexes). In contrast, 
only two pmp genes (22%) had dN/dS values of >1, and all housekeeping 
genes had dN/dS values of <1 (Figure 3.2A and Table A.4 in Annexes). 
Analyses of the overall dN/dS values using the codon-based Z test of 
selection (see Materials and Methods) yielded statistically significant 
values for 10 inc genes (ct116/incE, ct118/incG, ct119/incA, ct222, 
ct223, ct228, ct229, ct249, ct288, and ct813) but only for one pmp gene 
and for no housekeeping gene (Figure 3.2A and Table A.4 in Annexes). 
This indicated that these 10 inc genes are likely under positive selection. 
We then aimed to understand which group of strains might cause the 
detection of this possible evolutionary trend. For this, we assessed the 
impact of artificially removing ocular, urogenital, or LGV strains from the 
analyses (Figure 3.2B and Tables A.4, A.5, A.6, and A.7 in Annexes).  
 









Figure 3.2 – Evolutionary dynamics of inc genes. Genes encoding polymorphic 
membrane proteins (pmp genes) or housekeeping (HK) proteins were used as 
reference. (A) Ratio of nonsynonymous (dN) to synonymous (dS) substitutions among C. 
trachomatis strains. The dashed line indicates neutrality (dN/dS = 1). The arrows specify 
genes likely under positive selection, according to the codon-based Z test of selection 
(see Materials and Methods). (B) Distribution of dN versus dS values for the 10 inc genes 
likely under positive selection, comparing the impact of artificially discarding ocular, 
urogenital, or LGV strains relative to the analysis with all C. trachomatis strains. The 
straight line in each graph indicates neutrality (dN/dS = 1). In all cases, inc genes likely 
under positive selection (codon-based Z test of selection) are depicted as black circles, 
while inc genes for which statistical support of likely positive selection can no longer be 
detected after discarding a particular group of strains are depicted as white circles. All 
these analyses were performed by bootstrapping with 1,000 replicates. For sake of 
clarity, SEMs for values in both panels are presented only in Tables A.4, A.5, A.6, and 
A.7 in Annexes. 
 
This showed that discarding LGV strains caused major alterations on the 
dN and dS values and confined the ability to detect Z-test-based likely 
positive selection to only one inc gene, whereas discarding ocular or 
urogenital strains had less pronounced effects (Figure 3.2B and Tables 
A.4, A.5, A.6, and A.7 in Annexes). In addition, within each of the 10 
proteins encoded by inc genes likely under positive selection, we found 
113 amino acid residues that are disease group specific (Table 3.3). 
Among these residues, 104 (92%) were in Inc proteins from LGV strains, 
77 (74%) of which localized in regions of the proteins predicted to be on 
the cytoplasmic side of the inclusion membrane (Table 3.3). Overall, this 
suggested that the evolutionary dynamics of inc genes is distinct from 
that of pmp genes or housekeeping genes and that LGV-specific amino 
acid residues in a subset of Inc proteins might be involved in the unique 
ability of C. trachomatis LGV strains to infect macrophages and 
disseminate to lymph nodes. 
 
 




Table 3.3 – Amino acids residues within Inc proteins encoded by genes likely 










V37A, V38A, S39C, S64G, 






A33V, F77C, C79Y, N87S, 













Y10C, I75-, C89Y, L125I, 







G11R, A65T, K100R, I108L, 
K127G, N130D, P134-, 
C153Y, E160D, T166K, 
H200Y, E204D, N207R, 
L208M, R231L, V241A, 









I22T, A68V, A72P, C90Y, 







A39S, V99I, G112E, K114E, 
F121S, Q125R, V126A, 
H137Y, Q144K, Y152H, 





CT249 116 [51-72], 
[78-97] 







A67T, I69V, E102A, S121P, 
A194T, S198T, N203K, 
T209I, A258T, I260V, I261V, 
L318W, S346G, L388V, -







N7T, V76I, E107K, K125E, 
R128Q, T145A, E161K, 
A163G, E168K, E171K, 
E172Q, I181V, I236T 
  
aBased on the protein sequence annotation of C. trachomatis strain D/UW3. 
bPositions of transmembrane (TM) domains in the corresponding Inc proteins, obtained 
from reference (Dehoux et al., 2011), except for CT223, for which we found only the two 
indicated TM domains. 
cResidues specific to Inc proteins from each disease group are in bold, relative to the 
amino acid in the same position in the other disease groups, and those in regions 
predicted to be on the cytoplasmic side of the inclusion membrane are underlined (we 
considered that the loop region within two TM segments faces the lumen of the 






3.4.3 Disease group-specific expression of C. trachomatis inc 
genes 
To analyze if there were differences in the expression of inc genes 
between C. trachomatis strains that correlate with the type of infection or 
with tissue tropism, we used RT-qPCR to determine the mRNA levels of 
the 48 selected inc genes (Table 2.1 in Chapter 2) throughout the 
developmental cycle of C. trachomatis. We aimed to find inc genes 
showing differences in the highest mRNA levels during the cycle (peak 
of expression) or in the variation of mRNA levels throughout 
development (profile of expression) between C. trachomatis strains. 
We first infected HeLa 229 cells with ocular (C/TW3), urogenital 
(E/Bour), or LGV (L2/434) prototype strains. Total RNA was isolated at 
2, 6, 12, 20, 30, and 42 h postinfection, which was used to generate 
cDNA for RT-qPCR assays (complete data are shown in Tables A.8, 
A.9, and A.10 in Annexes). Generally, the comparison of the peak of 
expression revealed differences from 30- to 60-fold (depending on the 
strain) between inc genes (Figure 3.3A). However, the averages of the 
peaks of expression of inc genes in C/TW3, E/Bour, and L2/434 were 
not significantly different between strains (Figure 3.3A). Regarding the 
profile of expression, essentially as previously described (E. I. Shaw et 
al., 2000; Belland et al., 2003; Nicholson et al., 2003) we identified inc 
genes whose expression was highest at 2 or 6 h postinfection and then 
either decreased or remained constant throughout the cycle (early-cycle 
genes), inc genes whose expression was highest only at 12 or 20 h 
postinfection and then decreased or remained constant at later time 
points (mid-cycle genes), and inc genes whose expression was highest 
only at 30 or 42 h postinfection (late-cycle genes) (Figure 3.3B and C).  
 





Figure 3.3 – mRNA levels of inc genes during the developmental cycle of different 
C. trachomatis strains. The mRNA levels of 48 inc genes were analyzed by RT-qPCR 
throughout the developmental cycle of the prototype strains C/TW3, E/Bour, and L2/434. 
(A) Peak of expression (highest mRNA levels during the developmental cycle) of each 
inc gene. The P values were calculated by two-tailed t tests. (B) Number of inc genes 
showing the indicated profiles of expression (variation of mRNA levels during the 
developmental cycle). (C) Examples of different profiles of expression. The expression 
values (mean ± SEM) resulted from raw RT-qPCR data (x105) of each gene normalized 
to that of the 16S rRNA gene and are from at least two independent experiments. 






Figure 3.4 – Differences in the mRNA levels of inc genes throughout the 
developmental cycle of C. trachomatis C/TW3, E/Bour, and L2/434. The expression 
values (mean ± SEM) of the indicated inc genes result from the RT- qPCR raw data 
(x105) of each gene normalized against the 16SrRNA, from at least two independent 
experiments. Complete data are shown in Tables A.8, A.9, and A.10 (Annexes). 




We also identified four inc genes in E/Bour and five inc genes in L2/434 
that were simultaneously early- and late-cycle genes, showing identically 
high mRNA levels both at 2 and 6h postinfection and at 30 and 42h 
postinfection but lower expression at mid-cycle (Figure 3.3B). This was 
typically the case of ct214 and ct288 in L2/434 (Figure 3.4). Generally, 
35 inc genes showed the same profile of expression in the three C. 
trachomatis strains, and the majority of inc genes showed an early-cycle 
profile of expression (34 in C/TW3, 27 in E/Bour, and 32 in L2/434) 
(Figure 3.3B). In spite of these common features, we identified 9 inc 
genes (ct005, ct058, ct192, ct214, ct232/incB, ct249, ct288, ct440, and 
ct442) whose peak of expression consistently showed >2-fold 
differences between strains and/or whose profile of expression displayed 
differences that could not be explained by distinct growth kinetics of the 
strains (Figure 3.4). With the exception of ct214, all these genes showed 
consistently higher peaks of expression in L2/434 than in C/TW3 and/or 
E/Bour; ct442 also showed a higher peak of expression in E/Bour than in 
C/TW3 (Figure 3.4). 
To analyze whether the differences found in the expression of ct005, 
ct058, ct192, ct214, ct232/incB, ct249, ct288, ct440, and ct442 were 
strain specific or disease group specific, we determined the mRNA 
levels of these genes during the developmental cycle of additional C. 
trachomatis strains. For this, we infected HeLa 229 cells with ocular 
B/Har36 (prototype), urogenital F/CS465-95 (clinical isolate), LGV 
L2b/CS19-08 (clinical isolate), or LGV L3/404 (prototype) strains. The 
infected cells were processed for RT-qPCR assays and analyzed as 
described above (complete data are shown in Tables A.8, A.9, A.10, 
A.11, A.12, A.13, and A.14 in Annexes). We detected disease group-
specific differences in gene expression only for ct058, ct192, and ct214 
(Figure 3.5): ct058 showed an early-cycle gene profile of expression in 





ocular and urogenital strains; ct192 showed only a clear early-cycle 
gene profile of expression in LGV strains, and its expression levels were 
generally higher in LGV strains than in ocular or urogenital strains; ct214 
displayed an early- and late-cycle gene profile of expression in LGV 




Figure 3.5 – Disease group-specific differences in the mRNA levels of ct058, ct192, 
and ct214 throughout the Chlamydia trachomatis infectious cycle. The mRNA 
levels of ct058, ct192, and ct214 were analyzed by RT-qPCR throughout the 
developmental cycle of the indicated prototype (B/Har36, C/TW3, E/Bour, L2/434, and 
L3/404) and clinical (F/CS465-95 and L2b/CS19-08) strains. The expression values 
(mean ± SEM) resulted from raw RT-qPCR data (x105) of each gene normalized to that 
of the 16S rRNA gene and are from at least two independent experiments. Complete 
data are shown in Tables A.8, A.9, A.10, A.11, A.12, A.13, and A.14 (Annexes). 




Therefore, we have identified three inc genes (ct058, ct192, and ct214) 
with differences in expression between C. trachomatis strains that 
correlate with the type of infection and tissue tropism, in particular with 
LGV isolates. 
 
3.4.4 Identification of LGV-specific nucleotides in the promoter 
regions of ct058, ct192, and ct214 
We next attempted to obtain insights into the genetic basis for the 
disease group-specific expression of ct058, ct192, and ct214 by 
analyzing the promoter regions of these genes in C. trachomatis L2/434. 
The gene organization of these inc genes suggested that the promoter 
region of ct214 should lie between the start codons of ct214 and ct215 
or within the first codons of ct215 (Figure 3.6A). However, the 
localization of the promoter regions of ct058 or ct192 was unclear, as 
these genes could be co-transcribed with ct059 or ct193, respectively 
(Figure 3.6A). Therefore, we used RT-PCR with a cDNA template 
generated from total RNA of HeLa 229 cells infected with C. trachomatis 
L2/434 to determine the possible transcriptional linkages between ct058 
and ct059 and between ct192 and ct193. This indicated that ct058 is co-
transcribed with ct059, which likely encodes a ferredoxin, and 
transcription of ct192 is unlinked from ct193 (Figure 3.6B). We 
previously detected clearly measurable mRNA levels of ct059 in C. 
trachomatis ocular and urogenital strains (Borges et al., 2010). We 
confirmed this using the same biological samples in which the levels of 
ct058 mRNA were vestigial (data not shown). Therefore, we tentatively 
propose that expression of ct058 in ocular and urogenital strains might 
be downregulated by specific 3’-to-5’ posttranscriptional processing of 






Figure 3.6 - Genetic organization of ct058, ct192, and ct214. (A) Scheme of the 
genetic organization of the three inc genes (the nomenclature of D/UW3 is used) 
depicting the fragments amplified in the transcriptional linkage analysis and the 
approximate locations of the transcriptional start sites (TSSs) determined by RACE in 
L2/434. (B) Transcriptional linkage analysis in L2/434: gDNA+, PCR from total DNA 
isolated from cells infected with L2/434; cDNA+, PCR from cDNA generated with reverse 
transcriptase (RT) from total RNA isolated from cells infected with L2/434; cDNA-, as for 
cDNA+ but without RT; gDNA-, PCR from DNA of uninfected cells. 
 
To precisely define the promoter regions of ct059-ct058, ct192, and 
ct214, we determined their TSSs by RACE, using as the template total 
RNA of cells infected with C. trachomatis L2/434 and primers 
complementary to the ct059, ct192, or ct214 mRNA (Figure 3.7). When 
we used a primer complementary to the ct058 mRNA, we were unable to 
identify a ct058-exclusive TSS upstream from its start codon in L2/434 
(data not shown). The TSS of ct214 matched the one previously 
identified by deep sequencing in strain L2b/UCH-1 (Albrecht et al., 
2009), while the TSSs of ct059-ct058 and ct192 have not been identified 
before. 
C. trachomatis encodes three σ factors: σ66, the homolog of the E. coli 
main σ factor (σ70); σ28, a minor σ factor; and σ54, an alternative σ factor  
(Mathews and Timms, 2006). By inspecting the nucleotide sequences 
immediately upstream from the determined TSSs of ct059-ct058, ct192,  
 





Figure 3.7 – Identification of LGV-specific nucleotides in the promoter regions of 
ct192 and ct214 and within ct059-ct058. Schematic view of the nucleotide sequences 
of the ct059 promoter region, ct059-ct058 intragenic region, and first codons of ct058 
(A), and of the promoter regions of ct192 (B) and ct214 (C) in L2/434 strain. The TSSs 
are labeled +1, and the predicted -10 and -35σ66-like hexamers are underlined. The 
sequences of the three LGV strains used in RT-qPCR assays are 100% identical within 
the depicted regions (Figure 3.5 and Figure A.1 in Annexes). The identified LGV-specific 
nucleotides are indicated with an arrow, and letters below the sequence represent 
nucleotides present in those positions in the ocular and urogenital strains used in RT-
qPCR assays. The full nucleotide sequences of these regions in the strains used in RT-
qPCR assays are shown in Figure A-1 (Annexes). 
 
and ct214 for σ66-, σ54-, and σ28-like promoters (Mathews and Timms, 
2006), we identified only σ66-like promoters (Figure 3.7 and Figure A.1 in 
Annexes). Finally, we analyzed the promoter regions of ct059-ct058, 
ct192, and ct214 and the ct059-ct058 transcript for LGV-specific 
nucleotide differences in all strains used in the RT-qPCR assays. We 
found LGV-specific nucleotides upstream from the predicted -35 region 
of ct059 (Figure 3.7A and Figure A.1A in Annexes). Furthermore, we 





of ct059 and between the stop codon of ct059 and the start codon of 
ct058 (Figure 3.7A and Figure A.1A in Annexes). In particular, three of 
these LGV-specific nucleotide differences were clustered 30 to 35 
nucleotides upstream from the start codon of ct058 (Figure 3.7A and 
Figure A.1A in Annexes). However, it is unclear how these LGV-specific 
differences could explain the vestigial mRNA levels of ct058 in ocular 
and urogenital strains or have a discriminatory role in the proposed 
hypothetical degradation of the ct058 transcript in those strains. The 
scenario was simpler for ct192 and ct214, as we identified discrete LGV- 
specific nucleotides within the promoter regions of these genes that may 
explain their disease group-specific expression (Figure 3.7B and C and 









In this Chapter, we found that amino acid differences between Inc 
proteins and distinct mRNA levels among inc genes throughout the 
developmental cycle of C. trachomatis strains correlate with the specific 
invasiveness and tropism of LGV isolates. Thus, we propose the novel 
hypothesis that a subset of Inc proteins may contribute to the specificity 
of infection by LGV strains. In fact, the vast majority of amino acid 
differences between Inc proteins are due to variations between proteins 
from LGV and trachoma biovars (Figure 3.1). This could simply reflect 
the evolutionary history of C. trachomatis (Harris et al., 2012). However, 
most inc genes had dN/dS values of >1 among C. trachomatis strains, 
and according to the Z test of selection, 10 inc genes are likely under 
positive selection. In contrast, pmp genes or selected housekeeping 
genes of C. trachomatis mostly had dN/dS values of <1 (Figure 3.2). 
Moreover, polymorphisms in C. trachomatis genomes are essentially 
driven by fixation of silent mutations (Borges et al., 2012). This suggests 
that the amino acid differences between Inc proteins should not be 
explained solely by genetic drift. In addition, almost all disease group-
specific amino acids of Inc proteins encoded by genes likely under 
positive selection were found among proteins of LGV strains, and the 
majority of these amino acids localized in regions of the proteins 
predicted to face the host cell cytosol (Table 3.3). However, it must be 
clarified that other proteins in addition to Inc proteins are likely involved 
in the specificity of infection by LGV strains (Joseph et al., 2011; Borges 
et al., 2012). Moreover, the overall determinants of tissue tropism of C. 
trachomatis should be complex and multifactorial and should certainly 
also include, e.g., the products of the trpRBA operon (Allan C. Shaw et 
al., 2000; Fehlner-Gardiner et al., 2002; Caldwell et al., 2003) or of the 





We have done a focused and in-depth study of the variability of Inc 
proteins and evolution and expression of inc genes among C. 
trachomatis serovars, encompassing most of the available genomic 
information. We reveal that the overall degree of variation in the amino 
acid sequences of Inc proteins among strains is similar to that of a 
characteristic family of C. trachomatis polymorphic proteins (Pmps). Our 
results strengthen previous studies that suggested that some C. 
trachomatis Inc proteins could contribute to tissue tropism (Brunelle et 
al., 2004; Nunes et al., 2008; Borges et al., 2012; Lutter et al., 2012) and 
confirm recent data suggesting that many inc genes could be under 
positive selection (Joseph et al., 2011; Borges et al., 2012). However, 
almost all of these previous studies analyzed a limited number of 
sequences, as the majority of the 51 genomic sequences used in this 
Chapter became available only very recently (Harris et al., 2012). 
Our findings also revealed that differential gene expression could be a 
mechanism contributing to the different invasiveness and tissue tropism 
of C. trachomatis strains. A previous work have identified differences in 
expression between pmp genes from reference and clinical strains 
(Nunes et al., 2007), but disease group-specific differences in 
expression of C. trachomatis genes have not been noticed before. The 
inc genes ct058, ct192, and ct214 evidenced LGV-specific gene 
expression (Figure 3.5), and we have further identified LGV-specific 
nucleotides in the promoter regions of ct192 and ct214 and within the 
ct059-ct058 transcript (Figure 3.7). This was directly analyzed for the 
strains used in RT-qPCR assays, but the specificity is maintained within 
all 51 C. trachomatis genomes (Table A.3 in Annexes) that we used in 
our studies (data not shown). As only 3 of 48 inc genes showed LGV-
specific gene expression, it is unlikely that this specificity is a common 
feature among C. trachomatis genes. 




For ct214, we tentatively propose that the LGV-specific nucleotides 
could differentially affect its expression at either the transcriptional or 
posttranscriptional level. For example, a recent study showed that a 
Salmonella small noncoding RNA can discriminate mRNA regions that 
differ by a single nucleotide (Papenfort et al., 2012). The picture is more 
complex for ct058 and ct192. Regarding ct058, in L2/434 this gene is co-
transcribed with ct059, and mRNA levels of ct059 were also detected 
previously in ocular and urogenital strains (Borges et al., 2010), which 
we confirmed (data not shown). We speculate that specific processing of 
the ct059-ct058 transcript selectively reduces the levels of ct058 mRNA 
in ocular and urogenital strains. Furthermore, ct058 is a pseudogene in 
many ocular strains (but not in those used in the RT-qPCR assays) 
(Table 3.1 and also data not shown), and ct192 is a pseudogene at least 
in the ocular strain B/Jali20 (Table 3.1). This does not necessarily have 
an impact on the interpretation of the data, as for example the LGV-
specific pseudogene ct300 showed similar mRNA levels during the 
developmental cycles of C/TW3, E/Bour, and L2/434 (Tables A.8, A.9, 
and A.10). Another issue is that there are different annotations in 
GenBank of the start codon of ct192 in the archetypal ocular (A/Har13), 
urogenital (D/UW3), and LGV (L2/434) strains (Table 3.1). This alone 
could explain the differential expression of ct192, owing to dissimilar 
promoter regions. However, inspection of the nucleotide sequence 
immediately upstream from the annotated start codons of ct192 in each 
of these three strains reveals a strong putative ribosome binding site 
only in L2/434 (Table 3.1). Therefore, it is likely that the start codon of 
ct192 is conserved between C. trachomatis strains and corresponds to 
the one annotated in L2/434. In this situation, ct192 is a pseudogene in 
all ocular strains (Table 3.1), and the differences in the mRNA levels of 
ct192 between LGV and ocular or urogenital strains may be tentatively 
explained by the single-nucleotide differences found within its promoter 





It is not possible to make a rigorous side-by-side comparison between 
our RT-qPCR data and previous analyses of inc gene expression by RT-
PCR (E. I. Shaw et al., 2000) and microarrays (Belland et al., 2003; 
Nicholson et al., 2003), as the sensitivities of the methods used are quite 
different. In general, we have confirmed that inc genes display different 
profiles of expression but that they are mostly early-cycle genes, which 
supports the idea that many Inc proteins should play a role in modifying 
the inclusion membrane early during development (Valdivia, 2008; Betts 
et al., 2009). We also found inc genes displaying an early- and late-cycle 
profile of expression. A similar profile has been observed in microarray 
studies (Belland et al., 2003), and it was suggested to result from 
“carryover” mRNA of highly expressed late genes from the previous 
infectious cycle. However, the first time point we analyzed was at 2h 
postinfection, when carryover mRNA would have been degraded. 
Furthermore, at 30 or 42h postinfection, several late-cycle inc genes 
showed levels of expression at least comparable to those of early- and 
late-cycle inc genes (see Tables A.8, A.9, A.10, A.11, A.12, A.13, and 
A.14 in Annexes). This suggests that the expression of some inc genes 
could be induced early in the cycle, downregulated at mid-cycle, and 
induced again at late-cycle. 
Although human macrophages have strong antimicrobial activity against 
C. trachomatis ocular and urogenital strains, they support the growth of 
LGV strains (Yong et al., 1987). We hypothesize that specific amino 
acids in Inc proteins, or their earlier and/or higher expression, could 
specifically enable LGV strains to inhibit phagolysosomal fusion in 
macrophages and/or prevent the formation of reactive oxygen or 
nitrogen species (Flannagan et al., 2012). Unfortunately, little is known 
about the function of the Inc proteins that we have identified as 
potentially involved in these processes. CT222 and CT118/IncG 
colocalize with kinases of the Src family in discrete regions of the 




inclusion membrane that associate with host cell centrosomes (Mital et 
al., 2010), CT223/IPAM and CT813/InaC reprogram the host 
microtubule network (Alzhanov et al., 2009; Dumoux et al., 2015; Kokes 
et al., 2015), and CT228 might be involved in the mechanism of release 
of C. trachomatis. However, it is unclear how this may relate to our 
hypothesis. More recently, it was described a comprehensive Inc-human 
protein-protein interaction network (Mirrashidi et al., 2015), where the 
authors show that CT058 might interact with elements of endosomes, 
the endoplasmic reticulum and mitochondria, and that CT192 might 
interact with elements of the centrosomes. Nevertheless, these 
interactions need further confirmation. On the other hand, Inc proteins 
that could manipulate intracellular membrane trafficking, such as those 
that have SNARE-like motifs (CT119/IncA) (Delevoye et al., 2008) or 
interact with Rab GTPases (CT229) (Rzomp et al., 2006), are good 
candidates to selectively inhibit macrophage phagolysosomal fusion. 
Recently, it was also shown that Incs can interact with each other (Mital 
et al., 2013; Gauliard et al., 2015). For example, CT222 was described 
to interact with himself, CT115/IncD, CT223, CT224, and CT850. 
Instead of a direct host target, Incs could form specific multi-protein 
complexes in the inclusion membrane, which in turn interact with host 
cell components or confer structure stability to the inclusion. Therefore, 
small variations in the amino acid sequence or in the gene expression of 
one Inc protein might not affect its function but the function of the entire 
complex. Not all C. trachomatis Inc proteins tentatively proposed to be 
specifically involved in inhibiting phagolysosomal fusion have 
homologues in other chlamydial species, which also avoid this host cell 
degradation pathway (Lutter et al., 2010; Dehoux et al., 2011). It is 
possible that each chlamydial species evolved particular Inc proteins, 
and other virulence proteins, to account for the specificity of each type of 
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4.1 Abstract  
After invasion of host cells, Chlamydia trachomatis resides within a 
membranaceous vacuolar compartment, known as the inclusion, and 
uses a type III secretion system to translocate several inclusion 
membrane (Inc) proteins that decorate the inclusion membrane. In 
Chapter 3, we hypothesized that a subgroup of Inc proteins might be 
determinant in the ability of some strains of C. trachomatis to infect 
macrophages and disseminate into lymph nodes. To test this 
hypothesis, we needed to further our understanding of the biological role 
of Inc proteins. For this, in this Chapter, we first used a yeast-two hybrid 
(Y2H) screen of a mammalian cDNA library to identify candidate 
interacting partners of C. trachomatis Incs CT228, CT249, and CT288. 
We further characterized the interaction between CT288 (563 amino 
acid residues) and the coiled coil domain containing protein 146 
(CCDC146; 955 amino acid residues), a human protein of unknown 
function that localizes at the centrosome. By Y2H, we determined that 
the C-terminal regions of CT288 (amino acids 292-563) and of 
CCDC146 (amino acids 692-955) are necessary for the interaction. The 
interaction between CT288 (CT288ΔNΔTMD; deleted of its N-terminus and 
the hydrophobic motifs that characterize Inc proteins) and full-length of 
CCDC146 or CCDC146692-955 was further validated by 
immunoprecipitation experiments after ectopic expression of the proteins 
in mammalian cells. Furthermore, ectopically expressed CCDC146692-955 
can interact with full-length CT288 expressed by C. trachomatis during 
infection. Immunofluorescence microscopy of mammalian cells infected 
by C. trachomatis showed that ectopically expressed CCDC146 
localizes at the inclusion membrane. Thus, our data reveals a new host 
cell target for an Inc protein, possibly involved in the previous described 







Throughout the developmental cycle Chlamydia trachomatis maintains 
an intact membranaceous compartment (inclusion) and manipulates 
host cellular processes via the delivery of type III secretion (T3S) 
effector proteins directly into the host cytosol and membranes (Valdivia, 
2008; Betts et al., 2009). Among these effectors, the Inc proteins have a 
privileged localization at the inclusion membrane, likely directed by a 
characteristic bi-lobed hydrophobic domain (Li et al., 2008; Mital et al., 
2010; Dehoux et al., 2011). 
Host cell interacting partners have been found for several C. trachomatis 
Inc proteins, which revealed possible effector functions. For example, 
CT228 interacts with the myosin phosphatase target subunit 1 (MYPT1), 
an element of the myosin phosphatase pathway, favoring the extrusion 
mechanism for the bacterial egress from the host cell (Lutter et al., 
2013); CT229 binds Rab4, suggesting that it might play a role in 
regulating the intracellular trafficking or fusogenicity of the chlamydial 
inclusion (Rzomp et al., 2006); CT115/IncD interacts with the ceramide 
transfer protein (CERT), which is involved in the non-vesicular transfer of 
ceramide from the endoplasmic reticulum (ER) to the Golgi (Derré et al., 
2011; Agaisse and Derré, 2014); CT119/IncA binds to VAMP3 and 
VAMP8 through a SNARE domain and promotes fusion of membranes 
during infection (Hackstadt et al., 1999; Delevoye et al., 2008); 
CT118/IncG interacts with the phosphoserine-binding protein 14-3-3-β, 
which is involved in host signal-transduction pathways (Scidmore and 
Hackstadt, 2001); CT850 binds dynein light chain (DYNLT1) and 
promotes the positioning of the inclusion at the centrosomal region (Mital 
et al., 2015); CT223/IPAM (inclusion protein acting on microtubules) and 
CT813/InaC (inclusion membrane protein for actin assembly) interact 
with the host centrosomal protein CEP170 and ARF1, respectively, and 
actively participate in the modification of the microtubule organization 




around the inclusion (Dumoux et al., 2015; Kokes et al., 2015); 
CT116/IncE interacts with sorting nexins, leading to the disruption of the 
retromer function (Mirrashidi et al., 2015). In this last study, Mirrashidi 
and colleagues used 58 purified Inc proteins to affinity purify host cell 
interacting partners followed by their identification by mass spectrometry 
(Mirrashidi et al., 2015). This revealed a comprehensive Inc-human 
protein-protein interaction network, where published Inc-host protein 
interactions have been validated and high-confidence host cell targets 
were identified for 38 Inc proteins (Mirrashidi et al., 2015). In summary, 
these discoveries further indicated that Inc proteins are important factors 
to mediate the interaction between the inclusion and the host cell. 
We previously identified the majority of Incs as T3S substrates (Chapter 
2), and hypothesized that a subset of Inc proteins could contribute to the 
unique tropism and invasiveness of C. trachomatis lymphogranuloma 
venereum (LGV) strains (serovars L1-L3), relative to ocular (serovars A-
C) and urogenital (serovars D-K) strains (Chapter 3). To test this 
hypothesis, in this Chapter, we aimed to unveil the biological role of Incs 
from this subset of proteins (Table 3.3 in Chapter 3), by performing 
yeast-two hybrid (Y2H) screens of a mammalian cDNA library to search 
for putative interacting partners of Incs CT228, CT249, and CT288, for 
which host cell interacting partners were unknown at the time. We found 
an interaction between Inc CT288 and the human centrosomal protein 
CCDC146, which was further validated biochemically by co-
immunoprecipitation experiments. We also showed by 
immunofluorescence microscopy that both proteins co-localize at the 






4.3 Materials and Methods 
4.3.1 Mammalian cell lines 
HeLa 229 cells (from the ATCC) were used to propagate C. trachomatis, 
and for infections with C. trachomatis. HEK293T cells (from the ATCC) 
were used for the experiments involving transfections for co-IPs. Both 
cell lines were maintained at 37°C in a 5% CO2 atmosphere in DMEM 
(Life Technologies) supplemented with 10% (v/v) FBS (Life 
Technologies). When HEK293T cells were seeded for co-IP 
experiments, the tissue culture plates were previously coated with 
0.001% (v/v) poly-L-lysine (Sigma-Aldrich) in PBS. 
 
4.3.2 Bacterial strains and growth conditions 
Escherichia coli TOP10 (Life Technologies) was used for standard 
cloning methods and for plasmid amplification, and the methylation 
deficient E. coli K12 ER2925 (Dam and Dcm negative; New England 
Biolabs) was used to purify plasmids for C. trachomatis transformation. 
E. coli strains were routinely grown at 37ºC in LB medium with the 
appropriate antibiotics and supplements. Plasmids were introduced into 
E. coli TOP10 and into E. coli K12 ER2925 by standard methods 
(electroporation or CaCl2 transformation). 
 
4.3.3 Plasmids and DNA primers 
The plasmids used and constructed in this Chapter are listed in Table 
A.2, and primers are listed in Table A.1 (Annexes). The construction of 
the plasmids is detailed in Table A.2 (Annexes). Plasmids were 
constructed and purified using proofreading Phusion DNA polymerase, 
restriction enzymes, T4 DNA Ligase, and DreamTaq DNA polymerase 
(all from Life Technologies), a DNA Clean & Concentrator-5 (Zymo 




Research), a Zymoclean Gel DNA Recovery Kit (Zymo Research), and a 
GeneElute plasmid miniprep kit (Sigma). The accuracy of the nucleotide 
sequence of the inserts in the constructed plasmids was verified by DNA 
sequencing (Stab Vida).  
 
4.3.4 Y2H screens 
The Matchmaker® Gold Yeast Two-Hybrid System (Clontech) was used 
for the Y2H screen of a pre-transformed Mate & Plate™ Library – 
normalized Universal Human HeLa cDNA library (Clontech), following 
the instructions of the manufacturer. In summary, the yeast 
Saccharomyces cerevisiae Y2HGold was transformed with plasmid 
derivatives from pGBKT7 (Table A.2 in Annexes) and mated with yeast 
strain Y187 carrying the HeLa cDNA library cloned into pGADT7. The 
two strains were mated and plated in lower stringency or double dropout 
(DDO) media (SD/–Leu/–Trp) supplemented with X-α-Galactosidase (X) 
and Aureobasidin A (A) (all from Clontech), and incubated 3-5 days at 
28-30ºC. The blue colonies grown on DDO/X/A media were patched into 
a higher stringency or quadruple dropout (QDO) media (SD/–Ade/–His/–
Leu/–Trp) supplemented with X-α-Galactosidase and Aureobasidin A, 
and incubated 3-5 days at 28-30ºC. The blue colonies that grew in 
QDO/X/A were further analyzed for autonomous system activation, and 
for identification of the target protein, by sequencing the plasmid DNA (at 
Stab Vida) with primers listed in Table A-1 (Annexes). For CT228, we 
analyzed 5.87x105 clones, patched 1 blue colony and recovered 1 from 
high stringent media for further analysis. For CT249, we analyzed 
5.78x106 clones, patched 60 blue colonies and recovered 19 from high 
stringent media for further analysis. For CT288, we analyzed 1.43x108 
clones, patched 60 blue colonies and recovered 41 from high stringent 





4.3.5 Preparation of yeasts extracts 
Protein extracts of the S. cerevisiae Y2HGold strains expressing Gal4BD 
fusion proteins were prepared by the TCA method (Matchmaker® Gold 
Yeast Two-Hybrid System supporting protocols). Briefly, an overnight 
culture was incubated at 28-30°C with agitation (130 rpm) for 6 h. The 
final OD600 was measured and the cells were chilled on ice and 
centrifuged at 1000 g for 5 min and at 4ºC. The cell pellets were washed 
with ice-cold sterile H2O (MilliQ®), centrifuged again, and immediately 
stored at -80ºC. Then, each cell pellet was resuspended in 100 μl ice-
cold TCA buffer per 7.5 OD600 unit (20 mM Tris pH 8.0, 50 mM 
ammonium acetate, 2 mM EDTA, and freshly added 0.1 mM PMSF), 
100 μl ice-cold 20% TCA (v/v) per 7.5 OD600 unit and approximately 100 
μl of 500 μm glass beads (Sigma). To disrupt the yeast cell wall, the cell 
pellets were subjected to vortex for 4 periods of 1 min each and at room 
temperature, placing the tubes on ice for 30 secs in between each 
vortexing step. The supernatant above the settled glass beads was 
transferred to a fresh 1.5 ml tube and the beads were washed in a 1:1 
mixture of TCA buffer and 20% TCA. The tubes with the washed beads 
were vortexed again for 2 times during 1 min and at room temperature. 
The supernatant above the glass beads was collected and joined with 
the first supernatant. The proteins in the supernatant were pelleted by 
centrifugation at 17000 g for 10 min and at 4°C. The pellets were 
resuspended in 10 μl of TCA-Laemmli buffer per OD600 unit (to prepare 1 
ml, added 480 μl SDS/glycerol solution [SDS 7.3% (w/v), glycerol 29.1% 
(v/v), Tris-base 83.3 mM, a spatula tip-full of bromophenol blue], 400 μl 
Tris/EDTA [200 mM Tris-base and 20 mM EDTA], 50 μl β-
mercaptoethanol, 20 μl of 10 mM PMSF, and 50 μl MilliQ® H2O). 
Denatured the samples 10 min at 100 ºC, and centrifuged 10 min at 
17000 g, and at room temperature. Recovered the supernatant and 
proceeded to immunoblotting. 




4.3.6 Manipulation of C. trachomatis 
C. trachomatis prototype serovar L2 strain 434/Bu (L2/434; from the 
ATCC) was maintained and propagated in HeLa 229 cells using 
standard techniques (Scidmore, 2005). For immunofluorescence 
microscopy (see below), cells were seeded at 5x104 cells per well on 
glass coverslips, and for immunoblotting of whole cell extracts (see 
below), cells were seeded at 1x105 cells per well, in all cases in 24-well 
tissue culture plates. HeLa 229 cells were equilibrated in HBSS and 
infected or mock-infected at a MOI of 1. After an incubation of 30 min at 
37ºC in a 5% CO2 atmosphere, the inoculum was removed and fresh 
DMEM containing 50 μg/ml of gentamicin was added. At this point and 
where appropriate, cells were transfected with plasmids encoding for 
EGFP, EGFP-CCDC1461-955, or CCDC1461-955-HA (Table A.2 in 
Annexes). Twenty-four hours post-infection, the cells were collected for 
whole cell extracts for immunoblotting, or fixed with 1% (v/v) PFA or 
methanol for immunofluorescence microscopy. For the co-IP 
experiments, HEK293T cells were seeded at 5x106 per well of a 6-well 
tissue culture plate. The cells were infected with C. trachomatis 
transformed with pSVP255 (see below) at a MOI of 2, and transfected 
with plasmids encoding for EGFP, EGFP-CCDC146692-955, or EGFP-
CCDC1461-955 as explained above for infection of Hela 229 cells. For the 
transformation of C. trachomatis, Hela 229 cellular extracts containing C. 
trachomatis elementary bodies (EBs) were isolated by sonication from a 
44 h infection with the L2/434 strain. The lysate was centrifuged and the 
supernatant was frozen at -80°C in 4SP (sucrose phosphate buffer) 0.4 
mM sucrose, 17 mM Na2HPO4, 3 mM NaH2PO4 and pH7.4). For 
titrations, HeLa 229 cells were seeded onto glass coverslips and 
infected with several dilutions of the cellular extracts containing EBs. At 
30 h post-infection, cells were fixed, immunolabeled, and inclusions 





4.3.7 C. trachomatis transformation 
C. trachomatis L2/434 was transformed with plasmid pSVP255 (Table 
A.2 in Annexes), encoding full-length CT288 with a C-terminal 2HA tag 
(CT2881-563-2HA). Transformation of C. trachomatis was performed 
essentially as previously described (Agaisse and Derré, 2013), but with 
some modifications. First, 20 µl of a cellular extract containing C. 
trachomatis EBs stored in 4SP were added to 6 μg of plasmid DNA 
diluted in 200 μl of CaCl2 buffer (10 mM Tris pH 7.4, 50 mM CaCl2). The 
mixture was then homogenized using a vortex, and incubated for 30 min 
at room temperature. Meanwhile, 4x106 HeLa 229 cells were trypsinized 
and centrifuged for 5 min at 237 g and at room temperature. Cells were 
washed with PBS and resuspended in 200 μl of CaCl2 buffer. The cells 
were added to the mixture and incubated 20 min at room temperature. 
One hundred 100 μl of the whole mixture (cells, plasmid DNA, and 
Chlamydia) were transferred to 3 ml of pre-warmed DMEM in a 8.5 cm2 
Petri dish and incubated for 44 h at 37ºC in a 5% CO2 atmosphere. The 
medium was then removed and the cells were osmotically lysed with 2 
ml of sterile H2O (MilliQ®). The lysate was centrifuged for 5 min at 237 
g, and at room temperature, after which 2 ml of the supernatant were 
added to 2 ml of sucrose-phosphate-glutamate buffer (SPG; 0.2 mM 
sucrose, 17 mM Na2HPO4, 3 mM NaH2PO4, 5 mM L-glutamic acid). This 
was then used as inoculum to add to newly seeded HeLa 229 cells 
(4x106 cells in a 75 cm2 surface area flask), previously equilibrated in 
HBSS. After an incubation of 1h at room temperature with gentle 
rocking, the inoculum was removed, and DMEM supplemented with 0.3 
U/ml penicillin and 1 μg/ml cycloheximide was added. The cells were 
then incubated for 44 h at 37ºC in a 5% CO2 atmosphere. The infected 
cells were collected by scrapping in 3 ml SPG, and lysed by sonication 
(2 pulses of 20 s with 100 W and a cycle of 0.5). The lysate was then 
centrifuged for 5 min at 237 g and at room temperature, after which, the 
supernatant was split in two and used to re-infect newly seeded HeLa 




229 cells (1.3x106 cells in two 25 cm2 surface area flasks), previously 
equilibrated in HBSS. After an incubation of 1 h at room temperature and 
gentle rocking, the inoculum was removed, and DMEM supplemented 
with 0.3 U/ml penicillin and 1 μg/ml cycloheximide was added. The cells 
were then incubated for 3 days at 37ºC in a 5% CO2 atmosphere. The 
infected cells in both flasks were collected by scrapping in 1.5 ml SPG, 
and lysed by sonication followed by centrifugation as described above. 
The whole supernatant was used to re-infect newly seeded HeLa 229 
cells (1.3x106 cells in a 25 cm2 surface area flask), previously 
equilibrated in HBSS. After an incubation of 1 h at room temperature, the 
inoculum was removed, and DMEM supplemented with 1 U/ml penicillin 
and 1 μg/ml cycloheximide was added. The cells were incubated for 3 
days at 37ºC in a 5% CO2 atmosphere. At this point, the presence of 
wild type inclusions, as detected by phase-contrast microscopy, 
indicated a successful transformation. The infected cells containing 
transformed C. trachomatis were collected by scrapping in 1.5 ml SPG, 
and lysed by sonication followed by centrifugation as described above, 
after which an adequate amount of the supernatant (depending on the 
outcome of the previous infection) was used to re-infect newly seeded 
HeLa 229 cells (1.3x106 cells in a 25 cm2 surface area flask), previously 
equilibrated in HBSS. After an incubation of 1 h at RT, the inoculum was 
removed, and DMEM supplemented with 1 U/mL penicillin and 1 μg/mL 
cycloheximide was added. The cells were incubated 44 h at 37ºC in a 
5% CO2 atmosphere. The transformed C. trachomatis was continually 
passaged for approximately 10 rounds of re-infection, then stored at -
80ºC and titrated for further experiments. 
 
4.3.8 Transient transfection of mammalian cells 
HeLa 229 and HEK293T cells were transfected with plasmid DNA by 





instructions, but using 250 ng of DNA per well of a 24-well tissue culture 
plate or 1250 ng of DNA per well of a 6-well tissue culture plate. Cells 
were transfected immediately after infection with C. trachomatis and 
incubated at 37°C in a 5% CO2 atmosphere for the indicated time 
periods prior to collection and immunoblotting, or fixation and 
immunolabeling. 
 
4.3.9 Preparation of cell lysates, fractionation and co-IP 
For the co-IP, we used the GFP Trap kit (Chromotek), according to the 
protocol of the manufacturer with minor adjustments. In experiments 
involving only co-transfection, 5x106 HEK293T cells per well of a 6-well 
tissue culture plate, in a total of 6 wells per condition, were transfected 
with combinations of two plasmids, one encoding for EGFP fusion 
proteins and the other encoding for HA-tagged proteins. In experiments 
involving infection and transfection, 5x106 HEK293T cells per well of a 6-
well tissue culture plate, in a total of 12 wells per condition, were infected 
with C. trachomatis transformed with pSVP255 at a MOI of 2, and 
transfected with plasmids encoding for EGFP, EGFP-CCDC146692-955, or 
EGFP-CCDC1461-955 (Table A.2 in Annexes). In both cases, the cells 
were collected by trypsinization after a period of incubation of 24 h at 
37ºC in a 5% CO2 atmosphere. The cells were pelleted by centrifugation 
and washed with PBS. In the case of the infection and transfection 
experiments, an additional step of cross-link with paraformaldehyde was 
done to increase the possibility of capturing the interaction between 
CT288 and CCDC146. For that, the cell pellets were resuspended in 1 
ml of paraformaldehyde 1% (w/v) in PBS per 1x107 cells and incubated 
7 min at room temperature. The cells were immediately centrifuged for 3 
min at 1800 g and at room temperature. Then, washed the pellets two 
times with 500 μl 1.25 M glycine, and centrifugations of 3 min at 1800 g 
and at room temperature. The remainder of the protocol was identical for 




co-transfection, and infection and transfection experiments. The cell 
pellets were lysed in 200 μl ice-cold co-IP Lysis buffer (20 mM Tris-HCl 
pH 7.5, 137 mM NaCl, 2 mM EDTA, 1.0% NP40, freshly added protease 
Inhibitors and PMSF) for 30 min on ice, and mixed by pipetting every 10 
min. The lysates were centrifuged for 10 min at 17000 g and at 4ºC, and 
the supernatants were either used for analysis in SDS-PAGE (input of 
co-IP) or added to 800 μl of ice-cold GFP Trap buffer (10 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 0.5 mM EDTA). Then, 750 μl of the diluted 
supernatant were added to previously washed GFP Trap beads and 
incubated overnight at 4ºC with end-over-end mixing. Washed the beads 
six times with GFP Trap buffer and centrifugations of 2 min at 2000 g 
and at 4ºC. Finally, the pelleted beads (output of co-IP) and the input of 
co-IP were resuspended in 20 μl SDS-PAGE Laemmli Buffer 2X [Tris-
HCl 100 mM, pH 6.8, SDS 4.0% (w/v), glycerol 20% (v/v), β-
mercaptoethanol 0.2 M, bromophenol blue 0.2% (w/v)]. Denatured the 
samples 10 min at 100ºC and proceeded to immunoblotting. 
 
4.3.10 Antibodies 
For immunoblotting, mouse anti-myc antibody (Calbiochem) was used at 
1/1000, mouse anti-α-tubulin (Sigma-Aldrich) was used at 1/1000, rat 
anti-HA 3F10 (Roche) was used at 1/1000, goat anti-GFP (Sicgen) was 
used at 1/1000, and goat anti-MOMP (Abcam) was used at 1/1000. 
Horseradish peroxidase-conjugated secondary antibody anti-mouse (GE 
Healthcare) was used at 1/10000, anti-rat (Sigma-Aldrich) was used at 
1/10000, and anti-goat (Jackson ImmunoResearch Laboratories) was 
used at 1/10000. For immunofluorescence, mouse anti-γ-tubulin 
antibody (Sigma-Aldrich) was used at 1:200, mouse anti-CT442 antibody 
(Li et al., 2008) was used at 1:200, rat anti-HA 3F10 antibody (Roche) 
was used at 1:200, goat anti-GFP antibody (Sicgen) was used at 1:200, 





antibody donkey anti-goat conjugated to cyanine 5 (Jackson 
ImmunoResearch Laboratories) was used at 1:200, anti-rat conjugated 
to rhodamine RedX (Jackson ImmunoResearch Laboratories) was used 
at 1:200, and goat anti-mouse AF568 (Invitrogen) was used at 1:200. 
 
4.3.11 Immunoblotting 
To prepare total mammalian cell extracts, HeLa 229 cells were 
trypsinized, collected and centrifuged 5 min at 2300 g and at 4ºC. The 
pellet was washed twice with ice-cold PBS, and resuspended in 50 μl 
SDS-PAGE Laemmli Buffer 1X [Tris-HCl 50 mM, pH 6.8, SDS 2.0% 
(w/v), glycerol 10% (v/v), β-mercaptoethanol 0.1 M, bromophenol blue 
0.1% (w/v)] and 1 μl benzonase. The proteins were denatured 10 min at 
100ºC. Total yeast cell extracts, total mammalian cell extracts, and 
fractionated co-IP samples were resolved in 12% SDS-PAGE, followed 
by immunoblotting. Proteins in the gel were transferred onto PVDF 
membranes (Bio-Rad) and blocked in 5% (w/v) dried skimmed milk 
diluted in PBS containing 0.1% (v/v) Tween-20. The membranes were 
probed with primary and horseradish peroxidase-conjugated secondary 
antibodies, and detected using the Western Lightning Plus-ECL kit 
(Perkin Elmer) in a Chemidoc XRS+ system (Bio-Rad) or by exposure to 
Amersham Hyperfilm ECL (GE Healthcare) in a dark room. 
 
4.3.12 Immunofluorescence microscopy 
For immunofluorescence microscopy, cells were either fixed with 
paraformaldehyde 4% (w/v) 15 min at RT or with methanol 5 min at -
20ºC (whenever the antibody for γ-tubulin was used). Antibodies were 
diluted in PBS with 0.1% (v/v) Triton-X100 and 10% (v/v) horse serum. 
The cells in the coverslips were washed in PBS with 0.1% (v/v) Triton-
X100 and incubated for 1 h with primary antibodies. The cells in the 




coverslips were washed again in PBS with 0.1% (v/v) Triton-X100 and 
incubated with appropriate secondary antibodies for another 1 h. The 
cells in the coverslips were washed again first in PBS with 0.1% (v/v) 
Triton-X100, then PBS, and finally in sterile H2O (MilliQ®). In the end, 
coverslips were mounted onto glass slides using Aqua-poly/Mount 
mounting medium (Polysciences). Samples were analyzed using a 
widefield fluorescence microscope (Leica DMRA2) or a confocal laser 
scanning microscope (Zeiss LSM 710 META) at the Instituto Gulbenkian 
da Ciência (IGC) or at the Centro de Doenças Crónicas (CEDOC), 
respectively. All images were obtained by confocal microscopy and 







4.4.1 Y2H screen using Inc proteins as baits for a mammalian 
cDNA library 
To identify host cell interacting partners of Inc proteins, we performed 
Y2H screens using Inc proteins CT228, CT249, and CT288 as bait for 
fragments of proteins expressed by a mammalian cDNA library. As Inc 
proteins possess bi-lobed hydrophobic regions, we used plasmids 
encoding the DNA-binding domain of the yeast transcription factor Gal4 
containing a myc epitope at the C-terminal (Gal4BD-myc) fused to 
CT228 (amino acids 1-591), CT249 (amino acids 1-351), or CT288 
(amino acids 1-563) deleted of their predicted transmembrane domains 
(TMDs) (Dehoux et al., 2011). In particular, for CT228 and CT249, we 
constructed plasmids encoding CT228 without amino acids 38 to 86, and 
CT249 without amino acids 51 to 97 (Gal4BD-myc-CT228ΔTMD and 
Gal4BD-myc-CT249ΔTMD proteins; Figure 4.1A). For CT288, we 
constructed a plasmid encoding CT288 lacking the first 35 amino acids 
and the two bi-lobed hydrophobic domains (amino acids 36 to 88 and 
242 to 291; Gal4BD-myc-CT288ΔNΔTMD; Figure 4.1A). Each plasmid was 
introduced in S. cerevisiae Y2HGold and expression of the Gal4BD-myc-
Inc proteins was analyzed by immunoblotting of yeast protein extracts 
using an anti-myc antibody. Figure 4.1B shows that all fusion proteins 
were expressed and migrated on SDS-PAGE as expected from their 
predicted molecular mass of 32 kDa (Gal4BD-myc-CT228ΔTMD), 23 kDa 
(Gal4BD-myc-CT249ΔTMD), and 66 kDa (Gal4BD-myc-CT288ΔNΔTMD). We 
also verified that the Gal4BD-myc-Inc proteins did not autonomously 
activate the reporter genes in the absence of a prey protein, by plating 
the transformed Y2HGold strains in normal and in higher stringency 
medium (Figure 4.2A, B and C; upper panels). Based on these results, 
we selected the plasmids encoding the CT228ΔTMD, CT249ΔTMD, and 
CT288ΔNΔTMD Gal4BD-myc fusion proteins for the Y2H screens. 





Figure 4.1 – Fragments of the C. trachomatis Inc proteins CT228, CT249 and CT288 
used in the Y2H screen.  (A) Domain organization of CT228, CT249, and CT288 fused 
to the Gal4 DNA-binding domain containing a myc epitope at the C-terminal (Gal4BD-
myc-Inc). (B) Immunoblot of yeast protein extracts (see materials and methods) from 
3x107 yeast cells (considering that 1 OD600 = 3x107 yeast cells) after expression of 
CT228, CT249, and CT288 Gal4BD-myc-Inc fusion proteins. 
 
The yeast strains harboring each plasmid were used as bait to screen 
the yeast strain Y187 containing a normalized universal human HeLa 
cDNA library constructed in pGADT7 as fusions to the Gal4 activation 
domain containing a HA epitope at the C-terminal (Gal4AD-HA-prey). 
The interacting prey plasmids were isolated and tested for autonomous 
system activation. This showed that the only interaction found for CT228 





CT249 were not false positives, and that 38 of the 41 interactions found 
for CT288 were not false positives (examples in Figure 4.2). Next, 
among the real positive interactions, we looked for in-frame fusions to 
the GAL4AD-HA by sequencing the inserts in the plasmids. A BLAST 
analysis of the DNA sequences revealed in-frame fusions for the only 
interaction found for CT228, for 3 of the 4 real interactions found for 




Figure 4.2 – Yeast two-hybrid screen of a mammalian cDNA library using portions 
of CT228, CT249, and CT288. Examples of the interactions found in the Y2H screen 
using the Incs CT228 (A), CT249 (B), and CT288 (C). The interactions were verified by 
plating the yeast strain Y2HGold harboring different combinations of plasmids encoding 
Gal4BD-myc-Inc fusions of CT228, CT249, and CT288, the Gal4AD-HA-prey fusion of 
the putative interacting partners, or empty plasmids in normal DDO medium, and in 
higher stringency QDO/X/A medium. LCA5L is the Leber-congenital amaurosis 5 like 
protein, USP11 is the ubiquitin specific peptidase 11, and CCDC146 is the human coiled 
coil domain containing protein 146 (Table 4.1). 




Table 4.1– Candidate binding partners of CT228, CT249, and CT288 identified in 
the Y2H screen of a mammalian cDNA library. 
Inc 
Protein 




CT228 LCA5L – Leber-congenital amaurosis 5 like 
protein 
Yes (5-279) 1 in 1 
CT249 USP11 – Ubiquitin specific peptidase 11 Yes (678-963) 1 in 4 
PEX1 – Peroxisomal biogenesis factor 1 Yes (897-1283) 1 in 4 
NOL11 – Nucleolar protein 11 Yes (302-719) 1 in 4 
Homo sapiens 3 BAC RP11-65D10 No 1 in 4 
CT288 CCDC146 – Coiled coil domain containing protein 
146 
Yes (692-955) 9 in 38 
LCA5L – Leber-congenital amaurosis 5 like 
protein 
Yes (5-279) 2 in 38 
Homo sapiens anterior gradient 3 homolog 
(Xenopus laevis) (AGR3) 
Yes (1-166) 1 in 38 
Homo sapiens coiled-coil domain containing 42 
(CCDC42) 
Yes (6-242) 1 in 38 
Homo sapiens inhibitor of kappa light polypeptide 
gene enhancer in B-cells  (IKBKAP) 
Yes (1156-1331) 1 in 38 
Homo sapiens fasciculation and elongation 
protein zeta 2 (zygin II) (FEZ2) 
Yes (181-353) 1 in 38 
Homo sapiens THO complex 7 homolog 
(Drosophila) (THOC7) 
Yes (1-254) 1 in 38 
Homo sapiens exocyst complex component 1 
(EXOC1) 
Yes (120-358) 1 in 38 
Homo sapiens MLF1 interacting protein (CENP-
50) 
Yes (194-418) 1 in 38 
Homo sapiens catenin (cadherin-associated 
protein) 
Yes (690-860) 1 in 38 
Homo sapiens COP9 constitutive 
photomorphogenic homolog subunit 4 
Yes (1-406) 1 in 38 
Homo sapiens protein phosphatase 2, regulatory 
subunit B' (PP2A) 
Yes (274-429) 1 in 38 
Homo sapiens structural maintenance of 
chromosomes 3 (SMC3) 
Yes (828-1217) 1 in 38 
Homo sapiens superkiller viralicidic activity 2-like Yes (895-1042) 1 in 38 
Homo sapiens interferon-induced protein 44-like 
(IFI44L) 
Yes (327-452) 1 in 38 
Homo sapiens mediator complex subunit 4 Yes (1-270) 1 in 38 
Homo sapiens fasciculation and elongation 
protein zeta 1 (zygin I) 
Yes (238-392) 1 in 38 
Homo sapiens inhibitor of growth family, member 
5 (ING5) 
Yes (1-130) 1 in 38 
Homo sapiens nucleoporin 88kDa (NUP88) Yes (517-741) 1 in 38 











CT288 Homo sapiens translocated promoter region, 
nuclear basket protein (TPR) 
No 2 in 38 
Homo sapiens heparan sulfate 6-O-
sulfotransferase 2 (HS6ST2) 
No 1 in 38 
Homo sapiens receptor accessory protein 5 No 1 in 38 
Homo sapiens tripartite motif containing 22 
(TRIM22) 
No 1 in 38 
Homo sapiens spermatogenic leucine zipper 1 No 1 in 38 
Homo sapiens solute carrier family 35 No 1 in 38 
Homo sapiens bromodomain adjacent to zinc 
finger domain 
No 1 in 38 
DNA region of the chromosome 8, nothing 
specific 
No 1 in 38 
 
As the human coiled-coil domain containing protein 146 (CCDC146) 
appeared in a high number of hits in the Y2H screen using CT288 as 
bait (9 of the 28 in-frame hits), we decided to characterize in more detail 
the putative interaction between CT288 and CCDC146. 
CCDC146 is a 955 amino acids protein of unknown function, and the 
region encoded in the recovered prey plasmids contained its C-terminal 
region (amino acids 692 to 955) (Figure 4.2C). A BLAST analysis with 
this protein did not reveal significant identity to known protein domains, 
with the exception of a structural maintenance of chromosomes (SMC) 
domain (Strunnikov and Jessberger, 1999). CCDC146 was recently 
described to be localized at the centrosome of mammalian cells (Firat-
Karalar et al., 2014). 
 
4.4.2 Characterization of the interaction between CT288 and 
CCDC146 by Y2H 
We next used Y2H to identify the region of CT288 involved in binding to 
the C-terminal region of CCDC146 (amino acids 692 to 955). For that, 
we constructed plasmids encoding the Gal4BD-myc fused to amino 




acids 89-241 of the N-terminal and to amino acids 292-563 of the C-
terminal region of CT288 (Gal4BD-myc-CT28889-241 and Gal4BD-myc-
CT288292-563, respectively) (Figure 4.1A). We confirmed that the Gal4BD-
myc-Inc fusion proteins were expressed and migrated on SDS-PAGE 
according to their predicted molecular mass of 34 and 47 kDa (Gal4BD-
myc-CT28889-241 and Gal4BD-myc-CT288292-563, respectively) (Figure 
4.1B). We also confirmed that the Gal4BD-myc-Inc proteins did not 
autonomously activate the system (Figure 4.3; upper panels). 
 
 
Figure 4.3 – The C-terminal region of CT288 is responsible for the interaction with 
the C-terminal region of CCDC146. The interaction between the two regions of CT288 
and the C-terminal region of CCDC146 were verified by plating the yeast strain Y2HGold 
harboring different combinations of plasmids encoding the Gal4BD-myc fusions of 
CT288, the Gal4AD-HA fusion of CCDC146 (Gal4AD-HA-CCDC146692-955), or empty 
plasmids in normal DDO medium, and in higher stringency QDO/X/A medium. 
 
Combinations of two plasmids, one encoding for the Gal4BD-myc 
fusions of CT288 or empty plasmid (pGBKT7), and the other encoding 
for the Gal4AD-HA CCDC146 fusion (Gal4AD-HA-CCDC146692-955) or 
empty plasmid (pGADT7) were introduced into S. cerevisiae Y2HGold. 
Then, the yeast strains were plated, in parallel, in normal and in higher 
stringency medium. We only observed growth in form of blue colonies 
when both CT288292-563 and CCDC146692-955 were present, indicating that 
the region of CT288 responsible for the binding to CCDC146 lies 





4.4.3 CT288 from C. trachomatis strains L2/434, C/TW3, and 
E/Bour interact with CCDC146 by Y2H 
We previously found several amino acid differences in the sequence of 
CT288 among the different C. trachomatis strains (Table 3.3 in Chapter 
3). Using Y2H, we next evaluated if CT288 from C. trachomatis ocular 
(serovar C) or urogenital (serovar E) strains could also interact with 
CCDC146. The plasmid used in the Y2H screen was constructed using 
ct288ΔNΔTMD amplified from chromosomal DNA of C. trachomatis L2/434. 
We constructed similar plasmids, encoding Gal4BD-myc fusions of 
CT288ΔNΔTMD, where the ct288 truncated gene was amplified from 
chromosomal DNA of C. trachomatis C/TW3 and E/Bour (Table A.2 and 
Table A.3 in Annexes). Immunoblotting analyses confirmed that all 
fusion proteins were expressed and migrated in a similar pattern in SDS-
PAGE (Figure 4.4A). Y2HGold strains harboring combinations of 
plasmids encoding for the different Gal4BD-myc-CT288ΔNΔTMD fusions, 
and for the Gal4AD-HA fusion of CCDC146, or empty plasmids, were 
plated in normal medium and in higher stringency medium. We could 
verify that CT288ΔNΔTMD from each of the three C. trachomatis strains 
was able to interact with CCDC146 by Y2H (Figure 4.4B). 
 
 





Figure 4.4 – CT288 from different C. trachomatis strains (L2/434, C/TW3, and 
E/Bour) interact with CCDC146 by Y2H. The sequence of ct288ΔNΔTMD from C. 
trachomatis strain L2/434 (the one used in the Y2H screen), C/TW3, and E/Bour were 
used to construct Gal4BD-myc-CT288ΔNΔTMD fusions. (A) Immunoblot of yeast extracts 
after expression of the different Gal4BD-myc-CT288ΔNΔTMD fusions from 3x107 yeast 
cells. (B) Interactions were verified by plating the Y2HGold strain harboring combinations 
of plasmids encoding for the different Gal4BD-myc-CT288ΔNΔTMD fusions, and for the 
Gal4AD-HA fusion of CCDC146, or empty plasmids, in normal DDO medium and in 
higher stringency QDO/X/A medium. 
 
4.4.4 Reciprocal co-immunoprecipitation of CT288 and CCDC146 
after ectopic expression of the proteins in mammalian cells 
To further test the interaction between CT288 and CCDC146, we 
performed co-IP assays after transient expression of the proteins in 
mammalian HEK293T cells. We constructed transfection plasmids 
encoding CT288, full-length (FL) CCDC146, or the C-terminal region of 
CCDC146 (amino acid residues 692-955) fused to the C-terminus of 
EGFP (EGFP-CT288ΔNΔTMD, EGFP-CCDC146FL, and EGFP-
CCDC146692-955), or with a HA tag at their C-termini (CT288ΔNΔTMD-HA, 
CCDC146FL-HA, and CCDC146692-955-HA). These plasmids were then 
used to transiently transfect HEK293T cells for 24 h, using combinations 





(each with a different tag, EGFP or HA). As negative control, HEK293T 
cells were transiently transfected with plasmids encoding EGFP alone 
and HA-tagged CT288 or CCDC146. The cells were then lysed and 
EGFP or EGFP fusion proteins were immunoprecipitated. Subsequent 
immunoblotting analyses using anti-GFP and anti-HA antibodies 
revealed that CT288ΔNΔTMD-HA was pulled-down by the 
immunoprecipitation of EGFP-CCDC146692-955 (Figure 4.5; middle panel) 
or EGFP-CCDC146FL (Figure 4.5; right panel), but not by the 
immunoprecipitation of EGFP alone (Figure 4.5; left panel). Similarly, 
CCDC146692-955-HA (Figure 4.6A) or CCDC146FL-HA (Figure 4.6B) were 
pulled-down by the immunoprecipitation of EGFP-CT288ΔNΔTMD but not 
by EGFP alone (Figure 4.6). 
 
 
Figure 4.5 – Immunoprecipitation of transiently expressed EGFP-CCDC146692-955 or 
EGFP-CCDC146FL is able to pull-down transiently expressed CT288ΔNΔTMD-HA in 
non-infected mammalian cells. Immunoblots of the supernatant fraction of HEK293T 
cells co-transfected for 24 h with combinations of plasmids encoding for EGFP, EGFP-
CCDC146FL, or EGFP-CCDC146692-955, and a plasmid encoding for CT288ΔNΔTMD-HA 
(input – 0.5% loaded in SDS-PAGE) and of proteins immunoprecipitated by GFP 









Figure 4.6 – Immunoprecipitation of transiently expressed EGFP-CT288ΔNΔTMD is 
able to pull-down transiently expressed CCDC146FL-HA or CCDC146692-955-HA in 
non-infected mammalian cells. Immunoblots of the supernatant fraction of HEK293T 
cells co-transfected for 24 h with combinations of plasmids encoding for EGFP or EGFP-
CT288ΔNΔTMD, and plasmids encoding for CCDC146FL-HA (A) or CCDC146692-955-HA (B) 
(input – 0.5% loaded in SDS-PAGE) and of proteins immunoprecipitated by GFP 
antibodies using the GFP Trap kit (output – 20% loaded in SDS-PAGE). 
 
4.4.5 CT288 expressed by C. trachomatis during infection 
interacts with the C-terminal region of CCDC146 
Next, we sought to test if CT288 and CCDC146 interact during infection. 
For this, we constructed a C. trachomatis L2/434 strain expressing full-
length CT288 with a double HA tag at its C-terminus (CT288FL-2HA). 
Immunoblotting analysis of whole cell extracts of HeLa 229 cells infected 
with the transformed and the parental C. trachomatis strain revealed that 
CT288FL-2HA was expressed and migrated on SDS-PAGE as expected 







Figure 4.7 – CT288 localizes at the inclusion membrane in cells infected by C. 
trachomatis expressing CT288FL-2HA. (A) Immunoblots of total extracts of HeLa 229 
cells left uninfected or infected for 24 h with C. trachomatis L2/434 or C. trachomatis 
expressing CT288FL-2HA. Proteins were detected with anti-HA, anti-MOMP, or anti-α-
tubulin (as loading control) antibodies. (B) and (C) Hela 229 cells infected by C. 
trachomatis expressing CT288FL-2HA for 24h were fixed with paraformaldehyde 4% 
(w/v), immunolabeled with anti-HA and anti-MOMP (B) or anti-HA and anti-CT442 (C) 
antibodies, and analyzed by immunofluorescence microscopy. In (B) the upper panel 
shows cells infected by transformed and untransformed C. trachomatis and the bottom 
panel shows one cell infected by transformed C. trachomatis. MOMP is the major outer 
membrane protein and localizes at the bacterial outer membrane, and CT442 is a known 
Inc protein. Scale bar is 10 μm. 




Immunofluorescence microscopy analyses of HeLa 229 cells infected by 
C. trachomatis expressing CT288FL-2HA with antibodies against HA and 
the major outer membrane protein (MOMP) of C. trachomatis, indicated 
that, as expected, CT288-2HA accumulates around the inclusion 
suggesting a localization at the bacterial vacuolar membrane (Figure 
4.7B). Additional immunofluorescence microscopy analyses using 
antibodies against HA and Inc CT442 (Li et al., 2008), confirmed the 
localization of CT288FL-HA at the inclusion membrane (Figure 4.7C). 
We then used C. trachomatis expressing CT288FL-HA to infect for 24 h 
HEK293T cells that were also transiently transfected with plasmids 
encoding for EGFP or EGFP-CCDC146692-955. Before lysis, 1% (w/v) 
paraformaldehyde was used as a cross-linking agent to maximize the 
probability of capturing the interaction between CT288 and CCDC146. 
The cells were then lysed and EGFP or EGFP-CCDC146692-955 fusion 
proteins were immunoprecipitated. Subsequent immunoblotting analyses 
using anti-GFP and anti-HA antibodies revealed that CT288FL-HA was 
pulled-down by the immunoprecipitation of EGFP-CCDC146692-955 but 
not by EGFP alone (Figure 4.8). 
 
 
Figure 4.8 – Immunoprecipitation of ectopically expressed EGFP-CCDC146FL pulls-
down CT288FL-2HA in mammalian cells infected by C. trachomatis expressing 
CT288FL-2HA. Immunoblots of the supernatant fraction of HEK293T cells infected for 24 
h by C. trachomatis expressing CT288FL-2HA and transfected with plasmids encoding for 
EGFP or EGFP-CCDC146692-955 (input – 0.5% loaded in SDS-PAGE) and of proteins 






However, we could not replicate the same results when using full-length 
EGFP-CCDC146FL to pull-down CT288FL-2HA from cells infected by C. 
trachomatis expressing CT288FL-2HA (data not shown). Nevertheless, 
collectively these results support that CT288 interacts with CCDC146. 
 
4.4.6 The subcellular localization of CCDC146 is altered in cells 
infected by C. trachomatis 
A recent study indicated that endogenous CCDC146 concentrates at the 
centrosome (Firat-Karalar et al., 2014). To analyze the localization of 
ectopically expressed CCDC146, HeLa 229 cells were transiently 
transfected for 24 h with plasmids encoding EGFP-CCDC146FL or 
CCDC146FL-HA. The transfected cells were fixed with methanol and 
immunolabeled with anti-GFP and anti-γ-tubulin, or anti-HA and anti-γ-
tubulin, and analyzed by immunofluorescence microscopy. Although we 
observed EGFP-CCDC146FL or CCDC146FL-HA dispersed in the cytosol 
of HeLa 229 cells, we could also detect the proteins concentrated at the 
centrosome (Figure 4.9A and B; upper panels). 





Figure 4.9 – CCDC146 loses its localization at the centrosome in mammalian cells 
infected with C. trachomatis. HeLa 229 cells transfected with plasmids encoding for 
EGFP-CCDC146FL (A) or CCDC146FL-HA (B), were either left uninfected (UI) or infected 
with C. trachomatis L2/434 for 24h. The cells were fixed with methanol, immunolabeled 
with anti-GFP (A) or anti-HA (B), and anti-γ-tubulin antibodies, and analyzed by 
immunofluorescence microscopy. (C) and (D) Percentage (%) of co-localization of 
EGFP-CCDC146FL (C) or CCDC146FL-HA (D), and anti-γ-tubulin. Data represents one 
single experiment where 100 cells were counted. The arrows in each panel highlight the 





Next, we investigated if the localization of ectopically expressed 
CCDC146 was altered due to infection by C. trachomatis. Hela 229 cells 
left uninfected or infected by C. trachomatis L2/434 for 24 h, and 
transiently expressing EGFP-CCDC146FL or CCDC146FL-HA, were fixed 
with methanol, immunolabeled with antibodies against GFP or HA, and 
γ-tubulin, and analyzed by immunofluorescence microscopy. In infected 
cells, both EGFP-CCDC146FL and CCDC146FL-HA apparently 
concentrated around the inclusion, suggesting a possible localization at 
the inclusion membrane (Figure 4.10A and B; lower panels). 
Furthermore, while in uninfected cells we could detect a co-localization 
of EGFP-CCDC146FL or CCDC146FL-HA with γ-tubulin in about 90% of 
the cases, in infected cells we only detected co-localization of EGFP-
CCDC146FL or CCDC146FL-HA with γ-tubulin in about 40% of the cases 
(Figure 4.10C and D). This indicates that the subcellular localization of 
CCDC146 is altered during infection with C. trachomatis. 
 
4.4.7 CCDC146 co-localizes with Inc proteins at the inclusion 
membrane in cells infected by C. trachomatis 
We then addressed whether the ring-like accumulation of EGFP-
CCDC146FL or CCDC146FL-HA seemingly around the inclusion 
membrane corresponded to localization at the inclusion membrane. For 
this, HeLa 229 cells infected by C. trachomatis L2/434, and transiently 
expressing EGFP-CCDC146FL or CCDC146FL-HA, were fixed with 
paraformaldehyde 4% (w/v) and immunolabeled with anti-GFP or anti-
HA, and anti-MOMP (Figure 4.10A and B) or anti-CT442 (Figure 4.10C 
and D) antibodies. Immunofluorescence confocal microscopy analyses 
showed that EGFP-CCDC146FL and CCDC146FL-HA were in fact 
surrounding the bacterial inclusion (Figure 4.10A and B). Furthermore, 
EGFP-CCC146FL and CCDC146FL-HA co-localized with Inc CT442 
around the inclusion (Figure 4.10C and D). 





Figure 4.10 – CCDC146 localizes at the inclusion membrane in cells infected by C. 
trachomatis. HeLa 229 cells transfected with a plasmid encoding for EGFP-CCDC146FL 
(A and C), or CCDC146FL-HA (B and D), were infected with C. trachomatis L2/434 for 
24h. Cells were then fixed with paraformaldehyde 4% (w/v), immunolabeled with anti-
GFP and anti-MOMP (A), or anti-CT442 (C), and with anti-HA and anti-MOMP (B), or 







Finally, we examined the localization of ectopically expressed EGFP-
CCDC146FL in HeLa 229 cells infected by C. trachomatis expressing 
CT288FL-2HA (Figure 4.11). The infected and transfected cells were 
fixed with paraformaldehyde 4% (w/v) and immunolabeled with anti-HA 
and anti-GFP antibodies. In agreement with the previous analyses 
(Figure 4.9 and Figure 4.10), immunofluorescence microscopy analyses 
revealed that while EGFP is spread throughout the cytosol, EGFP-
CCDC146FL co-localizes with CT288FL-2HA at the inclusion membrane 
(Figure 4.11A). Altogether, these results indicate that CCDC146 and 








Figure 4.11 – CCDC146 co-localizes with CT288 at the inclusion membrane of HeLa 
299 cells infected by C. trachomatis expressing CT288FL-2HA. (A) HeLa 229 cells 
transfected with a plasmid encoding for EGFP or EGFP-CCDC146FL, and infected by C. 
trachomatis expressing CT288FL-2HA for 24h, were fixed with paraformaldehyde 4% 
(w/v), immunolabeled with anti-HA and anti-GFP antibodies, and analyzed by 
immunofluorescence microscopy. (B) Co-localization profile graphs of the 
immunofluorescence signal of GFP and anti-HA taken from confocal images. While in 
the case of EGFP, the signal does not overlap the signal of the CT288FL-2HA, in the 
case of EGFP-CCDC146FL, the signal completely overlaps the signal of the CT288FL-









In this Chapter, we performed Y2H screens of a mammalian cDNA 
library to identify host cell candidate interacting partners of Inc proteins 
CT228, CT249, and CT288. We found an interaction between CT288 
and the human centrosomal protein CCDC146. We further validated this 
interaction by co-IP experiments and described that during infection, 
CCDC146 co-localizes with CT288 at the inclusion membrane. 
Therefore, we unveil CCDC146 as a new host cell target for CT288, 
possibly involved in the association of C. trachomatis with the host cell 
centrosome, which occurs during infection with this bacterium. 
Among the results for the other chlamydial Inc proteins (CT228 and 
CT249), at the same time we performed the Y2H screen with CT228, it 
was found by Lutter et al. that CT228 interacts with MYPT1 (Lutter et al., 
2013). In another study, among new candidate binding partners of Inc 
proteins identified by affinity purification-mass spectroscopy (AP-MS), 
the authors also validated the interaction between CT228 and MYPT1 
(Mirrashidi et al., 2015). As we could not replicate the results obtained 
by those authors and only found the interaction between CT228 and 
LCA5L, we decided to discard this result (Table 4.1). 
For CT249, the most relevant Y2H results indicate that this protein might 
interact with USP11 (ubiquitin specific peptidase 11) and PEX1 
(peroxisome biogenesis factor 1) (Table 4.1). USP11 has been proposed 
to regulate TNFα mediated NF-κB activation, and to participate in DNA 
damage repair functions within the BRCA2 pathway (Schoenfeld et al., 
2004; Sun et al., 2010). PEX1 plays a role in the import of proteins into 
peroxisomes and peroxisome biogenesis (Tamura et al., 1998). C. 
trachomatis is known to impair the DNA damage response, and is also 
known to hijack peroxisomes and utilize their enzymatic capacity to 
produce bacteria-specific phospholipids (Chumduri et al., 2013; 




Boncompain et al., 2014). In the AP-MS protein-protein interaction 
network study, it was proposed that CT249 could interact with host 
proteins involved in cell division and lipid binding (Mirrashidi et al., 
2015). The overlap of functions found in these studies could indicate that 
the interactions found in our Y2H screen with CT249 might be relevant 
for the C. trachomatis infectious cycle. However, we did not further 
characterize these interactions. 
The Y2H screen using CT288 revealed, among others, the interaction 
with CCDC146, which appeared 9 times in the Y2H screen, and with 
three other proteins related to chromosome partitioning and cell division 
(CENP-50, SMC3, and a subunit of PP2; Table 4.1). CCDC146 is a 
human protein of unknown function described to be localized at the 
centrosome, and possesses a region with similarity with the structural 
maintenance of chromosomes (SMC) domain (Strunnikov and 
Jessberger, 1999; Firat-Karalar et al., 2014). This protein contains 
several coiled-coil regions, which are common among structural and 
motor proteins, and are usually involved in protein-protein interactions. 
The centromere protein 50 (CENP-50) belongs to the  CENP-O class of 
proteins, suggested to be involved in the prevention of premature sister 
chromatin separation during the recovery from spindle damage 
(Minoshima et al., 2005; Hori et al., 2008). SMC3 possesses a SMC 
domain, and proteins possessing this domain are predicted to act as 
building blocks of chromosome structure, and to play a role in shaping 
chromatin and chromosomes (Strunnikov and Jessberger, 1999). PP2 
(protein phosphatase 2) is a serine/threonine phosphatase that localizes 
at the centromeres and likely promotes chromosome–spindle 
interactions during cell division (Foley et al., 2011). The possibility that 
these proteins (CENP-50, SMC3, and PP2) bind CT288, or interfere with 





We previously hypothesized that CT288 could be involved in the tissue 
tropism and type of infection associated with C. trachomatis. We found 
several amino acid differences in the sequence of CT288 among the 
different C. trachomatis strains that could separate the LGV strains 
(serovars L1-L3) from the ocular (serovars A-C) and urogenital (serovars 
D-K) strains (Table 3.3 in Chapter 3). Using Y2H, we investigated 
whether different versions of the CT288 protein, encoded by the DNA 
sequence of C. trachomatis C/TW3 (ocular strain), E/Bour (urogenital), 
and L2/434 (LGV strain; used in the Y2H screen), could interact with 
CCDC146. In the assay we performed all versions of CT288 interacted 
in a similar way with CCDC146 (Figure 4.4). However, the Y2H agar 
plating assay is not sensitive enough to detect possible small differences 
in the affinity of the interaction. In order to more accurately assess the 
binding of the different CT288 proteins to CCDC146, liquid α- or β-
Galactosidase assays should be performed.  
We determined by Y2H that the C-terminal region of CT288 (amino 
acids 292-563) is necessary for the interaction with the C-terminal region 
of CCDC146 (amino acids 692-955) (Figure 4.3). Moreover, this region 
of CT288 is believed to be on the host cytosol side of the inclusion 
membrane (Dehoux et al., 2011). We also performed co-IP experiments 
to validate the interaction between CT288 and CCDC146. We observed 
that both the C-terminal and full-length CCDC146 were able to pull-down 
the truncated CT288 protein (without the N-terminal region and the two 
TMDs; CT288ΔNΔTMD) (Figure 4.5). In addition, CT288ΔNΔTMD was able to 
pull-down both the CCDC146 C-terminal and full-length protein (Figure 
4.6). In a more physiological approach, the C-terminal region of 
CCDC146 was able to precipitate full-length CT288 protein, expressed 
from the transformed C. trachomatis strain, in mammalian cells infected 
with this strain (Figure 4.8). 




We used immunofluorescence microscopy to determine the fate of 
CCDC146 in mammalian cells infected with C. trachomatis. In uninfected 
cells, CCDC146 concentrates at the centrosome (Figure 4.9) (Firat-
Karalar et al., 2014). In C. trachomatis infected cells, we observed a shift 
in the localization of CCDC146 from the centrosomes to the inclusion 
membrane (Figure 4.9 and Figure 4.10). Moreover, we found that 
CCDC146 co-localizes with CT288 in the inclusion membrane in cells 
infected by C. trachomatis expressing CT288-2HA (Figure 4.11). 
Collectively, these results indicate that during infection by C. 
trachomatis, CCDC146 binds to CT288 and that this binding might lead 
to the recruitment of CCDC146 to the inclusion membrane. 
CT288 is a 563 amino acids protein that (apart from the two bi-lobed 
hydrophobic domains) does not show significant identity to any known 
protein domains. CT288 is present in all Chlamydia but not in other 
Chlamydia-like organisms and in other bacteria. In contrast with other 
Inc proteins, in the AP-MS protein-protein interaction network study, no 
relevant results were found for this Inc protein (Mirrashidi et al., 2015). 
CCDC146 is conserved among a large number of eukaryotes, including 
mammals, birds, and amphibians. This protein has 955 amino acids and 
the C-terminal region was recovered in the Y2H screen (amino acids 
692 to 955). 
The primary localization of CCDC146 is at the centrosome, that 
functions as the main microtubule organizing center (MTOC) in animal 
cells, and the coordinator of the cellular architecture and the bipolar 
spindles for DNA segregation during mitosis (Bettencourt-Dias and 
Glover, 2007). After invasion Chlamydia traffics along microtubules to 
the centrosome/MTOC in a dynein-dependent manner and maintains a 
tight association with it throughout the developmental cycle (Figure 4.12) 
(Grieshaber et al., 2003; Grieshaber et al., 2006; Richards et al., 2013). 





loss of control of the centrosome duplication pathway that results in 
amplified centrosome numbers (Grieshaber et al., 2006; Johnson et al., 
2009; Knowlton et al., 2011). Infection by Chlamydia also affects host 
cell cytokinesis, by disrupting the cell cycle control, resulting in increased 
accumulation of host cell nuclei within cells (Greene and Zhong, 2003; 
Alzhanov et al., 2009; Brown et al., 2014). These events lead to the 
assembly of multipolar spindles that unequally distribute chromosomes 
during cell division (Grieshaber et al., 2006; Alzhanov et al., 2009; 
Brown et al., 2014). As a consequence of chromosome instability, 
transformation and tumor development is likely to occur, and might 
explain the link between chlamydial infections and both human 
papilloma virus and cervical cancer (Koskela et al., 2000; Sluder and 
Nordberg, 2004; Dahlström et al., 2011; Weitzman and Weitzman, 2014; 
Nam et al., 2015).  
An earlier study reported that an active chlamydial transcription and 
translation machinery is necessary for Chlamydia to initiate trafficking to 
the MTOC (Scidmore et al., 1996). This led to the suggestion that 
chlamydial proteins actively modify the inclusion membrane to facilitate 
this process. Due to their characteristic localization, Inc proteins are 
good candidates to be the factors that mediate these interactions. 
However, only a few Incs were associated with the centrosome. Earlier, 
it was reported that CT223 blocks cytokinesis in vitro, leading to 
multinucleation of the host cell (Alzhanov et al., 2009). Recently, the 
same protein, now named inclusion protein acting on microtubules 
(IPAM), was described to interact with the centrosomal protein CEP170 
(Dumoux et al., 2015). IPAM and CEP170 co-localize at the inclusion 
membrane and interact to assemble microtubule superstructures 
necessary to maintain the inclusion shape and the success of the 
chlamydial infectious cycle (Figure 4.12) (Dumoux et al., 2015). The Inc 
CT813/InaC was reported to bind to host ARF and 14-3-3 proteins, and 




to promote the formation of F-actin structures around the inclusion, also 
important for the maintenance of the inclusion shape (Figure 4.12) 
(Kokes et al., 2015). During infection, inclusion fusion is also an 
important event that occurs at the MTOC, and the host motor protein 
dynein and intact microtubules are key players in this process (Richards 
et al., 2013). 
 
 
Figure 4.12 – Schematic model of the interactions between chlamydial proteins 
and centrosomal proteins. The centrosome coordinates cell architecture and regulate 
anterograde (kinesin-dependent) and retrograde (dynein-dependent) cargo transport. 
During infection, Chlamydia reside within a membranaceous compartment (inclusion), 
and traffic along the microtubules to the centrosome/MTOC in a dynein dependent 
manner, maintaining a tight association with the centrosome throughout the infectious 
cycle. Inc proteins were described to participate in these events. CT850 interacts with 
DYNLT1 to promote the positioning of the inclusion at the MTOC. CT223/IPAM interacts 
with the centrosomal protein CEP170, and CT813/InaC interacts with ARF and 14-3-3 
proteins, promoting the assembly of microtubule superstructures necessary for inclusion 
shape and successful chlamydial infection. The interaction found in this Chapter 
between CT288 and the host cell centrosomal protein CCDC146 might also be functional 






The only chlamydial factor known to be involved in homotypic inclusion 
fusion is IncA, in which the encoded SNARE-like motif is believed to 
interact with host VAMP3 and VAMP8, and to promote fusion of 
compartments (Hackstadt et al., 1999; Delevoye et al., 2008). There is 
also a group of Incs (CT232/IncB, CT101, CT222, and CT850) that 
appear to localize in microdomains at the inclusion membrane, in 
regions that are enriched with active Src family kinases, which are 
associated with tyrosine phosphorylation processes (Mital et al., 2010). 
These microdomains are localized at the point of contact of the 
centrosome with the inclusion membrane and might act as a scaffold for 
interactions controlling trafficking, positioning and integrity of the 
chlamydial inclusion (Mital et al., 2010). Recently, CT850, one of the Inc 
proteins found in those microdomains, was described to interact with the 
dynein light chain DYNLT1 (Mital et al., 2015). This interaction is 
necessary for a proper localization of the inclusion within the centrosome 
region (Figure 4.12) (Mital et al., 2015). In the recent study where new 
host cell candidate binding partners of Inc proteins were identified by 
AP-MS, several Incs were associated with host cell cycle/division or 
centrosome processes (CT005, CT192, CT324, CT383, CT449, CT556, 
CT728, CT788, CT036, CT135, CT249, and CT846). However, these 
interactions still need further confirmation. 
Although in this Chapter we could not verify the importance of the 
interaction between CT288 and CCDC146 in the context of the C. 
trachomatis developmental cycle, we hypothesize that this interaction 
might be functional during infection and important for the inclusion 
dynamics with the centrosome (Figure 4.12). Thus, we propose 
CCDC146 as a new host cell target protein for the Inc protein CT288. 
Further studies are needed to corroborate this hypothesis. 
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The work developed in this thesis provided novel insights into the 
mechanisms involved in infections by Chlamydia trachomatis. In 
particular: i) we provide additional and thorough support for inclusion 
membrane (Inc) proteins being type III secretion (T3S) substrates 
(Chapter 2); ii) we found evidence for a role of a subset of Inc proteins in 
the tissue tropism and type of infections associated with C. trachomatis 
(Chapter 3); and iii) we discovered an interaction between the Inc CT288 
and the host centrosomal protein coiled coil domain containing protein 
146 (CCDC146), which during infection of host cells by C. trachomatis 
we found to localize at the inclusion membrane (Chapter 4). 
 
5.1 T3S of Inc proteins 
The first reports of Inc proteins were given in 1995 and 1998 (Rockey et 
al., 1995; Bannantine et al., 1998). By using sera from guinea-pigs that 
recovered from ocular infections with C. psittaci, three proteins were 
isolated and characterized that localized at the inclusion membrane of 
infected cells. Due to their localization, the genes encoding these 
proteins were named incA, incB, and incC, for inclusion membrane 
proteins A, B, and C, respectively. Amino acid sequence and secondary 
structure analyses of these proteins revealed little similarity between 
them, except for a long hydrophobic region indicative of a membrane 
spanning domain (Rockey et al., 1995; Bannantine et al., 1998). 
With the first chlamydial genomes available, the use of bioinformatics 
allowed the search for other proteins encoded in the genome possessing 
the characteristic bi-lobed hydrophobic motif of at least 50 amino acids 
(Bannantine et al., 2000). Several candidate Inc proteins (~70) were 
discovered by this approach; however, an important question arose from 
these findings, which was how do these proteins could reach the 





possesses a functional type III secretion system (T3SSs) (Fields and 
Hackstadt, 2000), it was hypothesized that Inc proteins could be 
translocated from the bacteria into the host cell by this mechanism. 
Subtil and colleagues found that the N-terminal of C. trachomatis and C. 
pneumoniae Inc proteins was sufficient for driving T3S of a fusion 
protein by the S. flexneri T3SS (Subtil et al., 2001; Subtil et al., 2005). 
Later, in a comprehensive bioinformatics study, Dehoux and colleagues 
identified and analyzed all candidate Inc proteins in the available 
genomes of seven chlamydial species (discovering a total of 537 
putative Incs) (Dehoux et al., 2011). However, the presence of T3S 
signals was not tested for all of them. Other authors tried to determine 
the localization of all Inc proteins by generating antibodies against a set 
of ~50 recombinant Inc proteins, and they could confirm the localization 
at the inclusion membrane for ~20 Incs (Li et al., 2008). Subsequent 
studies increased the number of validated Inc proteins (possessing the 
bi-lobed hydrophobic motif and localizing at the inclusion membrane) to 
~25 (Cortes et al., 2007; Li et al., 2008; Mital et al., 2010; Dehoux et al., 
2011; Flores and Zhong, 2015). 
As a follow up of these studies, we asked if the presence of a T3S signal 
could be further evidence (in addition to the bi-lobed hydrophobic 
domain) that an Inc protein localizes at the inclusion membrane. 
Focusing on a set of 48 C. trachomatis known and putative Inc proteins 
(Li et al., 2008), we identified T3S signals in the N-terminal of about 80% 
of the Incs. However, we could not identify a T3S signal in a subset of 
known Inc proteins, demonstrating that definitive localization at the 
inclusion membrane needs confirmation by immunolocalization studies 
in Chlamydia-infected cells. These studies are now facilitated by the 
recent advances in genetic manipulation of Chlamydia. In fact, C. 
trachomatis strains expressing recombinant Inc proteins with a FLAG 
epitope tag were constructed (Bauler and Hackstadt, 2014; Weber et al., 




2015). Subsequent immunolocalization studies of these recombinant 
proteins in host cells infected by C. trachomatis encoding FLAG-tagged 
Inc proteins allowed the identification of 10 additional Inc proteins 
localizing at the inclusion membrane (CT006, CT134, CT135, CT179, 
CT192, CT224, CT227, CT345, CT383, and CT449) (Weber et al., 
2015). Overall, our results were in agreement with these observations, 
as we identified T3S signals in 7 of these 10 Inc proteins (CT135, CT92, 
CT225, CT227, CT345, CT383, and CT449). Furthermore, for 4 Inc 
proteins (CT483, CT484, CT565, and CT728), in which we did not 
identify a T3S signal, those authors also did not detect localization of the 
recombinant FLAG-tagged proteins at the inclusion membrane (Weber 
et al., 2015). However, for 6 Inc proteins (CT036, CT058, CT195, 
CT214, CT365, and CT789), in which we identified T3S signals, those 
authors did not detect localization of the recombinant FLAG-tagged 
proteins at the inclusion membrane (Weber et al., 2015). 
While our experiments and those previously done in other laboratories 
(Fields et al., 2003; Subtil et al., 2005; Dehoux et al., 2011) clearly 
support that the majority of Inc proteins are translocated into the host 
cell by a T3SS, at a mechanistic level it remains to be understood how 
they insert into the inclusion membrane after translocation. This 
presumably involves the characteristic bi-lobed hydrophobic domain but 
the molecular details are unknown. 
 
5.2 A role of Inc proteins in tissue tropism and type 
of infection associated with C. trachomatis 
The epitheliotropic (ocular and genital) and lymphogranuloma venereum 
(LGV) strains share > 98% of identity at the DNA level (Stephens et al., 
1998; Carlson et al., 2005; Thomson et al., 2008; Seth-Smith et al., 





Harris et al., 2012). Hence, the different tissue tropisms and disease 
outcomes associated to infections by C. trachomatis are likely a 
consequence of small-scale mutational changes or of variations in gene 
expression. A clear example is the loss of tryptophan synthase function 
in the strains associated with ocular infections. All ocular strains have a 
defective trpB gene within the tryptophan (trpBA) operon, while 
urogenital and LGV strains have an intact copy of the gene (Allan C. 
Shaw et al., 2000; Fehlner-Gardiner et al., 2002; Caldwell et al., 2003). 
Other examples include variations in a few genes located in the plasticity 
zone (the Chlamydia cytotoxin gene and genes encoding phospholipase 
D-like proteins), TARP and Pmps (Carlson et al., 2004; Gomes et al., 
2006; Nelson et al., 2006; Lutter et al., 2010). 
The first report of Inc proteins possibly involved in the tissue tropism and 
different types of infection was given by Brunelle and colleagues in 2004 
(Brunelle et al., 2004). By using DNA microarray analyses, the authors 
compared the genome of serovar D to that of other 14 serovars, and 
found 4 inc genes (ct116/incE, ct223, ct288, and ct618) among 11 genes 
with differences associated with LGV strains. Two other groups 
performed phylogenetic and molecular evolutionary analyses in the 
genomes of strains representative of each disease group and also found 
that inc genes and Inc proteins clearly separate epitheliotropic from LGV 
strains (Nunes et al., 2008; Thomson et al., 2008). Three different 
groups analyzed the temporal gene expression of chlamydial genes 
during the developmental cycle (E. I. Shaw et al., 2000; Belland et al., 
2003; Nicholson et al., 2003). These studies were performed only with 
serovars D and L2, thus, did not cover all the three disease groups. 
Furthermore, different methodologies were used and therefore, definitive 
conclusions about the variations in gene expression identified in these 
studies could not be made. Given that the genes encoding Inc proteins 
comprise ~10% of the genome (Dehoux et al., 2011), it was suggested 




that inc genes or Inc proteins could contribute to C. trachomatis tissue 
tropism, and in particular to disseminating infections caused by LGV 
strains. However, a thorough and detailed analysis of all putative inc 
genes and Inc proteins in all 15 serovars had never been pursued. 
Focusing on a set of 48 known and putative C. trachomatis Inc proteins 
(Li et al., 2008), we could identify small differences in the amino acid 
sequence of a subgroup of Inc proteins and in the expression of inc 
genes that correlate with the specific tissue tropism and type of infection 
associated with LGV strains. Recently, a similar study was published, 
where the authors used the whole genome (~900 genes) of ~50 C. 
trachomatis strains for the phylogenetics and molecular evolutionary 
analyses (Ferreira et al., 2015). In agreement with our work, the 
evolutionary analyses revealed that the genes with significant dN/dS > 1 
were those mainly encoding Inc protein and other T3SS effectors, 
supporting the hypothesis that proteins directly involved in host cell-
pathogen interactions during infection are subjected to selective 
pressures (Ferreira et al., 2015). 
Most studies on C. trachomatis tissue tropism are based on 
bioinformatics and the relevance of the correlations found remains to be 
directly analyzed. With the ongoing developments in the genetic 
manipulation of C. trachomatis and with the animal models available (the 
pig-tailed macaque for eye infections and the C. muridarum mouse 
model for genital and LGV infections), it is conceivably possible that in 
the future the exact role of specific C. trachomatis genes, such as inc 
genes, on tissue tropism can be demonstrated. 
The thorough analysis of inc gene expression we conducted helped to 
classify inc genes according to their levels and profiles of expression. 
These data could be used to gain insights into the mechanisms of 





inc genes is controlled by σ66 (preliminary results suggest strong -10 and 
-35 elements in several inc genes), then other mechanisms to 
differentially regulate the temporal classes of genes must be present. 
Additionally, multiple mechanisms of transcriptional regulation might 
occur, such as DNA supercoiling or late regulation by the repressor early 
upstream ORF (EUO) and σ28 (Cheng and Tan, 2012; Rosario and Tan, 
2012). Bioinformatics analyses of the putative promoter regions could be 
performed in an attempt to find possible binding sites for transcription 
regulators. This knowledge could then be used to identify transcriptional 
regulators either by using Escherichia coli as a heterologous host 
(Abdelrahman et al., 2011), or by constructing libraries of recombinant 
proteins of putative transcriptional regulators in C. trachomatis using 
transformation methods (Weber et al., 2015). 
 
5.3 Binding between Inc protein CT288 and the 
host cell centrosomal protein CCDC146 
We used yeast-two hybrid screening to find host cell interacting 
partners of three Inc proteins (CT228, CT249, CT288) hypothesized 
to contribute to the tissue tropism and type of infection associated 
with C. trachomatis (as shown in Chapter 3), with the expectation that 
the host cell interacting proteins found could suggest a function for 
these Inc proteins. We focused on the interaction between CT288 
and CCDC146, a human protein of unknown function that localizes at 
the centrosome, and more specifically at the centrioles (Firat-Karalar 
et al., 2014). We validated the interaction between CT288 and 
CCDC146 by co-IP and described that CCDC146 co-localizes with 
CT288 in the inclusion membrane during infection by C. trachomatis. 
The centrosome is an important structure in eukaryotic cells that 
functions as coordinator of cellular architecture (Bettencourt-Dias and 




Glover, 2007), and it is known that C. trachomatis maintains a tight 
association with it throughout the infectious cycle (Grieshaber et al., 
2003; Grieshaber et al., 2006; Richards et al., 2013). In addition, a few 
centrosomal proteins were already identified as host cell targets of Inc 
proteins, indicating that Inc proteins are involved in the cross-talk 
between the inclusion and the centrosome (Mital et al., 2010; Dumoux et 
al., 2015; Kokes et al., 2015). Therefore, the interaction found in this 
Chapter between CT288 and the host cell centrosomal protein 
CCDC146 might be functional and relevant during C. trachomatis 
infections. 
Due to time restrictions, it was not possible to evaluate the importance of 
the interaction between CT288 and CCDC146 during the developmental 
cycle of C. trachomatis. Future obvious experiments include the 
generation of a C. trachomatis ct288 mutant strain, and to silence the 
expression of the ccdc146 in host cells. We could then evaluate the 
importance of these two genes during infection by C. trachomatis of host 
cells. 
In the Y2H screenings, while we discarded the results obtained with 
CT228, we found several candidates for CT249 and CT288 that were 
not further investigated. For CT249, the interactions with a protein 
involved in DNA damage repair functions and with a protein involved in 
peroxisome biogenesis are of particular interest, as C. trachomatis is 
known to interfere with these processes during infection (Chumduri et 
al., 2013; Boncompain et al., 2014). For CT288, additional proteins 
related with centrosome functions (CENP-50, SMC3, and PP2) were 
also found in the Y2H screen using CT288 as bait. It will be interesting to 
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Table A.1 – List of primers used in this work. 
Lab # Description Chapter Sequence (5’-3’)a 
7 Yscu_Fw; upstream from yscU gene, for 
sequencing. 
2 AAAAAGCGCGATAGCAAGCC 
8 Yscu_Rv; downstream from yscU gene, for 
sequencing. 
2 ATAAGTGAACCTCTTGTTGG 
22 IncA_FL_Fw; used to construct pFA1 with 
a NdeI restriction site 
2 GGAATTCCATATGACAACGCCTACT
CTAATCG 
23 IncA_FL_Rv; used to construct pFA1 with 
a HindIII restriction site 
2 CCCAAGCTTAGTAGACTAGTTCTGC
AGCC 
24 IncC_FL_Fw; used to construct pFA2 with 
a NdeI restriction site 
2 GGAATTCCATATGACGTACTCTATGT
CCG 
25 IncC_FL_Rv; used to construct pFA2 with 
a HindIII restriction site 
2 CCCAAGCTTTTTACAGAAAAGAAGCA
TGC 
26 TEM1_Fw; used to construct pFA3 with a 
NdeI restriction site 
2 GGAATTCCATATGCACCCAGAAACG
CTGGTG 
28 pLJM3_Fw; upstream from multiple 
cloning site of pLJM3, for cloning and 
sequencing 
2 GATTAAGTTGGGTAACGCC 
29 pLJM3_Rv; downstream from multiple 
cloning site of pLJM3, for cloning and 
sequencing 
2 TTGTGTGGAATTGTGAGCG 
30 IncA10_Rv; used to construct pFA8 2 CACCAGCGTTTCTGGGTGAGGAGTC
ACGATTAGAGTAGG 




32 IncA20_Rv; used to construct pFA9 2 CACCAGCGTTTCTGGGTGGGCTGAG
TAGGAAGGTGCAGG 




34 IncA40_Rv; used to construct pFA10 2 CACCAGCGTTTCTGGGTGGGAGGCA
ATGGCTGCTATTTTC 




36 IncC10_Rv; used to construct pFA11 2 CACCAGCGTTTCTGGGTGGTGTGCT
ATATCGGACATAGAGTACG 




38 IncC20_Rv; used to construct pFA12 2 CACCAGCGTTTCTGGGTGGGGAGAC
GTGGGATTAGAAATATC 




40 IncC40_Rv; used to construct pFA13 2 CACCAGCGTTTCTGGGTGTAAAGAG
CCCACGGCAGAAGG 








Lab # Description Chapter Sequence (5’-3’)a 
AGGGGCAGTGATGTAG 




60 TEM1_Rv_HindIII; used to construct 




66 SycT-20-TEM1_Fw_NdeI; used to 





67 TEM1_Rv_XhoI; used to construct TEM-1 
hybrids with a XhoI restriction site 
2 GATCCTCGAGTTACCAATGCTTAATC
AGTGAGG 
94 TEM1_Rv_Seq; complementary to tem-1 
sequence, for sequencing 
2 CGATCAAGGCGAGTTACAT 
102 RplJ-20-TEM1_Fw_NdeI; used to 





429 CT005-20-TEM1_Fw_NdeI; used to 





430 CT006-20-TEM1_Fw_NdeI; used to 





431 CT036-20-TEM1_Fw_NdeI; used to 





432 CT101-20-TEM1_Fw_NdeI; used to 





433 CT134-20-TEM1_Fw_NdeI; used to 





434 CT135-20-TEM1_Fw_NdeI; used to 





435 CT164-20-TEM1_Fw_NdeI; used to 









Lab # Description Chapter Sequence (5’-3’)a 
construct pFA82 with a NdeI restriction site GGAGCTTTTTTAGCTTTGTGCATAGG
TGGTGTACTGTGCTGTATTCACCCA
GAAACGCTGGTG 
437 CT195-20-TEM1_Fw_NdeI; used to 





438 CT196-20-TEM1_Fw_NdeI; used to 





439 CT214-20-TEM1_Fw_NdeI; used to 





440 CT222-20-TEM1_Fw_NdeI; used to 





441 CT224-20-TEM1_Fw_NdeI; used to 





442 CT227-20-TEM1_Fw_NdeI; used to 





443 CT300-20-TEM1_Fw_NdeI; used to 





444 CT345-20-TEM1_Fw_NdeI; used to 





445 CT357-20-TEM1_Fw_NdeI; used to 





446 CT383-20-TEM1_Fw_NdeI; used to 





447 CT449-20-TEM1_Fw_NdeI; used to 








Lab # Description Chapter Sequence (5’-3’)a 
448 CT483-20-TEM1_Fw_NdeI; used to 





449 CT484-20-TEM1_Fw_NdeI; used to 





450 CT565-20-TEM1_Fw_NdeI; used to 





451 CT728-20-TEM1_Fw_NdeI; used to 





452 CT789-20-TEM1_Fw_NdeI; used to 





453 CT850-20-TEM1_Fw_NdeI; used to 





515 CT058-20-TEM1_Fw_NdeI; used to 






516 CT117-20-TEM1_Fw_NdeI; used to 






517 CT225-20-TEM1_Fw_NdeI; used to 






518 CT226-20-TEM1_Fw_NdeI; used to 






519 CT228-20-TEM1_Fw_NdeI; used to 






520 CT232-20-TEM1_Fw_NdeI; used to 








Lab # Description Chapter Sequence (5’-3’)a 
AAACGCTGGTG 
521 CT249-20-TEM1_Fw_NdeI; used to 






522 CT358-20-TEM1_Fw_NdeI; used to 






523 CT365-20-TEM1_Fw_NdeI; used to 






524 CT440-20-TEM1_Fw_NdeI; used to 






525 CT618-20-TEM1_Fw_NdeI; used to 






526 CT813-20-TEM1_Fw_NdeI; used to 






529 IncCD-20-TEM1_Fw_NdeI; used to 






531 CT192L2-20-TEM1_Fw_NdeI; used to 






 CT005-A_Fw; used for RT-qPCR 3 ATCGCGAGCAATGGAAACAG 
 CT005-B_Rr; used for RT-qPCR 3 CAGCTAACTCAACTTGTTCGAGCTT 
 CT006-A_Fw; used for RT-qPCR 3 TCAGGGTTGCTCCGGATATG 
 CT006-B_Rv; used for RT-qPCR 3 AAGGAGAAAAGGGACAGAAAGGTT 
 CT036-A_Fw; used for RT-qPCR 3 CGCATCGTGTGGATTCCTT 
 CT036-B_Rv; used for RT-qPCR 3 GCAAAGTCCGGAGGCTATGA 
 CT058-A_Fw; used for RT-qPCR 3 CCTGCTGCGATTGCAAATG 
 CT058-B_Rv; used for RT-qPCR 3 CCTAATCCTCCTTGGCCTCTCT 
 CT101-A_Fw; used for RT-qPCR 3 ACCGCTGCTATCTTTTCTGATGT 
 CT101-B_Rv; used for RT-qPCR 3 TTGAACAGAGCGTAGCTAACAGAAG 
 CT115-A_Fw; used for RT-qPCR 3 AGAGCGGTTGCATCGATCAC 
 CT115-B_Rv; used for RT-qPCR 3 TTACAGCATAAGTTGTTCCACATCAA 
 CT116-A_Fw; used for RT-qPCR 3 GTTTGGTGGGATGTCCATTTAAG 




Lab # Description Chapter Sequence (5’-3’)a 
 CT117-A_Fw; used for RT-qPCR 3 TGTAGGGCCTTTAGCCGTTTTA 
 CT117-B_Rv; used for RT-qPCR 3 CACAAGAAGCTCGCCAGTGTT 
 CT118-A_Fw; used for RT-qPCR 3 GCGTACAATCAATGCCTGTTATAGA 
 CT118-B_Rv; used for RT-qPCR 3 GCCGTTTGTAAGCATTTCGTTA 
 CT119-A_Fw; used for RT-qPCR 3 GCAGCCATTGCCTCCCTAA 
 CT119-B_Rv; used for RT-qPCR 3 GCCAACAAGATGTCCCAAAAG 
 CT134.A_Fw; used for RT-qPCR 3 CGGTTACGATGAGATTTGTTGTAGA 
 CT134-B_Rv; used for RT-qPCR 3 CGCCACTACTTTTTCTGCAGTCT 
 CT135-A_Fw; used for RT-qPCR 3 ACGAACGGATCATGTTTGAAGA 
 CT135-B_Rv; used for RT-qPCR 3 CGGCTTCGAGAACACTAGGAACT 
 CT164-C_Fw; used for RT-qPCR 3 TGTGAAGACGTATCGGGTTACATC 
 CT164-D_Rv; used for RT-qPCR 3 CAATAGGAGCAAGGAGCTAATCATT 
 CT179-A_Fw; used for RT-qPCR 3 CCCATATTCGAGAAGGGCTCTA 
 CT179-B_Rv; used for RT-qPCR 3 CGTGATCTCGTTGTTCCGATT 
 CT192-A_Fw; used for RT-qPCR 3 TGGGCAGCCATGTAGTTGAA 
 CT192-B_Rv; used for RT-qPCR 3 CATTACGGCCTATTTTACCAGCTTT 
 CT195-A_Fw; used for RT-qPCR 3 CAGTTTGGAACGAGATTGGAATAA 
 CT195-B_Rv; used for RT-qPCR 3 CAAACTCCTCGCGAACGAAT 
 CT196-A_Fw; used for RT-qPCR 3 CCTCTATTGCAGCAAGCTACTTTCT 
 CT196-B_Rv; used for RT-qPCR 3 CGATAACCAAAGTAACTCCCAGAGA 
 CT214-A_Fw; used for RT-qPCR 3 TTATTTCCGGACAAGCAGATGA 
 CT214-B_Rv; used for RT-qPCR 3 TTTTGATCCCAATCCGATTAGG 
 CT222-A_Fw; used for RT-qPCR 3 GATTGGAGCACTTCTATTGGGAAT 
 CT222-B_Rv; used for RT-qPCR 3 CCTATCAAACCTGCAGAACTTCCT 
 CT223-A_Fw; used for RT-qPCR 3 CCGCCTCTCTTCTTCTATGCA 
 CT223-B_Rv; used for RT-qPCR 3 AACAGCTCCCAAAGCAACCA 
 CT224-A_Fw; used for RT-qPCR 3 CCTTTGGTGGATAGCGCTTCT 
 CT224-B_Rv; used for RT-qPCR 3 GAGCGCAAGCACAGCAATAC 
 CT225-A_Fw; used for RT-qPCR 3 CGCAATTCAGATCAGCTATTACAAG 
 CT225-B_Rv; used for RT-qPCR 3 AATTTTCCGCGCACTTTCC 
 CT226-A_Fw; used for RT-qPCR 3 AACCGACGAGACTCCCTTCA 
 CT226-B_Rv; used for RT-qPCR 3 TCACGGCCTCTGGAGCTAAC 
 CT227-A_Fw; used for RT-qPCR 3 GAGAGCCCCGCAGAGTTGT 
 CT227-B_Rv; used for RT-qPCR 3 TCGTTTGCAATAAATATGCGTCTT 
 CT228-A_Fw; used for RT-qPCR 3 TCGTAGGCGCTTTAGTTGTTGTC 
 CT228-B_Rv; used for RT-qPCR 3 CGCACAAAACCAAAGCTAATACC 
 CT229-A_Fw; used for RT-qPCR 3 AATCGGGACCCCAGCTTCT 
 CT229-B_Rv; used for RT-qPCR 3 AGGGAACCAACCATAACTAAGATCA 
 CT232-A_Fw; used for RT-qPCR 3 CAGCAATAGTCCTTTCCATCGTT 
 CT232-B_Rv; used for RT-qPCR 3 CGGTGTTAAGTGCAGCAAGAAG 
 CT233-A_Fw; used for RT-qPCR 3 TGGCTGGGTCAACTAATGCA 
 CT233-B_Rv; used for RT-qPCR 3 TAGTGATGGAGGCGCTCACA 
 CT249-A_Fw; used for RT-qPCR 3 GCCGCTCTCGCCTTTAAACT 
 CT249-B_Rv; used for RT-qPCR 3 AGTAGGCACGTCGTGCTTGA 
 CT288-A_Fw; used for RT-qPCR 3 GCCTGCCTTTTATCGCTGTTAT 




Lab # Description Chapter Sequence (5’-3’)a 
 CT300-A_Fw; used for RT-qPCR 3 TAACGCAGCAATCGCAACTG 
 CT300-B_Rv; used for RT-qPCR 3 GCGGCAATGGTTATAAGACCTAAT 
 CT345-A_Fw; used for RT-qPCR 3 TCTGGAGTATTCCTTTCCCTTAGC 
 CT345-B_Rv; used for RT-qPCR 3 ACAAATGCCTGCGCCTAATAG 
 CT357-A_Fw; used for RT-qPCR 3 GCCCTTGCTTTAGGATTATGGA 
 CT357-B_Rv; used for RT-qPCR 3 CAGTAGTGCATGCTTGGTTGATG 
 CT358-A_Fw; used for RT-qPCR 3 AATAGCGTTTCTGGCATCGAA 
 CT358-B_Rv; used for RT-qPCR 3 GCAATAAGCAGGCTCCATCCTA 
 CT365-A_Fw; used for RT-qPCR 3 AGTTAGTTGGGAAACCGGTGATT 
 CT365-B_Rv; used for RT-qPCR 3 ACTCACGAATAGCTTGCTCTGTTTG 
 CT383-A_Fw; used for RT-qPCR 3 GGCGTGGCAATAGCCTTCTA 
 CT383-B_Rv; used for RT-qPCR 3 AGAGATCCGAGTGCACAAGAAAG 
 CT440-E_Fw; used for RT-qPCR 3 CTAACCTGCAGCCTTTTGTTCA 
 CT440-F_Rv; used for RT-qPCR 3 AATAATAAACAGGACTGCCGAACAC 
 CT442-A_Fw; used for RT-qPCR 3 TCGAATCTTCTATCTTCCACTGCAT 
 CT442-B_Rv; used for RT-qPCR 3 TCCTATCACCACTAATCCCACCTTA 
 CT449-A_Fw; used for RT-qPCR 3 TTCAGTTCCTTGGATCGTGTACA 
 CT449-B_Rv; used for RT-qPCR 3 CACTATTCGTTGCACCCAATTC 
 CT483-A_Fw; used for RT-qPCR 3 TCTTGGCGAGCCTCTCTATCC 
 CT483-B_Rv; used for RT-qPCR 3 AAGGCTCCCTACTTCGTATCGA 
 CT484-A_Fw; used for RT-qPCR 3 ACTCTTATTGCGCTATCTGCTCAA 
 CT484-B_Rv; used for RT-qPCR 3 CCAGCTCTGCGACCATTAAAGT 
 CT565-A_Fw; used for RT-qPCR 3 CTATTACGCTAAAAACGGGCCTAT 
 CT565-B_Rv; used for RT-qPCR 3 GCAACCCCGCATACCAAAG 
 CT628-A_Fw; used for RT-qPCR 3 TTCCGCAACCGCAACTACTT 
 CT618-B_Rv; used for RT-qPCR 3 GCTTTGAGCGAAGGGATGTT 
 CT728-A_Fw; used for RT-qPCR 3 GAGCCGCTGATCTCACAAATG 
 CT728-B_Rv; used for RT-qPCR 3 AAGAGAGGAGTCGGAACACACAA 
 CT789-A_Fw; used for RT-qPCR 3 CGTCCTGTCCGCTGGTTCT 
 CT789-B_Rv; used for RT-qPCR 3 TCCAGAGGCAATGCCAAAG 
 CT813-A_Fw; used for RT-qPCR 3 ATCCAAGGCTCTCGGAAGGA 
 CT813-B_Rv; used for RT-qPCR 3 TCCTGCGATCCATGAGGTTT 
 CT850-A_Fw; used for RT-qPCR 3 TGACGGCATCGCACAATT 
 CT850-B_Rv; used for RT-qPCR 3 CTTGCACTTCGCGGTTATAGG 
 16SRNA-9_Fw; used for RT-qPCR 3 GCGAAGGCGCTTTTCTAATTTAT 
 16SRNA-10_Rv; used for RT-qPCR 3 CCAGGGTATCTAATCCTGTTTGCT 
1005  CT058_Fw; used for the transcriptional 
linkage; amplification of ct058 from cDNA 
or genomic DNA 
3 GAAATGCTTTTTGGATGG  
1012  CT058_Rv; used for the transcriptional 
linkage; amplification of ct058 from cDNA 
or genomic DNA  
3 GAATGCATCGTTCACTCC  
1004  CT059_CT058_Fw; used for the 
transcriptional linkage; amplification of 
ct059-ct058 from cDNA or genomic DNA 
3 GCGTGATTGAGGTCTTGG  




Lab # Description Chapter Sequence (5’-3’)a 
transcriptional linkage; amplification of 
ct059-ct058 from cDNA or genomic DNA; 
used for the transcription start site; 
amplification and sequencing of: ct059 
promoter region and coding sequence; 
ct059-ct058 intergenic region; and ct058 
first 64 codons. In strains B/Har36, C/TW3, 
F/CS465-95, and L2b/CS019-08 
1011  CT059_SP1_Rv; used for the transcription 
start site; generation of single stranded 
(ss) cDNA from RNA 
3 AGAATCTTCAGGATCACC  
1003  CT059_SP2_Rv; used for the transcription 
start site; generation of double stranded 
(ds) cDNA from ss cDNA 
3 CCAAGACCTCAATCACGC  
1002  CT059_Prom_Fw; used for the 
transcription start site; amplification and 
sequencing of: ct059 promoter region and 
coding sequence; ct059-ct058 intergenic 
region; and ct058 first 64 codons. In 
strains B/Har36, C/TW3, F/CS465-95, and 
L2b/CS019-08 
3 ATCAATCAGCCATCTAGG  
852  CT192_Fw; used for the transcriptional 
linkage; amplification of ct192 from cDNA 
or genomic DNA 
3 CGCGGATCCCACATCCGAAGCAGCA
GGG  
948  CT192_Rv; used for the transcriptional 
linkage; amplification of ct192 from cDNA 
or genomic DNA 
3 CGCGGATCCTTAACAATCATTGGAA
AC  
1023  CT193_CT192_Fw; used for the 
transcriptional linkage; amplification of 
ct193-ct192 from cDNA or genomic DNA; 
used for the transcription start site; 
amplification and sequencing of the region 
upstream from start codon of ct192 in 
strains B/Har36, C/TW3, and L2b/CS019-
08 
3 AGAGATTAAAAGTTGCGG  
1020  CT193_CT192_Rv; used for the 
transcriptional linkage; amplification of 
ct193-ct192 from cDNA or genomic DNA; 
used for the transcription start site; 
amplification and sequencing of the region 
upstream from start codon of ct192 in 
strains B/Har36, C/TW3, and L2b/CS019-
08 
3 GCTCCACCAACAGCTGCAGC  
1034  CT192_SP1_Rv; used for the transcription 
start site; generation of single stranded 
(ss) cDNA from RNA 
3 TTTCTGCAGAATGACTGG  




Lab # Description Chapter Sequence (5’-3’)a 
start site; generation of double stranded 
(ds) cDNA from ss cDNA; amplification 
and sequencing of the region upstream 
from start codon of ct192 in strain 
F/CS465-95 
1019  CT192_Prom2_Fw; used for the 
transcription start site; amplification and 
sequencing of the region upstream from 
start codon of ct192 in strain F/CS465-95 
3 AGGGATAGGAGATTTGCC  
950  CT214_SP1_Rv; used for the transcription 
start site; generation of single stranded 
(ss) cDNA from RNA 
3 CGCGGATCCTTAACCAAATAATGCA
GG  
1036  CT214_SP2_Rv; used for the transcription 
start site; generation of double stranded 
(ds) cDNA from ss cDNA; amplification 
and sequencing of the region upstream 
from start codon of ct192 in strains 
B/Har36, C/TW3, F/CS465-95, and 
L2b/CS019-08 
3 TACAGCAGAGACTAACCC  
1035  CT214_Prom_Fw; used for the 
transcription start site; amplification and 
sequencing of the region upstream from 
start codon of ct192 in strains B/Har36, 
C/TW3, F/CS465-95, and L2b/CS019-08 
3 CTCCGTCAGAGCGGATGC  
1483 2xHA-IncDTerm_Rv_Sal; used to 




1486 2XHA-IncDTerm_Fwd_Not; used to 












1546 PromIncD_KpnI_Fwd; used to construct 
pSVP255 with a KpnI restriction site 
4 GATCGGTACCAACGGAGCCTTCTAG
CTATTTTG 








1567 CT288_NotI_Rv; used to construct 
pSVP255 with a NotI restriction site 
4 GATCGCGGCCGCGGTGATTATCTAA
CAGGTATTG 
599 CT288_Seq1; complementary to ct288 
sequence, for sequencing 
4 AGTTCTTGGTTCCAGATACG 
600 CT288_Seq2; complementary to ct288 
sequence, for sequencing 
4 TTCTGAGTCTAGAAGCTGCG 




Lab # Description Chapter Sequence (5’-3’)a 
C1 sequence, for sequencing 
628 EGFP-C1_Rv; complementary to pEGFP-
C1 sequence, for sequencing 
4 TTATGTTTCAGGTTCAGGG 
642 T7_Fw; complementary to pEF6/Myc-His 
C sequence, for sequencing 
4 TAATACGACTCACTATAGGGC 
644 pGADT7_Fw; complementary to pGADT7 
sequence, for sequencing 
4 CTATTCGATGATGAAGATACCCCAC
CAAACC 
645 pGADT7_RV; complementary to pGADT7 
sequence, for sequencing 
4 AGTGAACTTGCGGGGTTTTTCAGTAT
CTACGA 
862 CT288_del_241_292_Fw; used to 
construct pFA147, pFA184, pFA185, 
pFA139, and pFA197 
4 GCCAGCCGCACACTATATAAGTATTT
GCTCGAACATTCTCC 
863 CT288_del_241_292_Rv; used to 
construct pFA147, pFA184, pFA185, 
pFA139, and pFA197 
4 GGAGAATGTTCGAGCAAATACTTATA
TAGTGTGCGGCTGGC 
943 CT249_NdeI_Fw; used to construct 
pFA159 with a NdeI restriction site 
4 GGAATTCCATATGGGTATCAAACCTC
ATGATTATGGC 
944 CT288_NdeI_Fw; used to construct 
pFA147, pFA178, pFA184, and pFA185 
with a NdeI restriction site 
4 GGAATTCCATATGAAAAAGGCTCTG
GCTCAACG 
952 CT249_BamHI_Rv; used to construct 
pFA159 with a BamHI restriction site 
4 CGCGGATCCCTACGCCTTTGAAGTA
ATCG 
953 CT288_KpnI_Fw; used to construct 
pFA139 with a KpnI restriction site 
4 GATCGGTACCAAAAAGGCTCTGGCT
CAACG 
954 CT288_BamHI_Rv; used to construct 
pFA147, pFA179, pFA184, pFA185, and 
pFA139 with a BamHI restriction site 
4 CGCGGATCCTTAGTGATTATCTAACA
GG 
977 pGBKT7_Rv; complementary to pGBKT7 
sequence, for sequencing 
4 AAATCATAAGAAATTCGC 
1212 CT228_NdeI_Fw; used to construct 
pFA155 with a NdeI restriction site 
4 GGAATTCCATATGAGTACTACTATTA
GCGGA 
1216 CT228_BamHI_Rv; used to construct 
pFA155 with a BamHI restriction site 
4 CGCGGATCCCTAAGAAGCTTGGTTA
GC 
















1350 GFPC_CC_XhoI_Fw; used to construct 
pFA164 with a XhoI restriction site 
4 GATCCTCGAGctGAAGACAGTAGCAC
AGACAC 
1351 GFPC_CC_EcoRI_Rv; used to construct 








Lab # Description Chapter Sequence (5’-3’)a 
pFA167 with a EcoRI restriction site AGCACAGACAC 
1354 CCD_HA_EcoRI_Fw; used to construct 
pFA167 with a EcoRI restriction site 
4 GATCGAATTCACCATGGAAATTTGTG
TGACCCAG 
1355 CC_HA_NotI_Rv; used to construct 





1356 CC_Seq1_Fw; complementary to 
CCDC146 sequence, for sequencing 
4 TAAGAAAGATGGAACTGC 
1357 CC_Seq2_Rv; complementary to 
CCDC146 sequence, for sequencing 
4 TCTACTAACTTAGACTCC 
1358 CC_Seq3_Rv; complementary to 
CCDC146 sequence, for sequencing 
4 ATGAAATCCTTCTCCAGC 
1474 CT288_89-241_BamHI_Rv; used to 




1475 CT288_292-563_NdeI_Pf; used to 




1546 PromIncD_KpnI_Fw; used to construct 
pSVP255 with a KpnI restriction site 
4 GATCGGTACCAACGGAGCCTTCTAG
CTATTTTG 








1567 CT288_NotI_Rv; used to construct 
pSVP255 with a NotI restriction site 
4 GATCGCGGCCGCGGTGATTATCTAA
CAGGTATTG 
1730 GFPC_C692_XhoI_Fw; used to construct 
pFA196 with a XhoI restriction site 
4 GATCCTCGAGCTCAAATTTGTGTGA
CCCAG 
1733 CT288-2HA_BamHI_Fw; used to construct 
pFA197 with a BamHI restriction site 
4 GATCGGATCCACCATGGCGAAGGCT
CTGGCTCAAGC 
1734 CT288-2HA_EcoRI_Rv; used to construct 
pFA197 with a EcoRI restriction site 
4 GATCGAATTCTTAAGCATAATCAGGA
ACATCATACGG 
aRestriction sites are underlined; Kozak sequences are in bold; modifications to clone in 




Table A.2 – List of plasmids used in this work. 
Plasmid Description/ Construction Chapter Reference 
pLY16 yscU mutator. Construction of Y. 
enterocolitica HOPEMT YscU. 
2 (Sorg et al., 
2007)  
pFA1001 Y. enterocolitica virulence plasmid that 
encodes for the T3S system of strain 
ΔHOPEMT, with a deletion of YscU 
codons 1-356 
2 This work 
pLJM3 Expresses YopE under the control of its 
own promoter (PyopE). 
2 (Marenne et 
al., 2003)  
pCX340 Expresses mature TEM-1 β-lactamase. 2 (Charpentier 
and Oswald, 
2004)  
pFA1 Expresses IncA under the control of PyopE. 
The incA gene was amplified by PCR 
from L2/434 chromosomal DNA using 
primers #22 and #23. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA2 Expresses IncC under the control of PyopE. 
The incC gene was amplified by PCR 
from L2/434 chromosomal DNA using 
primers #24 and #25. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA3 Expresses mature TEM-1 β-lactamase 
under the control of PyopE. The tem-1 gene 
was amplified by PCR from pCX340 DNA 
using primers #26 and #60. The DNA 
product was digested with NdeI-HindIII 
and ligated into those sites of pLJM3. 
2 This work 
pFA8 Expresses IncA10-TEM-1 hybrid under the 
control of PyopE. Nucleotides 1 to 30 of 
incA were amplified by PCR from pFA1 
DNA using primers #28 and #30. Also 
tem-1 was amplified by PCR from 
pCX340 using primers #31 and #60. The 
DNA products were then fused by 
overlapping PCR using primers #28 and 
#60. The final DNA product was digested 
with NdeI-HindIII and ligated into those 
sites of pLJM3. 
2 This work 
pFA9 Expresses IncA20-TEM-1 hybrid under the 
control of PyopE. Nucleotides 1 to 60 of 
incA were amplified by PCR from pFA1 
DNA using primers #28 and #32. Also 
tem-1 was amplified by PCR from 




Plasmid Description/ Construction Chapter Reference 
pCX340 DNA using primers #33 and #60. 
The DNA products were then fused by 
overlapping PCR using primers #28 and 
#60. The final product was digested NdeI-
HindIII and ligated into those sites of 
pLJM3. 
pFA10 Expresses IncA40-TEM-1 hybrid under the 
control of PyopE. Nucleotides 1 to 120 of 
incA were amplified by PCR from pFA1 
DNA using primers #28 and #34. Also 
tem-1 was amplified by PCR from 
pCX340 using primers #35 and #60. The 
DNA products were then fused by 
overlapping PCR using primers #28 and 
#60. The final DNA product was digested 
with NdeI-HindIII and ligated into those 
sites of pLJM3. 
2 This work 
pFA11 Expresses IncC10-TEM-1 hybrid under the 
control of PyopE. Nucleotides 1 to 30 of 
incC were amplified by PCR from pFA2 
DNA using primers #28 and #36. Also 
tem-1 was amplified by PCR from 
pCX340 using primers #37 and #60. The 
DNA products were then fused by 
overlapping PCR using primers #28 and 
#60. The final DNA product was digested 
with NdeI-HindIII and ligated into those 
sites of pLJM3. 
2 This work 
pFA12 Expresses IncC20-TEM-1 hybrid under the 
control of PyopE. Nucleotides 1 to 60 of 
incC were amplified by PCR from pFA2 
DNA using primers #28 and #38. Also 
tem-1 was amplified by PCR from 
pCX340 using primers #39 and #60. The 
DNA products were then fused by 
overlapping PCR using primers #28 and 
#60. The final DNA product was digested 
with NdeI-HindIII and ligated into those 
sites of pLJM3. 
2 This work 
pFA13 Expresses IncC40-TEM-1 hybrid under the 
control of PyopE. Nucleotides 1 to 120 of 
incC were amplified by PCR from pFA2 
DNA using primers #28 and #40. Also 
tem-1 was amplified by PCR from 
pCX340 using primers #41 and #60. The 
DNA products were then fused by 
overlapping PCR using primers #28 and 
#60. The final DNA product was digested 




Plasmid Description/ Construction Chapter Reference 
with NdeI-HindIII and ligated into those 
sites of pLJM3. 
pFA14 Expresses YopE15-TEM-1 hybrid under 
the control of PyopE. Nucleotides 1 to 45 of 
yopE were amplified by PCR from pLJM3 
DNA using primers #28 and #42. Also 
tem-1 was amplified by PCR from 
pCX340 using primers #43 and #60. The 
DNA products were then fused by 
overlapping PCR using primers #28 and 
#60. The final DNA product was digested 
with NdeI-HindIII and ligated into those 
sites of pLJM3. 
2 This work 
pFA19 Expresses SycT20-TEM-1 hybrid under 
the control of PyopE. The sycT20-tem-1 was 
amplified by PCR from pCX340 using 
primers #66 and #67. The DNA product 
was digested with NdeI-XhoI and ligated 
into those sites of pLJM3. 
2 This work 
pFA37 Expresses RplJ20-TEM-1 hybrid under the 
control of PyopE. The rplJ20-tem-1 was 
amplified by PCR from pCX340 using 
primers #102 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA75 Expresses CT00520-TEM-1 hybrid under 
the control of PyopE. The ct00520-tem-1 
was amplified by PCR from pCX340 using 
primers #429 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA76 Expresses CT00620-TEM-1 hybrid under 
the control of PyopE. The ct00620-tem-1 
was amplified by PCR from pCX340 using 
primers #430 and #67. The DNA product 
was digested with NdeI-XhoI and ligated 
into those sites of pLJM3. 
2 This work 
pFA77 Expresses CT03620-TEM-1 hybrid under 
the control of PyopE. The ct03620-tem-1 
was amplified by PCR from pCX340 using 
primers #431 and #67. The DNA product 
was digested with NdeI-XhoI and ligated 
into those sites of pLJM3. 
2 This work 
pFA78 Expresses CT10120-TEM-1 hybrid under 
the control of PyopE. The ct10120-tem-1 
was amplified by PCR from pCX340 using 
primers #432 and #67. The DNA product 




Plasmid Description/ Construction Chapter Reference 
was digested with NdeI-XhoI and ligated 
into those sites of pLJM3. 
pFA79 Expresses CT13420-TEM-1 hybrid under 
the control of PyopE. The ct13420-tem-1 
was amplified by PCR from pCX340 using 
primers #433 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA80 Expresses CT13520-TEM-1 hybrid under 
the control of PyopE. The ct13520-tem-1 
was amplified by PCR from pCX340 using 
primers #434 and #67. The DNA product 
was digested with NdeI-XhoI and ligated 
into those sites of pLJM3. 
2 This work 
pFA81 Expresses CT16420-TEM-1 hybrid under 
the control of PyopE. The ct16420-tem-1 
was amplified by PCR from pCX340 using 
primers #435 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA82 Expresses CT17920-TEM-1 hybrid under 
the control of PyopE. The ct17920-tem-1 
was amplified by PCR from pCX340 using 
primers #436 and #67. The DNA product 
was digested with NdeI-XhoI and ligated 
into those sites of pLJM3. 
2 This work 
pFA83 Expresses CT19520-TEM-1 hybrid under 
the control of PyopE. The ct19520-tem-1 
was amplified by PCR from pCX340 using 
primers #437 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA84 Expresses CT19620-TEM-1 hybrid under 
the control of PyopE. The ct19620-tem-1 
was amplified by PCR from pCX340 using 
primers #438 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA85 Expresses CT21420-TEM-1 hybrid under 
the control of PyopE. The ct21420-tem-1 
was amplified by PCR from pCX340 using 
primers #439 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA86 Expresses CT22220-TEM-1 hybrid under 
the control of PyopE. The ct22220-tem-1 
was amplified by PCR from pCX340 using 




Plasmid Description/ Construction Chapter Reference 
primers #440 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
pFA87 Expresses CT22420-TEM-1 hybrid under 
the control of PyopE. The ct22420-tem-1 
was amplified by PCR from pCX340 using 
primers #441 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA88 Expresses CT22720-TEM-1 hybrid under 
the control of PyopE. The ct22720-tem-1 
was amplified by PCR from pCX340 using 
primers #442 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA89 Expresses CT30020-TEM-1 hybrid under 
the control of PyopE. The ct30020-tem-1 
was amplified by PCR from pCX340 using 
primers #443 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA90 Expresses CT34520-TEM-1 hybrid under 
the control of PyopE. The ct34520-tem-1 
was amplified by PCR from pCX340 using 
primers #444 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA91 Expresses CT35720-TEM-1 hybrid under 
the control of PyopE. The ct35720-tem-1 
was amplified by PCR from pCX340 using 
primers #445 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA92 Expresses CT38320-TEM-1 hybrid under 
the control of PyopE. The ct38320-tem-1 
was amplified by PCR from pCX340 using 
primers #446 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA93 Expresses CT44920-TEM-1 hybrid under 
the control of PyopE. The ct44920-tem-1 
was amplified by PCR from pCX340 using 
primers #447 and #67. The DNA product 
was digested with NdeI-XhoI and ligated 
into those sites of pLJM3. 
2 This work 
pFA94 Expresses CT48320-TEM-1 hybrid under 
the control of PyopE. The ct48320-tem-1 




Plasmid Description/ Construction Chapter Reference 
was amplified by PCR from pCX340 using 
primers #448 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
pFA95 Expresses CT48420-TEM-1 hybrid under 
the control of PyopE. The ct48420-tem-1 
was amplified by PCR from pCX340 using 
primers #449 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA96 Expresses CT56520-TEM-1 hybrid under 
the control of PyopE. The ct56520-tem-1 
was amplified by PCR from pCX340 using 
primers #450 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA97 Expresses CT72820-TEM-1 hybrid under 
the control of PyopE. The ct72820-tem-1 
was amplified by PCR from pCX340 using 
primers #451 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA98 Expresses CT78920-TEM-1 hybrid under 
the control of PyopE. The ct78920-tem-1 
was amplified by PCR from pCX340 using 
primers #452 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA99 Expresses CT85020-TEM-1 hybrid under 
the control of PyopE. The ct85020-tem-1 
was amplified by PCR from pCX340 using 
primers #453 and #67. The DNA product 
was digested with NdeI-XhoI and ligated 
into those sites of pLJM3. 
2 This work 
pFA112 Expresses CT05820-TEM-1 hybrid under 
the control of PyopE. The ct05820-tem-1 
was amplified by PCR from pCX340 using 
primers #515 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA113 Expresses CT11720-TEM-1 hybrid under 
the control of PyopE. The ct11720-tem-1 
was amplified by PCR from pCX340 using 
primers #516 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 




Plasmid Description/ Construction Chapter Reference 
the control of PyopE. The ct22520-tem-1 
was amplified by PCR from pCX340 using 
primers #517 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
pFA115 Expresses CT22620-TEM-1 hybrid under 
the control of PyopE. The ct22620-tem-1 
was amplified by PCR from pCX340 using 
primers #518 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA116 Expresses CT22820-TEM-1 hybrid under 
the control of PyopE. The ct22820-tem-1 
was amplified by PCR from pCX340 using 
primers #519 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA117 Expresses CT23220-TEM-1 hybrid under 
the control of PyopE. The ct23220-tem-1 
was amplified by PCR from pCX340 using 
primers #520 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA118 Expresses CT24920-TEM-1 hybrid under 
the control of PyopE. The ct24920-tem-1 
was amplified by PCR from pCX340 using 
primers #521 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA119 Expresses CT35820-TEM-1 hybrid under 
the control of PyopE. The ct35820-tem-1 
was amplified by PCR from pCX340 using 
primers #522 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA120 Expresses CT36520-TEM-1 hybrid under 
the control of PyopE. The ct36520-tem-1 
was amplified by PCR from pCX340 using 
primers #523 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA121 Expresses CT44020-TEM-1 hybrid under 
the control of PyopE. The ct44020-tem-1 
was amplified by PCR from pCX340 using 
primers #524 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
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pFA122 Expresses CT61820-TEM-1 hybrid under 
the control of PyopE. The ct61820-tem-1 
was amplified by PCR from pCX340 using 
primers #525 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA123 Expresses CT81320-TEM-1 hybrid under 
the control of PyopE. The ct81320-tem-1 
was amplified by PCR from pCX340 using 
primers #526 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA126 Expresses IncDD20-TEM-1 hybrid under 
the control of PyopE. The incDD20-tem-1 
was amplified by PCR from pCX340 using 
primers #529 and #60. The DNA product 
was digested with NdeI-HindIII and ligated 
into those sites of pLJM3. 
2 This work 
pFA128 Expresses CT192L220-TEM-1 hybrid 
under the control of PyopE. The ct192L220-
tem-1 was amplified by PCR from 
pCX340 using primers #531 and #67. The 
DNA product was digested with NdeI-XhoI 
and ligated into those sites of pLJM3. 
2 This work 
pGADT7 Yeast-two hybrid (Y2H) vector for 
expression of Gal4AD-myc fusion 
proteins. 
4 (Clontech) 
pGBKT7 Y2H vector for expression of Gal4BD-HA 
fusion proteins. 
4 (Clontech) 
pEGFP-C1 Mammalian transfection vector for 
expression of EGFP fusion proteins, 
under the control of the CMV promoter. 
4 (Clontech) 
pEF6/Myc-His C Mammalian transfection vector for 
expression of Myc-, His-, or HA-tagged 








p2TK2--SW2 C. trachomatis-E. coli shuttle vector 
encoding red shifted GFP (RSGFP) under 
the control of the promoter of incD (PincD). 
4 (Agaisse and 
Derré, 2013)  
PSVP247 Modified C. trachomatis-E. coli shuttle 
vector for expression of HA-tagged 
proteins under the control of PincD. 
Contains also the terminator sequence of 
incD. The DNA Sequence of 2xHA was 
amplified by PCR from pLJ1003 DNA 




Plasmid Description/ Construction Chapter Reference 
using primers #1486 e #1488. Also the 
DNA sequence of the incD terminator was 
amplified by PCR from L2/434 
chromosomal DNA using primers #1487 
and #1483. The DNA products were then 
fused by overlapping PCR using primers 
#1486 and #1483. The final DNA product 
was digested with NotI-SalI and ligated 
into those sites of p2TK2—SW2. 
pSVP255 C. trachomatis-E. coli shuttle vector 
expressing full-length CT288 with a C-
terminal 2HA tag (CT288FL-2HA) under 
the control of PincD. The ct288 gene and 
the PincD were amplified by PCR from 
L2/434 chromosomal DNA using primers 
#1565 and #1567, and #1546 and #1566, 
respectively. The DNA products were then 
fused by overlapping PCR using primers 
#1546 and #1567. The final DNA product 
was digested with KpnI-NotI and ligated 
into those sites of pSVP247. 
4 This Work 
pFA147 Y2H vector expressing Gal4BD-myc-
CT288ΔNΔTMD. Nucleotides 265 to 723, 
and 874 to 1689 of ct288 were amplified 
by PCR from L2/434 chromosomal DNA 
using primers #944 and #863, and #862 
and #954, respectively. The DNA 
products were then fused by overlapping 
PCR using primers #944 and #954. The 
final DNA product was digested with NdeI-
BamHI and ligated into those sites of 
pGBKT7. 
4 This Work 
pFA155 Y2H vector expressing Gal4BD-myc-
CT228ΔTMD. Nucleotides 1 to 111, and 259 
to 1773 of ct228 were amplified by PCR 
from L2/434 chromosomal DNA using 
primers #1212 and #1222, and #1221 and 
#1216, respectively. The DNA products 
were then fused by overlapping PCR 
using primers #1212 and #1216. The final 
DNA product was digested with NdeI-
BamHI and ligated into those sites of 
pGBKT7. 
4 This Work 
pFA159 Y2H vector expressing Gal4BD-myc-
CT249ΔTMD. Nucleotides 1 to 150, and 292 
to 1053 of ct249 were amplified by PCR 
from L2/434 chromosomal DNA using 
primers #943 and #1230, and #1229 and 
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#952, respectively. The DNA products 
were then fused by overlapping PCR 
using primers #943 and #952. The final 
DNA product was digested with NdeI-
BamHI and ligated into those sites of 
pGBKT7. 
pCT288Int18 pGADT7 derivative plasmid expressing 
Gal4AD-HA-CCDC146692-955 that was 
recovered from the Y2H screen using a 
CT288 fragment as bait. 
4 This Work 
pCT228Int3 pGADT7 derivative plasmid expressing 
Gal4AD-HA-LCA5L5-279 that was 
recovered from the Y2H screen using a 
CT228 fragment as bait. 
4 This Work 
pCT249Int4 pGADT7 derivative plasmid expressing 
Gal4AD-HA-USP11678-973 that was 
recovered from the Y2H screen using a 
CT249 fragment as bait. 
4 This Work 
pFA178 Y2H vector expressing Gal4BD-myc-
CT28889-241. Nucleotides 265 to 723 of 
ct288 were amplified by PCR from L2/434 
chromosomal DNA using primers #944 
and #1474. The DNA product was 
digested with NdeI-BamHI and ligated into 
those sites of pGBKT7. 
4 This Work 
pFA179 Y2H vector expressing Gal4BD-myc-
CT288292-563. Nucleotides 874 to 1689 of 
ct288 were amplified by PCR from L2/434 
chromosomal DNA using primers #1475 
and #954. The DNA product was digested 
with NdeI-BamHI and ligated into those 
sites of pGBKT7. 
4 This Work 
pFA184 Y2H vector expressing Gal4BD-myc-
CT288ΔNΔTMD. Nucleotides 265 to 723, 
and 874 to 1689 of ct288 were amplified 
by PCR from C/TW3 chromosomal DNA 
using primers #944 and #863, and #862 
and #954, respectively. The DNA 
products were then fused by overlapping 
PCR using primers #944 and #954. The 
final DNA product was digested with NdeI-
BamHI and ligated into those sites of 
pGBKT7. 
4 This Work 
pFA185 Y2H vector expressing Gal4BD-myc-
CT288ΔNΔTMD. Nucleotides 265 to 723, 
and 874 to 1689 of ct288 were amplified 
by PCR from E/Bour chromosomal DNA 




Plasmid Description/ Construction Chapter Reference 
using primers #944 and #863, and #862 
and #954, respectively. The DNA 
products were then fused by overlapping 
PCR using primers #944 and #954. The 
final DNA product was digested with NdeI-
BamHI and ligated into those sites of 
pGBKT7 
pFA139 pEGFP-C1 derivative plasmid encoding 
EGFP-CT288ΔNΔTMD. Nucleotides 265 to 
723, and 874 to 1689 of ct288 were 
amplified by PCR from L2/434 
chromosomal DNA using primers #944 
and #863, and #862 and #954, 
respectively. The DNA products were then 
fused by overlapping PCR using primers 
#944 and #954. The final DNA product 
was digested with KpnI-BamHI and 
ligated into those sites of pEGFP-C1. 
4 This Work 
pFA197 pEF6/Myc-His C derivative plasmid 
encoding CT288ΔNΔTMD-HA. Nucleotides 
265 to 723, and 874 to 1689 of ct288 
were amplified by PCR from pSVP255 
DNA using primers #1733 and #863, and 
#862 and #1734, respectively. The DNA 
products were then fused by overlapping 
PCR using primers #1733 and #1734. The 
final DNA product was digested with 
BamHI-EcoRI and ligated into those sites 
of pEF6/Myc-His C. 
4 This Work 
pFA164 pEGFP-C1 derivative plasmid encoding 
EGFP-CCDC146FL. Nucleotides 1 to 2865 
of CCDC146 were amplified by PCR from 
pCCDC146 DNA using primers #1350 
and #1351. The DNA product was 
digested with XhoI-EcoRI and ligated into 
those sites of pEGFP-C1. 
4 This Work 
pFA196 pEGFP-C1 derivative plasmid encoding 
EGFP-CCDC146692-955. Nucleotides 2073 
to 2865 of CCDC146 were amplified by 
PCR from pCCDC146 DNA using primers 
#1730 and #1351. The DNA product was 
digested with XhoI-EcoRI and ligated into 
those sites of pEGFP-C1. 
4 This Work 
pFA167 pEF6/Myc-His C derivative plasmid 
encoding CCDC146FL-HA. Nucleotides 1 
to 2865 of CCDC146 were amplified by 
PCR from pCCDC146 DNA using primers 
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#1352 and #1355. The DNA product was 
digested with EcoRI-NotI and ligated into 
those sites of pEF6/Myc-His C. 
pFA168 pEF6/Myc-His C derivative plasmid 
encoding CCDC146692-955-HA. 
Nucleotides 2073 to 2865 of CCDC146 
were amplified by PCR from pCCDC146 
DNA using primers #1354 and #1355. The 
DNA product was digested with EcoRI-
NotI and ligated into those sites of 
pEF6/Myc-His C. 
4 This Work 
Agaisse, H., and Derré, I. (2013) A C. trachomatis Cloning Vector and the Generation of 
C. trachomatis Strains Expressing Fluorescent Proteins under the Control of a C. 
trachomatis Promoter. PLoS One 8. 
Charpentier, X., and Oswald, E. (2004) Identification of the secretion and translocation 
domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, 
using TEM-1 beta-lactamase as a new fluorescence-based reporter. J Bacteriol 186: 
5486–5495. 
Marenne, M.N., Journet, L., Mota, L.J., and Cornelis, G.R. (2003) Genetic analysis of the 
formation of the Ysc-Yop translocation pore in macrophages by Yersinia enterocolitica: 
Role of LcrV, YscF and YopN. Microb Pathog 35: 243–258. 
Sorg, I., Wagner, S., Amstutz, M., Müller, S. a, Broz, P., Lussi, Y., et al. (2007) YscU 





Table A.3 – Accession numbers of C. trachomatis genomic and inc gene 
sequences used in this work. 
Strain Genome and inc accession numbers Reference 
A/Har13 CP000051 (Carlson et al., 2005)  
A/2497 FM872306 (Seth-Smith et al., 2009)  
A/363 HE601796 (Harris et al., 2012)  
A/5291 HE601810 (Harris et al., 2012) 
A/7249 HE601797 (Harris et al., 2012) 
B/TZ1A4828/OT FM872307 (Seth-Smith et al., 2009)  
B/Jali20 FM872308 (Seth-Smith et al., 2009)  
D/UW3/CX AE001273 (Stephens et al., 1998)  
D/SotonD1 HE601798 (Harris et al., 2012) 
D/SotonD5 HE601799 (Harris et al., 2012) 
D/SotonD6 HE601800 (Harris et al., 2012) 
E/Bour HE601870 (Harris et al., 2012) 
E/SW2 FN652779 (Unemo et al., 2010)  
E/SW3 HE601801 (Harris et al., 2012) 
E/SotonE4 HE601802 (Harris et al., 2012) 
E/SotonE8 HE601803 (Harris et al., 2012) 
E/11023 CP001890 (Jeffrey et al., 2010)  
E/150 CP001886 (Jeffrey et al., 2010) 
F/SW4 HE601804 (Harris et al., 2012) 
F/SW5 HE601805 (Harris et al., 2012) 
F/Soton3 HE601806 (Harris et al., 2012) 
G/9301 CP001930 (Jeffrey et al., 2010) 
G/9768 CP001887 (Jeffrey et al., 2010) 
G/11074 CP001889 (Jeffrey et al., 2010) 
G/11222 CP001888 (Jeffrey et al., 2010) 
G/SotonG1 HE601807 (Harris et al., 2012) 
Ia/Sotonia1 HE601808 (Harris et al., 2012) 
Ia/Sotonia3 HE601809 (Harris et al., 2012) 
J/6276 ABYD01000001 (Jeffrey et al., 2010) 
K/SotonK1 HE601794 (Harris et al., 2012) 
L1/440/LN HE601950 (Harris et al., 2012) 
L1/1322/p2 HE601951 (Harris et al., 2012) 
L1/115 HE601952 (Harris et al., 2012) 
L1/224 HE601953 (Harris et al., 2012) 
L2/434 AM884176 (Thomson et al., 2008) 
L2/25567R HE601954 (Harris et al., 2012) 
L2b/UCH-1 AM884177 (Thomson et al., 2008) 
L2b/8200/07 HE601795 (Harris et al., 2012) 
L2b/UCH-2 HE601956 (Harris et al., 2012) 
L2b/Canada1 HE601963 (Harris et al., 2012) 
L2b/Canada2 HE601957 (Harris et al., 2012) 
L2b/LST HE601958 (Harris et al., 2012) 




Strain Genome and inc accession numbers Reference 
L2b/795 HE601949 (Harris et al., 2012) 
L2b/Ams1 HE601959 (Harris et al., 2012) 
L2b/Ams2 HE601961 (Harris et al., 2012) 
L2b/Ams3 HE601962 (Harris et al., 2012) 
L2b/Ams4 HE601964 (Harris et al., 2012) 
L2b/Ams5 HE601965 (Harris et al., 2012) 
L2c CP002024 (Somboonna et al., 2011)  
L3/404/LN HE601955 (Harris et al., 2012) 
Carlson, J.H., Porcella, S.F., Mcclarty, G., and Caldwell, H.D. (2005) Comparative 
Genomic Analysis of Chlamydia trachomatis Oculotropic and Genitotropic Strains. Infect 
Immun 73: 6407–6418. 
Harris, S.R., Clarke, I.N., Seth-Smith, H.M.B., Solomon, A.W., Cutcliffe, L.T., Marsh, P., 
et al. (2012) Whole-genome analysis of diverse Chlamydia trachomatis strains identifies 
phylogenetic relationships masked by current clinical typing. Nat Genet 44: 413–419. 
Jeffrey, B.M., Suchland, R.J., Quinn, K.L., Davidson, J.R., Stamm, W.E., and Rockey, 
D.D. (2010) Genome sequencing of recent clinical Chlamydia trachomatis strains 
identifies loci associated with tissue tropism and regions of apparent recombination. 
Infect Immun 78: 2544–2553. 
Seth-Smith, H.M.B., Harris, S.R., Persson, K., Marsh, P., Barron, A., Bignell, A., et al. 
(2009) Co-evolution of genomes and plasmids within Chlamydia trachomatis and the 
emergence in Sweden of a new variant strain. BMC Genomics 10: 239. 
Somboonna, N., Wan, R., Ojcius, D.M., Pettengill, M. a, Joseph, S.J., Chang, A., et al. 
(2011) Hypervirulent Chlamydia trachomatis Clinical Strain Is a Recombinant between 
Lymphogranuloma Venereum (L2) and D Lineages. MBio 2: 1–12. 
Stephens, R.S., Kalman, S., Lammel, C., Fan, J., Marathe, R., Aravind, L., et al. (1998) 
Genome sequence of an obligate intracellular pathogen of humans: Chlamydia 
trachomatis. Science 282: 754–759. 
Thomson, N.R., Holden, M.T.G., Carder, C., Lennard, N., Lockey, S.J., Marsh, P., et al. 
(2008) Chlamydia trachomatis: genome sequence analysis of lymphogranuloma 
venereum isolates. Genome Res 18: 161–171. 
Unemo, M., Seth-Smith, H.M.B., Cutcliffe, L.T., Skilton, R.J., Barlow, D., Goulding, D., et 
al. (2010) The Swedish new variant of Chlamydia trachomatis: Genome sequence, 





Table A.4 – Molecular evolution analyses of inc, pmp, and housekeeping (HK) 
genes among all 51 C. trachomatis strainsa.  
All strains (ocular, urogenital, and LGV) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive neutral 
inc genes 
ct005 0,0018 0,0009 0,0084 0,0034 0,2104 0,1346 ND ND 
ct006 0,0019 0,0014 0,0002 0,0002 9,6440 11,5124 0,1136 ND 
ct036 0,0025 0,0011 0,0044 0,0021 0,5787 0,3661 ND ND 
ct058 0,0103 0,0022 0,0076 0,0031 1,3412 0,6151 0,2470 ND 
ct101 0,0025 0,0011 0,0044 0,0021 0,5787 0,3665 ND ND 
ct115 0,0296 0,0079 0,0262 0,0097 1,1287 0,5170 0,3669 ND 
ct116 0,0282 0,0068 0,0082 0,0042 3,4243 1,9470 0,0035 0,0063 
ct117 0,0188 0,0060 0,0088 0,0055 2,1380 1,4889 0,0870 ND 
ct118 0,0149 0,0042 0,0030 0,0029 5,0151 5,0390 0,0150 0,0290 
ct119 0,0087 0,0024 0,0033 0,0020 2,6132 1,7436 0,0250 0,0480 
ct134 0,0028 0,0017 0,0087 0,0054 0,3160 0,2723 ND ND 
ct135 0,0043 0,0015 0,0067 0,0032 0,6353 0,3720 ND ND 
ct147 0,0088 0,0011 0,0066 0,0013 1,3417 0,3109 0,0830 ND 
ct164 0,0030 0,0028 0,0000 0,0000 ND ND 0,1419 ND 
ct179 0,0036 0,0019 0,0040 0,0029 0,9096 0,8229 ND ND 
ct192 0,0106 0,0028 0,0093 0,0038 1,1456 0,5606 0,3880 ND 
ct195 0,0043 0,0013 0,0086 0,0031 0,5042 0,2346 ND ND 
ct196 0,0043 0,0029 0,0071 0,0053 0,6020 0,6127 ND ND 
ct214 0,0064 0,0015 0,0064 0,0028 1,0094 0,5038 0,4883 ND 
ct222 0,0197 0,0075 0,0110 0,0058 1,7925 1,1701 0,0240 0,0450 
ct223 0,0278 0,0047 0,0065 0,0045 4,2470 3,0401 0,0026 0,0050 
ct224 0,0043 0,0024 0,0018 0,0016 2,4013 2,4406 0,1639 ND 
ct225 0,0013 0,0010 0,0043 0,0039 0,3149 0,3740 ND ND 
ct226 0,0049 0,0023 0,0042 0,0030 1,1754 1,0150 0,4224 ND 
ct227 0,0052 0,0028 0,0017 0,0017 3,1477 3,5919 0,1405 ND 
ct228 0,0108 0,0034 0,0023 0,0024 4,6703 4,9840 0,0210 0,0480 
ct229 0,0263 0,0047 0,0055 0,0036 4,7722 3,2168 0,0002 0,0010 
ct232 0,0088 0,0036 0,0064 0,0048 1,3802 1,1794 0,3201 ND 
ct233 0,0069 0,0024 0,0125 0,0057 0,5492 0,3165 ND ND 
ct249 0,0211 0,0078 0,0000 0,0000 ND ND 0,0038 0,0050 




All strains (ocular, urogenital, and LGV) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive neutral 
ct300 0,0026 0,0020 0,0098 0,0062 0,2682 0,2621 ND ND 
ct345 0,0037 0,0023 0,0023 0,0024 1,6120 1,9630 0,3344 ND 
ct357 0,0047 0,0029 0,0057 0,0044 0,8135 0,8090 ND ND 
ct358 0,0232 0,0070 0,0241 0,0082 0,9597 0,4369 ND ND 
ct365 0,0054 0,0014 0,0042 0,0016 1,2691 0,5935 0,2977 ND 
ct383 0,0053 0,0020 0,0011 0,0010 4,8771 4,7082 0,0320 0,0630 
ct440 0,0021 0,0020 0,0000 0,0000 ND ND 0,1680 ND 
ct442 0,0231 0,0053 0,0140 0,0079 1,6499 1,0024 0,0741 ND 
ct449 0,0040 0,0028 0,0000 0,0000 ND ND 0,0784 ND 
ct483 0,0003 0,0003 0,0072 0,0048 0,0431 0,0516 ND ND 
ct484 0,0008 0,0006 0,0074 0,0039 0,1083 0,0988 ND ND 
ct565 0,0019 0,0018 0,0058 0,0035 0,3341 0,3630 ND ND 
ct618 0,0148 0,0033 0,0314 0,0085 0,4707 0,1649 ND ND 
ct728 0,0021 0,0012 0,0045 0,0025 0,4619 0,3808 ND ND 
ct789 0,0000 0,0000 0,0057 0,0064 0,0000 ND ND ND 
ct813 0,0164 0,0036 0,0040 0,0024 4,1404 2,6649 0,0028 0,0063 
ct850 0,0019 0,0009 0,0035 0,0017 0,5517 0,3792 ND ND 
pmp genes 
pmpA 0,0008 0,0003 0,0018 0,0008 0,4504 0,2703 ND ND 
pmpB 0,0083 0,0009 0,0051 0,0013 1,6211 0,4442 0,0220 0,0431 
pmpC 0,0058 0,0008 0,0040 0,0009 1,4323 0,3684 0,0653 ND 
pmpD 0,0024 0,0006 0,0039 0,0010 0,6290 0,2118 ND ND 
pmpE 0,0148 0,0017 0,0484 0,0052 0,3066 0,0486 ND ND 
pmpF 0,0415 0,0031 0,1595 0,0093 0,2603 0,0248 ND ND 
pmpG 0,0071 0,0014 0,0174 0,0029 0,4049 0,1040 ND ND 
pmpH 0,0166 0,0019 0,0923 0,0079 0,1794 0,0260 ND ND 
pmpI 0,0031 0,0008 0,0094 0,0020 0,3324 0,1100 ND ND 
HK genes 
yraL (ct048) 0,0057 0,0018 0,0078 0,0033 0,7375 0,3916 ND ND 
fer (ct059) 0,0048 0,0034 0,0242 0,0112 0,1992 0,1677 ND ND 
accD (ct293) 0,0035 0,0015 0,0433 0,0096 0,0807 0,0392 ND ND 
karG (ct675) 0,0063 0,0017 0,0560 0,0092 0,1124 0,0359 ND ND 
rrf (ct677) 0,0057 0,0025 0,0930 0,0163 0,0613 0,0288 ND ND 




All strains (ocular, urogenital, and LGV) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive neutral 
tsf (ct679) 0,0099 0,0024 0,1036 0,0140 0,0955 0,0263 ND ND 
rpsB (ct680) 0,0168 0,0036 0,1051 0,0131 0,1595 0,0398 ND ND 
yfO_1 (ct687) 0,0015 0,0009 0,0226 0,0054 0,0673 0,0417 ND ND 
aNon-synonymous (dN) and synonymous (dS) substitutions between inc, pmp, and 
housekeeping (HK) genes among all 51 C. trachomatis strains, and test of selection 
using the codon-based Z test using MEGA5 (Tamura et al., 2011) as described in 
Materials and Methods. When dN/dS > 1, we tested for positive selection. If the results of 
the codon based Z-tests of selection were significant (p < 0.05), we further tested for lack 
of neutrality (dN ≠ dS). Genes were considered likely under putative positive selection, 
only if both positive selection and neutrality tests were significant. The nucleotide 
sequences were obtained from the genomes of the 51 C. trachomatis strains listed in 
Table A.3. 
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011) 
MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, 






Table A.5 – Molecular evolution analyses of inc, pmp, and housekeeping (HK) 
genes among all 51 C. trachomatis strains minus urogenital strainsa. 
All strains minus urogenital (ocular and LGV) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive neutral 
inc genes 
ct005 ND ND ND ND ND ND ND ND 
ct006 ND ND ND ND ND ND ND ND 
ct036 ND ND ND ND ND ND ND ND 
ct058 ND ND ND ND ND ND ND ND 
ct101 ND ND ND ND ND ND ND ND 
ct115 ND ND ND ND ND ND ND ND 
ct116 0,0168 0,0048 0,0063 0,0039 2,6526 1,7899 0,0324 0,0650 
ct117 ND ND ND ND ND ND ND ND 
ct118 0,0118 0,0038 0,0026 0,0024 4,4573 4,3758 0,0166 0,0361 
ct119 0,0080 0,0023 0,0018 0,0016 4,5316 4,4106 0,0024 0,0045 
ct134 ND ND ND ND ND ND ND ND 
ct135 ND ND ND ND ND ND ND ND 
ct147 ND ND ND ND ND ND ND ND 
ct164 ND ND ND ND ND ND ND ND 
ct179 ND ND ND ND ND ND ND ND 
ct192 ND ND ND ND ND ND ND ND 
ct195 ND ND ND ND ND ND ND ND 
ct196 ND ND ND ND ND ND ND ND 
ct214 ND ND ND ND ND ND ND ND 
ct222 0,0160 0,0060 0,0101 0,0054 1,5857 1,0330 0,0809 ND 
ct223 0,0229 0,0042 0,0046 0,0034 4,9942 3,8494 0,0038 0,0092 
ct224 ND ND ND ND ND ND ND ND 
ct225 ND ND ND ND ND ND ND ND 
ct226 ND ND ND ND ND ND ND ND 
ct227 ND ND ND ND ND ND ND ND 
ct228 0,0075 0,0025 0,0015 0,0016 4,8536 5,1520 0,0210 0,0410 
ct229 0,0174 0,0036 0,0037 0,0024 4,7103 3,2301 0,0013 0,0035 
ct232 ND ND ND ND ND ND ND ND 
ct233 ND ND ND ND ND ND ND ND 
ct249 0,0159 0,0056 0,0000 0,0000 ND ND 0,0044 0,0062 




All strains minus urogenital (ocular and LGV) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive neutral 
ct300 ND ND ND ND ND ND ND ND 
ct345 ND ND ND ND ND ND ND ND 
ct357 ND ND ND ND ND ND ND ND 
ct358 ND ND ND ND ND ND ND ND 
ct365 ND ND ND ND ND ND ND ND 
ct383 ND ND ND ND ND ND ND ND 
ct440 ND ND ND ND ND ND ND ND 
ct442 ND ND ND ND ND ND ND ND 
ct449 ND ND ND ND ND ND ND ND 
ct483 ND ND ND ND ND ND ND ND 
ct484 ND ND ND ND ND ND ND ND 
ct565 ND ND ND ND ND ND ND ND 
ct618 ND ND ND ND ND ND ND ND 
ct728 ND ND ND ND ND ND ND ND 
ct789 ND ND ND ND ND ND ND ND 
ct813 0,0114 0,0028 0,0020 0,0015 5,5693 4,2519 0,0020 0,0032 
ct850 ND ND ND ND ND ND ND ND 
pmp genes 
pmpA ND ND ND ND ND ND ND ND 
pmpB ND ND ND ND ND ND ND ND 
pmpC ND ND ND ND ND ND ND ND 
pmpD ND ND ND ND ND ND ND ND 
pmpE ND ND ND ND ND ND ND ND 
pmpF ND ND ND ND ND ND ND ND 
pmpG ND ND ND ND ND ND ND ND 
pmpH ND ND ND ND ND ND ND ND 
pmpI ND ND ND ND ND ND ND ND 
HK genes 
yraL (ct048) ND ND ND ND ND ND ND ND 
fer (ct059) ND ND ND ND ND ND ND ND 
accD (ct293) ND ND ND ND ND ND ND ND 
karG (ct675) ND ND ND ND ND ND ND ND 
rrf (ct677) ND ND ND ND ND ND ND ND 




All strains minus urogenital (ocular and LGV) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive neutral 
tsf (ct679) ND ND ND ND ND ND ND ND 
rpsB (ct680) ND ND ND ND ND ND ND ND 
yfO_1 (ct687) ND ND ND ND ND ND ND ND 
aNon-synonymous (dN) and synonymous (dS) substitutions between inc, pmp, and 
housekeeping (HK) genes among all C. trachomatis strains minus urogenital strains, and 
test of selection using the codon-based Z test using MEGA5 (Tamura et al., 2011) as 
described in Materials and Methods. When dN/dS > 1, we tested for positive selection. If 
the results of the codon based Z-tests of selection were significant (p < 0.05), we further 
tested for lack of neutrality (dN ≠ dS). Genes were considered likely under putative 
positive selection, only if both positive selection and neutrality tests were significant. The 
nucleotide sequences were obtained from the genomes of the 51 C. trachomatis strains 
listed in Table A.3. 
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011) 
MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, 





Table A.6 – Molecular evolution analyses of inc, pmp, and housekeeping (HK) 
genes among all 51 C. trachomatis strains minus ocular strainsa. 
All strains minus ocular (urogenital and LGV) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive Neutral 
inc genes 
ct005 ND ND ND ND ND ND ND ND 
ct006 ND ND ND ND ND ND ND ND 
ct036 ND ND ND ND ND ND ND ND 
ct058 ND ND ND ND ND ND ND ND 
ct101 ND ND ND ND ND ND ND ND 
ct115 ND ND ND ND ND ND ND ND 
ct116 0,0280 0,0068 0,0068 0,0042 4,1397 2,7567 0,0015 0,0035 
ct117 ND ND ND ND ND ND ND ND 
ct118 0,0157 0,0045 0,0031 0,0031 5,0004 5,1294 0,0120 0,0286 
ct119 0,0083 0,0025 0,0037 0,0022 2,2331 1,4850 0,0560 ND 
ct134 ND ND ND ND ND ND ND ND 
ct135 ND ND ND ND ND ND ND ND 
ct147 ND ND ND ND ND ND ND ND 
ct164 ND ND ND ND ND ND ND ND 
ct179 ND ND ND ND ND ND ND ND 
ct192 ND ND ND ND ND ND ND ND 
ct195 ND ND ND ND ND ND ND ND 
ct196 ND ND ND ND ND ND ND ND 
ct214 ND ND ND ND ND ND ND ND 
ct222 0,0203 0,0077 0,0096 0,0057 2,1117 1,4924 0,0052 0,0133 
ct223 0,0254 0,0048 0,0060 0,0043 4,1962 3,0885 0,0033 0,0065 
ct224 ND ND ND ND ND ND ND ND 
ct225 ND ND ND ND ND ND ND ND 
ct226 ND ND ND ND ND ND ND ND 
ct227 ND ND ND ND ND ND ND ND 
ct228 0,0106 0,0035 0,0024 0,0024 4,4774 4,7061 0,0300 0,0560 
ct229 0,0262 0,0052 0,0050 0,0034 5,2698 3,6992 0,0023 0,0083 
ct232 ND ND ND ND ND ND ND ND 
ct233 ND ND ND ND ND ND ND ND 
ct249 0,0205 0,0077 0,0000 0,0000 ND ND 0,0048 0,0077 




All strains minus ocular (urogenital and LGV) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive Neutral 
ct300 ND ND ND ND ND ND ND ND 
ct345 ND ND ND ND ND ND ND ND 
ct357 ND ND ND ND ND ND ND ND 
ct358 ND ND ND ND ND ND ND ND 
ct365 ND ND ND ND ND ND ND ND 
ct383 ND ND ND ND ND ND ND ND 
ct440 ND ND ND ND ND ND ND ND 
ct442 ND ND ND ND ND ND ND ND 
ct449 ND ND ND ND ND ND ND ND 
ct483 ND ND ND ND ND ND ND ND 
ct484 ND ND ND ND ND ND ND ND 
ct565 ND ND ND ND ND ND ND ND 
ct618 ND ND ND ND ND ND ND ND 
ct728 ND ND ND ND ND ND ND ND 
ct789 ND ND ND ND ND ND ND ND 
ct813 0,0168 0,0037 0,0042 0,0025 3,9847 2,5200 0,0027 0,0084 
ct850 ND ND ND ND ND ND ND ND 
pmp genes 
pmpA ND ND ND ND ND ND ND ND 
pmpB ND ND ND ND ND ND ND ND 
pmpC ND ND ND ND ND ND ND ND 
pmpD ND ND ND ND ND ND ND ND 
pmpE ND ND ND ND ND ND ND ND 
pmpF ND ND ND ND ND ND ND ND 
pmpG ND ND ND ND ND ND ND ND 
pmpH ND ND ND ND ND ND ND ND 
pmpI ND ND ND ND ND ND ND ND 
HK genes 
yraL (ct048) ND ND ND ND ND ND ND ND 
fer (ct059) ND ND ND ND ND ND ND ND 
accD (ct293) ND ND ND ND ND ND ND ND 
karG (ct675) ND ND ND ND ND ND ND ND 
rrf (ct677) ND ND ND ND ND ND ND ND 




All strains minus ocular (urogenital and LGV) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive Neutral 
tsf (ct679) ND ND ND ND ND ND ND ND 
rpsB (ct680) ND ND ND ND ND ND ND ND 
yfO_1 (ct687) ND ND ND ND ND ND ND ND 
aNon-synonymous (dN) and synonymous (dS) substitutions between inc, pmp, and 
housekeeping (HK) genes among all C. trachomatis strains minus ocular strains, and 
test of selection using the codon-based Z test using MEGA5 (Tamura et al., 2011) as 
described in Materials and Methods. When dN/dS > 1, we tested for positive selection. If 
the results of the codon based Z-tests of selection were significant (p < 0.05), we further 
tested for lack of neutrality (dN ≠ dS). Genes were considered likely under putative 
positive selection, only if both positive selection and neutrality tests were significant. The 
nucleotide sequences were obtained from the genomes of the 51 C. trachomatis strains 
listed in Table A.3. 
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011) 
MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, 





Table A.7 – Molecular evolution analyses of inc, pmp, and housekeeping (HK) 
genes among all 51 C. trachomatis strains minus LGV strainsa. 
All strains minus LGV (ocular and urogenital) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive neutral 
inc genes 
ct005 ND ND ND ND ND ND ND ND 
ct006 ND ND ND ND ND ND ND ND 
ct036 ND ND ND ND ND ND ND ND 
ct058 ND ND ND ND ND ND ND ND 
ct101 ND ND ND ND ND ND ND ND 
ct115 ND ND ND ND ND ND ND ND 
ct116 0,0144 0,0045 0,0067 0,0040 2,1510 1,4507 0,1031 ND 
ct117 ND ND ND ND ND ND ND ND 
ct118 0,0034 0,0020 0,0000 0,0000 ND ND 0,0689 ND 
ct119 0,0031 0,0013 0,0021 0,0016 1,4726 1,2506 0,3118 ND 
ct134 ND ND ND ND ND ND ND ND 
ct135 ND ND ND ND ND ND ND ND 
ct147 ND ND ND ND ND ND ND ND 
ct164 ND ND ND ND ND ND ND ND 
ct179 ND ND ND ND ND ND ND ND 
ct192 ND ND ND ND ND ND ND ND 
ct195 ND ND ND ND ND ND ND ND 
ct196 ND ND ND ND ND ND ND ND 
ct214 ND ND ND ND ND ND ND ND 
ct222 0,0008 0,0006 0,0025 0,0026 0,3078 0,3852 ND ND 
ct223 0,0110 0,0026 0,0004 0,0003 28,016 24,1101 0,0401 0,0952 
ct224 ND ND ND ND ND ND ND ND 
ct225 ND ND ND ND ND ND ND ND 
ct226 ND ND ND ND ND ND ND ND 
ct227 ND ND ND ND ND ND ND ND 
ct228 0,0015 0,0009 0,0000 0,0000 ND ND 0,0580 ND 
ct229 0,0078 0,0024 0,0006 0,0005 12,070 10,8707 0,0679 ND 
ct232 ND ND ND ND ND ND ND ND 
ct233 ND ND ND ND ND ND ND ND 
ct249 0,0087 0,0036 0,0000 0,0000 ND ND 0,0101 0,0172 




All strains minus LGV (ocular and urogenital) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive neutral 
ct300 ND ND ND ND ND ND ND ND 
ct345 ND ND ND ND ND ND ND ND 
ct357 ND ND ND ND ND ND ND ND 
ct358 ND ND ND ND ND ND ND ND 
ct365 ND ND ND ND ND ND ND ND 
ct383 ND ND ND ND ND ND ND ND 
ct440 ND ND ND ND ND ND ND ND 
ct442 ND ND ND ND ND ND ND ND 
ct449 ND ND ND ND ND ND ND ND 
ct483 ND ND ND ND ND ND ND ND 
ct484 ND ND ND ND ND ND ND ND 
ct565 ND ND ND ND ND ND ND ND 
ct618 ND ND ND ND ND ND ND ND 
ct728 ND ND ND ND ND ND ND ND 
ct789 ND ND ND ND ND ND ND ND 
ct813 0,0046 0,0018 0,0024 0,0020 1,8906 1,7002 0,2028 ND 
ct850 ND ND ND ND ND ND ND ND 
pmp genes 
pmpA ND ND ND ND ND ND ND ND 
pmpB ND ND ND ND ND ND ND ND 
pmpC ND ND ND ND ND ND ND ND 
pmpD ND ND ND ND ND ND ND ND 
pmpE ND ND ND ND ND ND ND ND 
pmpF ND ND ND ND ND ND ND ND 
pmpG ND ND ND ND ND ND ND ND 
pmpH ND ND ND ND ND ND ND ND 
pmpI ND ND ND ND ND ND ND ND 
HK genes 
yraL (ct048) ND ND ND ND ND ND ND ND 
fer (ct059) ND ND ND ND ND ND ND ND 
accD (ct293) ND ND ND ND ND ND ND ND 
karG (ct675) ND ND ND ND ND ND ND ND 
rrf (ct677) ND ND ND ND ND ND ND ND 




All strains minus LGV (ocular and urogenital) 
Gene dN SEM dS SEM dN/dS SEM 
Z-test of selection 
positive neutral 
tsf (ct679) ND ND ND ND ND ND ND ND 
rpsB (ct680) ND ND ND ND ND ND ND ND 
yfO_1 (ct687) ND ND ND ND ND ND ND ND 
aNon-synonymous (dN) and synonymous (dS) substitutions between inc, pmp, and 
housekeeping (HK) genes among all C. trachomatis strains minus LGV strains, and test 
of selection using the codon-based Z test using MEGA5 (Tamura et al., 2011) as 
described in Materials and Methods. When dN/dS > 1, we tested for positive selection. If 
the results of the codon based Z-tests of selection were significant (p < 0.05), we further 
tested for lack of neutrality (dN ≠ dS). Genes were considered likely under putative 
positive selection, only if both positive selection and neutrality tests were significant. The 
nucleotide sequences were obtained from the genomes of the 51 C. trachomatis strains 
listed in Table A.3. 
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011) 
MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, 





Table A.8 – mRNA levels of inc genes during the developmental cycle of 
Chlamydia trachomatis C/TW3 straina. 
Chlamydia trachomatis C/TW3 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 




ct006 91,67 7,05 61,06 4,43 30,59 3,82 20,07 1,60 9,76 0,71 7,34 1,02 Early T2 
ct036 50,53 8,78 34,57 1,67 24,54 3,04 24,52 2,55 16,58 3,04 14,82 2,12 Early T2 
ct058 0,60 0,41 0,28 0,05 0,43 0,32 0,14 0,08 0,11 0,07 0,10 0,06 Early T2 
ct101 13,19 ND 18,46 4,59 41,32 8,36 52,79 4,28 30,16 ND 8,89 1,10 Mid T20 
ct115 427,48 184,83 250,63 92,39 163,71 23,87 81,98 19,32 31,18 14,73 17,10 3,04 Early T2 
ct116 575,31 65,26 435,69 78,80 403,62 116,39 264,47 77,90 100,28 40,59 48,84 1,50 Early T2 
ct117 331,73 11,70 249,55 28,31 368,20 18,41 222,35 51,12 69,31 26,01 34,48 ND Early T12 
ct118 200,24 23,06 196,98 3,93 324,39 31,76 184,41 21,14 62,80 18,71 25,96 3,43 Early T12 
ct119 17,18 4,89 11,39 0,88 24,31 1,91 28,02 2,06 27,21 1,18 12,62 1,55 Mid T20 
ct134 151,81 20,91 145,51 31,48 133,52 82,07 27,41 11,79 12,67 3,69 11,64 2,81 Early T2 
ct135 156,85 24,41 116,14 31,36 94,77 44,70 24,40 7,41 16,81 6,66 11,26 2,41 Early T2 
ct147 200,31 15,13 123,79 14,20 76,45 9,23 16,03 0,59 13,07 0,83 19,67 0,64 Early T2 
ct164 6,26 ND 4,56 0,87 13,53 ND 5,21 0,98 5,76 0,36 5,08 0,38 Early T12 
ct179 22,78 ND 23,69 2,69 50,50 9,72 26,53 5,45 14,70 ND 13,10 1,66 Mid T12 
ct192 8,26 2,02 25,27 1,03 19,71 6,87 6,55 2,78 3,90 0,92 3,70 0,15 Early T6 
ct195 15,97 ND 13,24 2,08 16,55 0,67 12,82 2,13 14,63 1,86 6,91 0,93 Early T12 
ct196 41,82 10,23 31,63 16,93 19,98 10,20 7,54 2,07 6,13 2,38 5,17 0,18 Early T2 
ct214 21,80 4,55 19,07 5,89 23,80 12,77 12,08 2,42 42,08 0,58 44,04 13,33 Late T42 
ct222 7,48 4,30 3,64 1,72 7,26 1,51 11,74 5,37 7,56 2,19 5,80 0,18 Mid T20 
ct223 5,53 3,81 3,64 1,53 15,16 1,01 52,81 23,09 22,16 8,22 10,78 2,15 Mid T20 
ct224 12,05 ND 5,78 0,42 5,19 0,46 6,13 0,49 10,78 2,19 5,12 0,99 Early T2 
ct225 10,25 0,45 5,47 0,98 10,16 1,60 12,62 1,70 17,34 1,74 7,51 0,94 Early T30 
ct226 6,74 2,43 10,11 ND 19,41 1,14 14,54 2,44 12,31 1,46 6,96 0,96 Mid T12 
ct227 17,00 5,78 12,24 0,76 15,88 7,48 6,44 0,31 7,73 2,08 5,55 0,32 Early T2 
ct228 75,13 3,97 76,00 6,79 73,19 29,83 28,44 13,41 11,23 3,65 8,94 0,27 Early T6 
ct229 372,22 54,35 239,91 76,64 82,41 29,58 23,63 7,19 24,23 1,88 53,43 14,36 Early T2 
ct232 79,65 14,68 95,63 18,56 78,47 30,62 60,31 33,40 24,45 9,31 11,15 3,16 Early T6 




Chlamydia trachomatis C/TW3 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct249 30,70 0,80 20,63 1,53 26,84 8,37 18,31 7,62 12,72 3,40 9,95 0,09 Early T2 
ct288 20,51 8,54 18,93 6,62 34,38 15,13 16,73 8,30 30,62 10,21 39,76 4,13 Early T42 
ct300 13,51 2,42 9,30 0,67 23,49 4,75 9,09 0,17 6,10 0,12 10,09 0,77 Early T12 
ct345 10,84 ND 8,64 2,54 23,25 ND 7,10 0,13 7,52 0,65 5,92 0,21 Mid T12 
ct357 75,87 3,78 64,74 2,02 45,12 6,94 21,44 0,88 20,07 0,27 30,73 2,24 Early T2 
ct358 60,13 6,58 58,77 2,01 107,26 13,67 40,50 3,47 19,95 1,04 26,56 0,60 Early T12 
ct365 8,05 0,58 4,36 0,43 8,18 4,54 5,80 0,92 15,69 2,01 24,31 4,05 Late T42 
ct383 39,53 12,33 37,70 9,15 47,55 6,08 38,29 5,79 15,93 7,16 11,41 1,53 Early T12 
ct440 11,01 4,43 10,55 0,86 13,77 3,60 9,16 3,54 6,91 1,11 5,37 0,07 Early T12 
ct442 7,69 2,87 7,35 3,90 5,26 2,32 2,92 0,01 7,52 2,65 10,07 1,41 Early T42 
ct449 31,43 6,97 27,75 3,52 31,75 11,12 8,75 2,25 5,07 0,33 4,52 0,28 Early T12 
ct483 15,40 1,68 11,44 1,72 20,66 4,38 17,68 0,39 13,93 2,35 9,10 0,70 Early T12 
ct484 9,31 2,60 6,58 0,59 18,28 1,32 11,34 0,73 8,47 0,31 4,57 0,25 Early T12 
ct565 92,29 9,79 45,42 5,62 39,20 1,43 26,97 3,64 199,71 83,87 304,06 58,56 Late T42 
ct618 275,96 6,34 275,62 21,44 451,48 28,23 264,33 9,19 50,71 1,42 33,89 0,45 Early T12 
ct728 17,62 2,63 40,01 2,37 119,14 9,26 91,03 7,68 68,44 2,64 33,07 1,08 Mid T12 
ct789 26,58 7,22 18,17 3,59 23,09 7,83 17,83 0,31 13,45 1,68 8,37 0,48 Early T2 
ct813 11,91 4,83 12,29 2,95 9,75 0,52 6,21 0,58 17,89 10,02 30,61 5,81 Late T42 
ct850 7,35 2,33 3,73 0,36 22,61 0,97 17,99 3,60 25,32 6,36 10,43 1,91 Mid T30 
aReal-time quantitative PCR (RT-qPCR) of mRNA levels of inc genes during the 
developmental cycle of Chlamydia trachomatis C/TW3 strain. The data shows for each 
inc at each time point the mean values (x105) ± SEM, normalized against the 
corresponding values of the 16SrRNA, from at least two independent experiments 





Table A.9 –mRNA levels of inc genes during the developmental cycle of Chlamydia 
trachomatis E/Bour straina. 
Chlamydia trachomatis E/Bour 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 




ct006 130,27 28,37 65,65 ND 45,01 1,19 23,85 2,49 10,76 2,22 25,65 2,17 Early T2 
ct036 92,07 32,06 67,23 ND 40,94 4,67 32,69 0,84 15,77 3,13 41,39 5,65 Early T2 
ct058 0,40 0,30 0,81 0,48 0,65 0,47 0,13 0,11 0,10 0,08 0,24 0,07 Early T6 
ct101 12,91 ND 22,71 2,61 40,44 1,60 35,47 0,66 10,37 2,09 23,75 2,08 Mid T12 
ct115 160,14 12,15 79,75 5,14 70,04 3,04 19,22 8,11 12,08 0,01 24,72 1,73 Early T2 
ct116 472,47 107,51 265,52 72,77 224,05 29,28 86,43 48,29 34,06 5,12 54,89 6,44 Early T2 
ct117 209,13 2,96 160,14 8,12 213,11 7,77 84,22 11,23 26,77 2,04 42,69 6,02 Early T12 
ct118 173,49 70,41 133,41 ND 177,53 31,36 92,39 2,44 24,57 6,20 47,30 15,77 Early T12 
ct119 4,48 1,14 12,49 ND 21,36 2,59 46,23 5,39 19,83 1,95 23,55 1,13 Mid T20 
ct134 297,41 130,60 173,09 79,97 89,70 35,53 26,25 19,96 16,74 5,23 48,29 17,54 Early T2 
ct135 272,79 116,21 134,17 51,39 88,81 23,86 25,79 16,41 17,86 4,81 39,89 6,52 Early T2 
ct147 138,02 6,12 73,36 10,37 82,72 5,10 10,82 0,25 33,42 2,18 51,36 3,35 Early T2 
ct164 5,92 2,42 7,94 1,62 8,26 1,50 9,46 0,46 5,30 0,29 18,02 2,55 Late T42 
ct179 18,84 7,41 34,25 ND 63,23 9,14 27,81 1,30 12,13 3,28 23,83 3,01 Mid T12 
ct192 4,26 1,69 7,10 3,83 4,35 0,83 2,91 1,12 4,32 0,02 18,30 3,03 Late T42 
ct195 13,64 3,92 16,56 0,83 18,21 0,83 21,90 2,70 13,52 1,05 20,23 3,57 Early T20 
ct196 65,34 28,14 33,40 20,10 15,81 6,70 8,77 6,24 6,39 1,42 23,78 1,66 Early T2 
ct214 16,41 6,80 11,79 4,02 10,54 2,61 12,21 4,89 48,09 0,35 55,17 8,76 Late T42 
ct222 4,86 3,07 6,91 5,37 7,39 3,12 8,82 3,62 6,87 0,97 20,01 1,78 Late T42 
ct223 14,51 12,39 8,03 5,53 22,92 1,94 52,41 21,45 22,44 6,27 29,87 0,03 Mid T20 
ct224 11,90 3,68 11,20 1,84 8,16 0,22 9,81 0,22 7,01 0,74 18,13 0,90 Early T42 
ct225 10,67 3,78 15,64 3,09 16,50 1,38 17,69 2,17 10,05 1,04 21,60 1,01 Early T42 
ct226 10,22 0,60 11,17 5,51 21,38 8,11 14,86 1,77 8,36 0,63 17,89 2,42 Mid T12 
ct227 28,37 13,85 36,93 20,77 25,19 9,74 8,83 5,74 7,37 0,69 26,62 2,14 Early T6 
ct228 210,25 59,54 187,71 66,67 199,68 24,15 53,40 37,36 18,50 0,49 36,11 8,07 Early T2 
ct229 491,19 117,14 174,29 66,33 47,15 6,64 12,96 5,21 59,03 4,57 125,67 49,47 Early T2 
ct232 145,79 83,39 70,00 25,56 44,49 10,94 21,31 14,14 11,90 4,85 24,62 2,97 Early T2 




Chlamydia trachomatis E/Bour 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct249 66,11 25,16 49,62 20,53 20,18 3,75 14,42 6,51 16,65 5,58 31,82 3,18 Early T2 
ct288 28,73 11,13 21,66 13,94 20,40 4,95 12,55 6,27 61,62 2,03 52,32 0,41 Late T30 
ct300 7,43 1,38 15,56 1,42 15,72 1,12 9,36 1,09 8,62 1,49 25,25 3,30 Early T42 
ct345 4,83 1,41 10,81 2,20 12,65 2,42 21,44 0,85 13,84 0,24 19,62 1,26 Mid T20 
ct357 63,83 9,81 36,62 6,07 32,74 4,06 23,37 1,27 21,56 4,03 29,74 4,07 Early T2 




ct365 5,22 0,23 9,51 0,72 7,07 1,23 7,20 1,32 16,55 2,01 27,67 3,81 Late T42 
ct383 41,27 8,12 24,65 1,16 38,91 3,49 18,87 3,11 13,62 1,65 18,89 2,73 Early T2 




ct442 7,51 4,21 7,34 5,33 3,87 1,43 4,97 0,17 17,21 3,26 30,92 2,77 Late T42 




ct483 19,74 2,33 18,46 4,62 20,82 4,87 16,57 0,95 11,23 0,11 21,35 1,19 Early T42 
ct484 9,78 ND 12,21 ND 9,74 1,85 10,79 1,50 9,28 2,63 17,60 0,94 Early T42 
ct565 43,37 5,73 28,20 5,11 27,65 1,30 111,13 43,30 284,17 5,01 398,46 47,97 Late T42 
ct618 456,52 19,28 296,09 19,93 235,44 8,84 86,28 1,71 30,12 1,27 36,26 3,96 Early T2 
ct728 13,24 ND 45,79 9,90 80,28 3,66 71,31 8,02 42,94 3,60 34,59 6,79 Mid T12 
ct789 25,74 3,82 28,47 5,15 24,34 0,91 23,54 1,79 13,01 0,17 24,22 1,24 Early T6 
ct813 5,08 1,30 4,74 1,82 6,50 0,23 3,72 0,11 31,28 15,74 56,08 31,18 Late T42 
ct850 5,40 0,87 8,88 1,29 24,04 4,05 14,64 1,64 11,56 5,00 17,60 3,26 Mid T12 
aReal-time quantitative PCR (RT-qPCR) of mRNA levels of inc genes during the 
developmental cycle of Chlamydia trachomatis E/Bour strain. The data shows for each 
inc at each time point the mean values (x105) ± SEM, normalized against the 
corresponding values of the 16SrRNA, from at least two independent experiments 






Table A.10 – mRNA levels of inc genes during the developmental cycle of 
Chlamydia trachomatis L2/434 straina. 
Chlamydia trachomatis L2/434 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 




ct006 106,04 29,67 132,78 ND 27,17 ND 10,53 4,51 8,06 0,68 8,37 2,12 Early T6 
ct036 84,10 11,58 52,81 16,11 11,77 3,43 16,60 3,82 10,13 0,77 9,93 2,54 Early T2 
ct058 28,82 15,47 51,40 30,05 22,64 8,73 10,75 6,61 4,45 0,55 6,83 1,14 Early T6 
ct101 6,63 3,34 27,89 10,76 30,64 7,80 34,08 12,26 7,63 1,77 7,31 0,69 Mid T20 
ct115 258,95 22,03 126,79 1,33 96,86 20,81 62,57 23,85 15,31 0,81 26,46 1,52 Early T2 
ct116 415,04 61,54 238,10 41,33 170,65 25,07 92,53 28,56 28,95 1,05 40,75 10,11 Early T2 
ct117 176,10 22,38 137,97 29,90 151,18 42,07 82,87 29,44 17,14 0,71 22,00 2,46 Early T2 
ct118 163,41 59,99 153,76 45,90 215,10 65,12 109,37 45,41 22,45 3,81 21,43 5,92 Early T12 
ct119 7,26 4,55 4,29 0,02 10,71 1,29 33,35 1,91 14,82 0,62 7,25 2,31 Mid T20 
ct134 369,19 168,94 204,78 85,05 92,14 31,13 33,57 21,44 14,59 1,93 19,70 1,54 Early T2 
ct135 255,73 98,72 162,86 76,44 66,40 25,82 26,76 13,14 12,88 0,21 18,24 3,31 Early T2 
ct147 124,57 9,03 129,62 25,79 68,39 3,50 25,95 0,28 21,89 1,64 27,53 1,93 Early T6 
ct164 9,11 2,71 9,61 1,86 9,82 1,32 11,98 1,11 4,47 0,12 3,74 0,37 Early T20 
ct179 54,71 3,10 79,12 13,31 31,26 7,29 35,44 9,17 23,56 1,80 19,85 6,77 Early T6 
ct192 115,14 13,19 53,71 1,29 16,38 1,15 5,46 1,31 3,21 0,76 6,71 3,34 Early T2 
ct195 18,00 6,59 17,26 2,65 15,52 4,88 16,31 2,72 6,16 0,89 5,49 0,78 Early T2 
ct196 130,15 65,05 42,64 12,60 12,11 0,63 5,85 2,33 4,65 0,20 6,99 2,13 Early T2 




ct222 2,54 0,62 4,37 1,24 23,41 7,36 16,26 6,44 6,39 0,23 7,67 1,35 Mid T12 
ct223 6,53 2,79 6,15 0,28 96,29 14,28 87,33 35,38 27,76 6,66 18,47 2,62 Mid T12 
ct224 6,21 2,79 10,64 2,24 7,97 1,17 7,18 2,57 3,90 0,19 4,74 1,38 Early T6 
ct225 11,33 5,55 13,39 4,00 17,76 4,30 14,60 5,71 6,14 0,51 6,61 2,00 Early T12 
ct226 13,58 4,89 14,18 5,36 19,34 2,71 13,22 1,41 6,04 1,45 6,24 2,27 Early T12 
ct227 33,46 17,48 27,99 1,34 11,79 2,58 7,44 3,01 3,96 0,10 5,99 2,66 Early T2 
ct228 208,44 55,66 105,75 15,64 31,60 1,89 10,87 3,32 6,86 0,44 12,67 3,80 Early T2 
ct229 758,67 178,59 265,91 46,22 38,12 10,04 14,43 5,33 22,81 0,34 45,61 0,68 Early T2 
ct232 326,18 96,78 294,04 3,21 117,49 18,03 58,85 16,80 18,79 4,01 15,38 0,36 Early T2 




Chlamydia trachomatis L2/434 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct249 113,93 26,16 72,74 2,54 30,02 6,54 21,43 6,92 10,38 0,93 14,90 0,54 Early T2 




ct300 17,29 4,10 31,93 8,34 21,71 4,57 19,12 2,41 16,79 0,78 29,37 2,75 Early T6 
ct345 4,56 1,12 10,86 0,52 13,81 0,40 17,20 1,49 10,20 0,81 5,44 0,56 Mid T20 








ct365 11,76 ND 8,06 1,89 5,18 0,90 9,76 1,82 32,44 3,33 26,03 1,96 Late T30 
ct383 95,36 20,18 57,68 6,91 26,40 3,87 20,72 ND 12,00 2,79 8,50 0,98 Early T2 
ct440 47,24 20,92 49,31 3,13 15,33 1,78 9,07 2,25 4,80 0,37 6,29 1,37 Early T6 
ct442 16,75 6,87 11,08 0,30 6,65 1,19 23,95 2,91 40,16 11,28 31,69 1,52 Late T30 
ct449 94,37 43,09 55,11 4,62 17,68 3,96 8,95 1,51 5,23 0,70 8,28 1,44 Early T2 
ct483 23,22 4,77 18,12 3,45 16,42 1,15 19,35 1,96 9,53 0,33 12,09 1,16 Early T2 
ct484 10,50 3,18 8,68 3,47 13,39 1,60 24,26 5,18 8,07 1,63 7,17 0,76 Early T20 
ct565 39,26 0,79 23,72 0,91 22,69 3,98 70,41 18,78 164,61 22,37 128,83 24,22 Late T30 
ct618 282,40 84,17 324,18 21,24 229,60 9,71 130,26 14,22 27,23 0,87 34,17 3,52 Early T6 
ct728 40,24 7,34 79,25 22,97 82,33 4,69 76,08 7,33 30,77 1,47 15,16 1,54 Mid T12 
ct789 57,27 10,47 38,58 8,60 24,81 3,29 23,17 3,37 8,33 2,92 7,45 0,76 Early T2 
ct813 7,53 2,32 9,64 1,20 15,86 4,34 8,87 0,83 51,37 25,19 45,72 13,93 Late T30 
ct850 6,22 3,52 10,17 3,77 19,20 5,72 23,86 5,65 12,52 0,98 8,23 1,53 Mid T20 
aReal-time quantitative PCR (RT-qPCR) of mRNA levels of inc genes during the 
developmental cycle of Chlamydia trachomatis L2/434 strain. The data shows for each 
inc at each time point the mean values (x105) ± SEM, normalized against the 
corresponding values of the 16SrRNA, from at least two independent experiments 






Table A.11 – mRNA levels of inc genes during the developmental cycle of 
Chlamydia trachomatis B/Har36 straina. 
Chlamydia trachomatis B/Har36 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct005 37,75 5,34 31,71 9,02 18,79 1,25 11,02 2,27 5,48 2,11 90,67 18,09 Late T42 
ct006 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct036 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct058 0,03 0,01 0,01 0,01 0,03 0,00 0,08 0,04 0,02 0,01 0,01 0,00 Mid T20 
ct101 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct115 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct116 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct117 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct118 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct119 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct134 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct135 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct147 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct164 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct179 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct192 6,13 2,47 12,42 6,27 10,22 0,92 8,33 2,02 2,27 0,86 1,82 0,51 Mid T6 
ct195 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct196 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct214 30,72 17,70 20,81 8,67 17,00 1,80 13,93 0,13 16,32 3,11 78,44 22,59 Late T42 
ct222 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct223 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct224 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct225 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct226 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct227 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct228 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct229 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct232 49,32 22,66 58,56 28,45 56,30 11,84 59,13 11,51 17,65 8,47 9,28 3,06 Early T20 




Chlamydia trachomatis B/Har36 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct249 25,11 9,55 20,91 6,97 17,70 4,67 26,63 1,84 11,98 2,64 8,48 0,23 Early T20 
ct288 12,25 3,24 10,49 4,50 11,13 3,34 8,79 0,56 5,14 1,61 33,15 4,85 Late T42 
ct300 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct345 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct357 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct358 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct365 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct383 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct440 10,48 3,18 11,37 3,78 13,61 0,77 14,00 3,59 7,06 2,61 3,98 1,21 Early T20 
ct442 4,89 0,02 4,20 1,04 4,79 0,98 22,61 0,76 15,12 5,82 14,61 4,71 Mid T20 
ct449 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct483 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct484 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct565 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct618 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct728 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct789 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct813 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct850 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
aReal-time quantitative PCR (RT-qPCR) of mRNA levels of inc genes during the 
developmental cycle of Chlamydia trachomatis B/Har36 strain. The data shows for each 
inc at each time point the mean values (x105) ± SEM, normalized against the 
corresponding values of the 16SrRNA, from at least two independent experiments 






Table A.12 – mRNA levels of inc genes during the developmental cycle of 
Chlamydia trachomatis F/CS465-95 straina. 
Chlamydia trachomatis F/CS465-95 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct005 55,95 5,01 31,64 2,27 25,35 2,17 12,96 0,46 160,43 9,03 190,35 1,84 Late T42 
ct006 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct036 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct058 0,06 0,03 0,01 0,01 0,05 0,05 0,03 0,00 0,02 0,00 0,01 0,01 Early T2 
ct101 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct115 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct116 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct117 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct118 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct119 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct134 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct135 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct147 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct164 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct179 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct192 3,32 0,39 2,47 1,05 2,59 0,77 1,86 0,03 1,98 0,57 1,70 0,95 Early T2 
ct195 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct196 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct214 14,04 0,32 10,36 0,10 6,27 0,76 5,64 0,55 53,56 1,50 36,15 4,04 Late T30 
ct222 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct223 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct224 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct225 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct226 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct227 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct228 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct229 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct232 34,84 11,68 25,41 2,24 27,00 3,38 25,28 1,10 10,86 2,19 6,21 2,06 Early T2 




Chlamydia trachomatis F/CS465-95 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct249 27,93 8,62 22,31 1,78 16,35 1,75 12,24 1,75 8,29 0,55 9,01 2,25 Early T2 
ct288 57,61 12,95 29,04 3,24 32,01 8,06 12,82 3,36 122,50 3,27 115,49 30,88 Late T30 
ct300 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct345 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct357 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct358 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct365 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct383 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct440 6,85 0,72 6,99 0,60 8,81 0,88 7,83 0,34 5,25 0,94 3,05 0,85 Early T12 
ct442 3,61 1,08 3,16 1,26 3,03 1,41 3,58 0,66 12,82 3,07 9,48 3,98 Late T30 
ct449 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct483 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct484 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct565 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct618 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct728 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct789 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct813 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct850 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
aReal-time quantitative PCR (RT-qPCR) of mRNA levels of inc genes during the 
developmental cycle of Chlamydia trachomatis F/CS465-95 strain. The data shows for 
each inc at each time point the mean values (x105) ± SEM, normalized against the 
corresponding values of the 16SrRNA, from at least two independent experiments 






Table A.13 – mRNA levels of inc genes during the developmental cycle of 
Chlamydia trachomatis L2b/CS19-08 straina. 
Chlamydia trachomatis L2b/CS19-08 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct005 50,19 5,53 45,67 6,89 22,54 7,02 14,11 5,24 171,04 59,72 260,88 14,60 Late T42 
ct006 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct036 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct058 8,11 0,67 9,78 2,93 10,02 4,34 4,55 1,02 2,19 0,77 6,04 3,03 Early T12 
ct101 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct115 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct116 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct117 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct118 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct119 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct134 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct135 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct147 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct164 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct179 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct192 39,84 3,67 30,38 7,39 12,12 0,42 6,69 1,26 3,71 0,11 10,61 2,95 Early T2 
ct195 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct196 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 




ct222 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct223 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct224 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct225 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct226 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct227 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct228 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct229 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct232 118,54 32,04 181,11 58,21 184,56 75,39 79,82 17,97 25,24 7,86 40,13 18,54 Early T12 




Chlamydia trachomatis L2b/CS19-08 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct249 38,21 13,32 31,45 9,09 16,70 5,97 11,87 1,75 7,88 3,55 14,94 7,11 Early T2 
ct288 14,14 3,09 10,59 2,39 7,09 2,25 10,12 2,89 61,11 30,63 56,41 14,82 Late T30 
ct300 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct345 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct357 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct358 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct365 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct383 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct440 13,18 3,01 18,71 1,77 9,03 1,38 6,87 1,06 4,28 0,11 10,74 2,19 Early T6 
ct442 7,45 1,00 8,15 5,53 5,18 3,35 18,28 4,37 29,10 10,93 27,00 7,43 Late T30 
ct449 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct483 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct484 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct565 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct618 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct728 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct789 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct813 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct850 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
aReal-time quantitative PCR (RT-qPCR) of mRNA levels of inc genes during the 
developmental cycle of Chlamydia trachomatis L2b/CS19-08 strain. The data shows for 
each inc at each time point the mean values (x105) ± SEM, normalized against the 
corresponding values of the 16SrRNA, from at least two independent experiments 






Table A.14 – mRNA levels of inc genes during the developmental cycle of 
Chlamydia trachomatis L3/404 straina. 
Chlamydia trachomatis L3/404 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct005 36,91 0,77 31,50 0,35 14,88 2,06 27,19 2,20 144,46 9,06 103,73 7,90 Late T30 
ct006 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct036 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct058 4,76 2,33 9,49 1,22 11,03 3,13 3,82 0,20 2,69 1,15 3,22 1,68 Early T12 
ct101 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct115 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct116 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct117 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct118 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct119 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct134 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct135 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct147 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct164 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct179 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct192 30,78 4,79 23,57 4,00 10,75 0,53 4,60 0,18 3,60 1,65 4,17 1,32 Early T2 
ct195 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct196 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 




ct222 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct223 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct224 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct225 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct226 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct227 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct228 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct229 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct232 109,37 25,18 168,47 45,40 135,46 16,09 62,16 0,51 18,57 0,01 24,92 4,48 Early T6 




Chlamydia trachomatis L3/404 
 





































T2 T6 T12 T20 T30 T42 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
ct249 68,13 22,47 45,22 2,76 25,77 4,18 15,92 0,44 10,67 2,43 12,38 2,18 Early T2 




ct300 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct345 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct357 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct358 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct365 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct383 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct440 16,86 5,83 16,50 4,36 12,27 0,96 7,81 0,95 4,41 1,35 4,73 1,76 Early T2 
ct442 15,70 1,79 15,13 4,98 7,43 0,19 23,01 1,18 29,95 26,78 33,04 3,63 Late T42 
ct449 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct483 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct484 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct565 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct618 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct728 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct789 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
ct813 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
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aReal-time quantitative PCR (RT-qPCR) of mRNA levels of inc genes during the 
developmental cycle of Chlamydia trachomatis L3/404 strain. The data shows for each 
inc at each time point the mean values (x105) ± SEM, normalized against the 
corresponding values of the 16SrRNA, from at least two independent experiments 









Figure A.1 – LGV-specific nucleotide differences in the promoter region of ct059, 
coding sequence of ct059, ct059-ct058 intragenic region, and first codons of ct058 
(A), the promoter region of ct192 (B) and of ct214 (C). The nomenclature of D/UW3 is 
used. A dot “.” indicates an identical nucleotide among all strains. The following features 
of strain L2/434 are depicted in the sequence (underlined and bold): the transcriptional 
start site of ct059, ct192, and ct214 determined by RACE (+1), the predicted start and 
stop codons of ct059, the deduced -10 and -35 hexamers within the promoter of ct059, 
ct192, and ct214, the predicted start codon of ct058, ct192, and ct214, and LGV specific 
nucleotide differences (arrows). 
 
 
 
